Document:

<PAGE>

                                LICENSE AGREEMENT

         This LICENSE AGREEMENT ("Agreement"), effective as of May 17th, 1999,
by and between ELI LILLY AND COMPANY, an Indiana corporation with its principal
office located at Lilly Corporate Center, Indianapolis, Indiana 46285 ("Lilly"),
and VERSICOR, INC., a Delaware corporation with its principal offices located at
34790 Ardentech Court, Fremont, California 94555 and Versicor's Affiliates
(together "Versicor").

                                    RECITALS

         1. WHEREAS, Lilly is engaged, among other things, in the business of
discovering, developing, manufacturing and marketing pharmaceutical products for
the treatment and prevention of infectious diseases;

         2. WHEREAS, Lilly's research for antifungal agents has resulted in
Lilly owning patents, patent applications and know-how relating to an
echinocandin B analog known as LY303366 (and analogs thereof);

         3. WHEREAS, Lilly has been developing intravenous and oral formulations
of LY303366 and generated regulatory filings, pre-clinical and clinical data and
other information related to LY303366;

         4. WHEREAS, Lilly is interested in exclusively licensing LY303366 to a
pharmaceutical company capable and desirous of developing and commercializing
both parenteral and enteral pharmaceutical products of LY303366 (and/or analogs,
salts or prodrugs thereof);

         5. WHEREAS, Versicor is a specialty pharmaceutical company which
concentrates in the development and commercialization of compounds in the area
of infectious diseases;

         6. WHEREAS, Versicor has the capability and expertise to develop and
commercialize both parenteral and enteral pharmaceutical products.

<PAGE>

         7. WHEREAS, Versicor is interested in exclusively licensing rights to
LY303366 from Lilly for the worldwide development and commercialization of both
the parenteral and enteral products of LY303366 (and/or analogs, salts or
prodrugs thereof); and

         8. WHEREAS, subject to the terms and conditions set forth in this
Agreement, Lilly is willing to exclusively license to Versicor and Versicor
desires to exclusively license from Lilly rights related to LY303366 so that
Versicor may be enabled to proceed with the further development and
commercialization of LY303366;

         NOW, THEREFORE, the Parties hereto, intending to be legally bound,
hereby agree as follows:

                                    SECTION 1

                                   DEFINITIONS

         1.1 DEFINITIONS. For purposes of this Agreement, the following terms
shall have the meanings set forth below:

         "AFFILIATES" shall mean, with respect to a Party to this Agreement, any
Persons directly or indirectly controlling, controlled by, or under common
control with, such other Person. For purposes hereof, the term "controlled"
(including the terms "controlled by" and "under common control with"), as used
with respect to any Person, shall mean the direct or indirect ability or power
to direct or cause the direction of management policies of such Person or
otherwise direct the affairs of such Person, whether through ownership of equity
participation, voting securities, beneficial interest, by contract or otherwise.
Affiliate shall specifically exclude third parties to which Versicor has granted
a sublicense pursuant to authority granted by this Agreement where Versicor has
no relationship to the sublicensee other than a licensor-licensee relationship.

         "APPLICATION FOR MARKETING AUTHORIZATION" shall mean (a) in the United
States a new drug application filed with the FDA pursuant to 21 U.S.C. Section
357 and 21 C.F.R. Section 314 ("NDA") with respect to the Product and (b) in any
country other than the United States, an equivalent application or set of
applications for marketing approval comparable to an NDA necessary to make and
sell Product commercially in such country.

                                      -2-
<PAGE>

         f)   is independently developed by an employee or agent of the
              receiving Party, subsequent to receipt of such information from
              the disclosing Party, as demonstrated by contemporaneous written
              records.

         "CO-PROMOTE" or "CO-PROMOTION" shall mean an arrangement, in one or
more jurisdictions where permitted, in which (i) there is a single registration
holder for the Product; (ii) a single Party responsible for the manufacture of
Product; (iii) a single Party establishing the price of Product; (iv) a single
Party booking sales; (v) a single trademark being used in connection with the
Product; (vi) both Parties promote and market sales of the Product in such
jurisdiction(s); and (vii) either or both names or logos of the Parties appear
on the Product.

         "DAMAGES" shall mean any and all costs, losses, claims, liabilities,
fines, penalties, damages and expenses, court costs, and reasonable fees and
disbursements of counsel, consultants and expert witnesses incurred by a Party
hereto (including any interest payments which may be imposed in connection
therewith).

         "DATA EXCLUSIVITY PERIOD" shall mean the period, if any, during which
the FDA, or other equivalent regulatory agency in the case of countries other
than the United States, prohibits reference, for purposes of seeking Regulatory
Approval, to clinical and other data contained in the Regulatory Approval
package of Versicor or its sublicensee which is not published or publicly
available outside of the Regulatory Approval package and relates to the Product,
without the consent of the Party holding the NDA or equivalent Regulatory
Approval.

         "EFFECTIVE  DATE" shall be the date set forth in the first paragraph of
this Agreement.

         "EUROPE" shall mean the European Union, including the following
countries: Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland,
Italy, Luxembourg, Netherlands, Portugal, Spain, Sweden, United Kingdom and any
other European Union countries at the time of the Effective Date.

         "FDA" shall mean the United States Food and Drug Administration, or any
successor thereto.

         "FTE" shall mean the equivalent of the scientific work on or directly
related to the

                                      -4-
<PAGE>

Product of one scientific person full time for one year (consisting of a total
of forty-seven (47) weeks or one thousand eight hundred eighty (1,880) hours per
year (excluding vacations and holidays).

          "GAAP" shall mean generally accepted accounting principles in the
United States, consistently applied.

         "HOSPITAL MARKET SECTOR" shall mean that segment of the Product market
in which the Product is administered by a licensed medical professional (i) in a
hospital or critical care setting; and/or (ii) in a facility that is recognized
as a hospital by the American Hospital Association in the United States or
equivalent associations in other countries.

         "INDEMNIFIED PARTY" shall have the meaning given in Section 8.2 hereof.

         "INDEMNIFYING PARTY" shall have the meaning given in Section 8.2
hereof.

         "INTRAVENOUS FORMULATION" shall mean parenteral (ip) formulations of
the Product Which may be administered by injection; referring particularly to
the introduction of substances by means of intravenous, subcutaneous,
intramuscular, or intramedullary injection.

         "LICENSED PATENTS" shall mean all (i) patents and patent applications
listed in EXHIBIT A attached hereto; (ii) any international counterparts
thereof; (iii) any divisionals, continuations, continuations-in-part (except as
provided below), refilings, and extensions of any of the foregoing patents and
patent applications; (iv) all substitutions, reissues, renewals, reexaminations,
patents of addition, and inventors' certificates thereof, patent term
extensions, supplementary protection certificates and pediatric data package
exclusivity extensions of the foregoing patents; and (v) all patents issuing
from any of the foregoing. "Licensed Patents" shall also include patents and/or
patent applications which are filed or which issue after the Effective Date to
the extent of any claims that covers the Licensed Technology and does not
include new matter. "Licensed Patents" shall not include any claims in
continuation-in-part patent applications (including all divisionals and
continuations of these continuations-in-part), patents issuing from
continuations-in-part (including all reissues, reexaminations, and extensions of
such patents), and all international counterparts thereof to the extent that
such claims are directed to new matter which is not the subject matter of those
patents and patent applications listed in EXHIBIT A.

                                      -5-
<PAGE>

For clarity, the Cal-Tech patent application (08/905359) to the modified ECB
Deacylase enzyme (the "Cal-Tech Patent Application") is intentionally not
included as a Licensed Patent; HOWEVER, Versicor shall have the right, pursuant
to a separate license agreement to be negotiated in good faith between the
Parties, to obtain a sublicense from Lilly to the Cal-Tech Patent Application as
related specifically to the Product.

         "LICENSED TECHNOLOGY" shall mean all tangible or intangible know-how,
trade secrets, inventions (whether or not patentable), data, clinical and
preclinical results, analytical reference materials and all confidential and/or
proprietary chemical substances, Biological Materials, assays, and technical
information (collectively, "Technology"), which has been developed or acquired
before the Effective Date (with the right to disclose and sublicense and subject
to the rights of Third Parties as of the Effective Date) by Lilly to the extent
such Technology is reasonably necessary or useful for the development,
manufacture, use, import, offer for sale or sale of the Product. Licensed
Technology does not include Transferred Assets.

         "LILLY DEVELOPMENT OPTION" shall mean Lilly's right to elect to assume
exclusive development and commercialization rights and obligations for the Oral
Formulation of the Product after completion of Phase II Clinical Trials by
Versicor, in accordance with Section 2.7.

         "NET SALES" shall mean, with respect to the Product, the gross amount
invoiced by Versicor, its Affiliates, and sublicensees to unrelated third
parties for sales of the Product, less:

                  (a) trade, quantity and cash discounts actually allowed;

                  (b) discounts, refunds, rebates, chargebacks, retroactive
price adjustments and any other allowances which effectively reduce the net
selling price;

                  (c) actual product returns, credits and allowances; and

                  (d) freight, insurance, taxes, customs, duties and other
government charges if separately set forth in the invoiced amount.

         Such amounts shall be determined from books and records maintained in
accordance with GAAP. No deductions shall be made for commissions paid to

                                      -6-
<PAGE>

individuals, whether they are with independent sales agencies or regularly
employed by Versicor, or sublicensees, and on its payroll, or for the cost of
collections.

         "MAJOR MARKET COUNTRY" or "MAJOR MARKET COUNTRIES" shall mean the
United States, Japan, United Kingdom, France, Germany, Italy and/or Spain.

         "NORTH AMERICA" or "NORTH AMERICAN" shall mean the United States,
Mexico and/or Canada, and their respective territories, possessions and
commonwealths.

         "ORAL FORMULATION" shall mean enteral formulations of the Product which
are administered orally and are absorbed through the intestine or
gastrointestinal tract; referring without limitation to the introduction of
substances by means of controlled time-release preparations, liquid suspensions,
and sublingual administration.

         "ORAL FORMULATION DEVELOPMENT PLAN" shall have the meaning described in
Section 6.7 herein.

         "OTHER FORMULATIONS" shall mean any means by which the Product is
administered other than by an Oral Formulation and/or Intravenous Formulation,
including, without limitation, the introduction of substances by means of
internasal administration, pulmonary absorption, rectal administration, topical
applications and the like.

         "PARTY" or "PARTIES" shall mean either Lilly or Versicor or both.

         "PERSON" shall mean a natural person, a corporation, a partnership, a
trust, a joint venture, a limited liability company, any governmental authority
or any other entity or organization.

         "PHASE II CLINICAL TRIALS" shall mean human clinical trials conducted
in patients anywhere in the world in accordance with good clinical practice to
demonstrate efficacy with the Product in the particular indication tested, as
well as to obtain a preliminary indication of the limit and/or daily dosage
regimen required.

         "PHASE III CLINICAL TRIALS" means large scale human clinical trials
conducted in patients anywhere in the world in accordance with good clinical
practice to generate data

                                      -7-
<PAGE>

concerning the efficacy and a level of safety in the particular indication
tested sufficient to obtain Approval of the Product.

         "PRODUCT" shall mean a finished or semi-finished good containing the
compound LY303366, having the chemical name (1-[(4R,5R)-4,5-Dihydroxy-N(2)-[[4"-
(pentyloxy)[1, 1' :4' 1"-terphenyl]-4-yl]carbonyl]-L-omithine]echinocandin B
(including analogs, salts, and prodrugs thereof), and all dosage strengths and
sizes thereof, that may, pursuant to applicable laws and regulations be
manufactured, marketed and sold upon Regulatory Approval, together with all
expansions and improvements thereon which may be included in any supplement,
modification or addition to the Regulatory Approval.

         "PRODUCT DATA PACKAGE" shall include the following information and data
directly related to the Product in the tangible possession or control of Lilly
as of the Effective Date: (a) Regulatory Documents; (b) pre-clinical and
clinical development protocols, data, and reports; (c) manufacturing development
technical reports; (d) toxicology reports; and (e) such other information and
data specifically identified in EXHIBIT C attached hereto. EXHIBIT C shall
represent a complete listing of the information and data included in Product
Data Package, as such term is used in this Agreement.

         "PRODUCT INVENTORY" shall mean LY303366, LY303366/Fructose complex,
freeze-dried vials containing LY303366 Intravenous Formulation, related
intermediates and certificates of analyses which Lilly owns or controls as of
the Effective Date, including without limitation Start-Up Inventory, which
inventory is listed in EXHIBIT D attached hereto. Lilly shall file such
amendments with the Regulatory Documents as appropriate to reflect the
manufacturing processes used in manufacturing the Product Inventory.

         "REGULATORY APPROVAL" shall mean (a) in the United States, approval by
the FDA of an Application for Marketing Authorization and satisfaction of any
related applicable FDA registration and notification requirements (if any) and
(b) in any country other than the United States, approval by regulatory
authorities having jurisdiction over such country of a single Application or set
of Applications for Marketing Authorization.

         "REGULATORY DOCUMENTS" shall mean the (a) United States investigational
new drug application (IND) #51,111, dated July 15, 1996; (b) United States IND
#54,597, dated November 20, 1997; (c) Spain CTA #PEI97-06 dated August 17, 1998;
(d) Canada IND ## 044571, 056065 and 056082, approved September 25, 1996, June
16, 1998, June

                                      -8-
<PAGE>

16, 1998, respectively; (e) Japan IND # 10-2469, dated August 3, 1998; and (g)
equivalent filings, authorizations and applications in the countries of France,
United Kingdom CTX 6/350/A #61292; and Belgium, Finland (KLN nro 130/98),
Germany (4013536), Argentina (2345/98) and Brazil; and (h) all amendments and
reports related to the aforementioned documents.

         "REASONABLE DILIGENCE" shall mean commercially reasonable efforts to
develop and obtain Regulatory Approval in the Territory, consistent with
accepted business practices and legal requirements, and comparable to efforts in
the pharmaceutical industry for compounds at an equivalent stage of development
and similar market potential,; PROVIDED, HOWEVER, that prior to the first human
dose for the Oral Formulation, "Reasonable Diligence" with respect to
development of the Oral Formulation shall be deemed satisfied upon the earlier
of (a) administration of the first human dose for the Oral Formulation; or (b)
cumulative out-of-pocket third party expenses by Versicor in connection with
Oral Formulation development pursuant to the Oral Formulation Development Plan
equal to or greater than Five Hundred Thousand Dollars ($500,000) on or before
December 31, 2000 and One Million Dollars ($1,000,000) on or before December
31, 2001.

         "REIMBURSABLE DEVELOPMENT EXPENSES" shall mean all internal and
external direct, actual and documented costs incurred by Versicor after the
Effective Date to develop the Oral Formulation of the Product, including,
without limitation, pre-clinical and clinical trial expenses (including, without
limitation, the direct cost of clinical trial materials), reasonable Third Party
costs, Regulatory Approval expenses and fees, and costs associated with
scientific personnel dedicated to development of the Oral Formulation of the
Product, where scientific personnel costs shall be calculated at a rate of Two
Hundred Thousand Dollars ($200,000) per FTE. The purchase of raw materials or
supplies or external Third Party services shall be calculated using actual
direct costs incurred by the Parties for such Third Party goods or services.

         "RESERVE INVENTORY" shall mean Product Inventory which is not being
purchased by Versicor as of the Effective Date and which is specifically
identified as Reserve Inventory in EXHIBIT D attached hereto.

         "ROW" shall mean all the countries and territories of the world, except
those in North America and Europe.

                                      -9-
<PAGE>

         "ROYALTY TERM" shall mean, with respect to each country in which
Product is sold the period of time equal to the longer of (i) ten (10) years
from the date of first sale of the Product in such country, (ii) the expiration
of the last-to-expire Licensed Patent listed in EXHIBIT A in such country that
claims such Product, or (iii) the period of time equal to the Data Exclusivity
Period in such country.

         "START-UP INVENTORY" shall mean Product Inventory which is being
purchased by Versicor as of the Effective Date of this Agreement and which is
specifically identified as Start-Up Inventory in EXHIBIT D attached hereto.

         "TERRITORY" shall mean all the countries and territories of the world.

         "TRANSFERRED ASSETS" shall mean the Start-Up Inventory and the Product
Data Package.

         "VERSICOR CO-PROMOTION RIGHT" shall have the meaning set forth in
Section 2.7(g).

         "VERSICOR IMPROVEMENTS" shall mean any inventions, patentable or not,
information and/or data that are generated, identified and/or discovered by
Versicor during the term of the Agreement, based on use or practice of the
Licensed Patents or Licensed Technology, and are related to the Product,
including, without limitation, pre-clinical studies and clinical trial
information, manufacturing processes, formulations, modes of delivery and/or
data necessary for the manufacture, use or sale of the Product, or peripheral
and/or SAR compounds, pharmaceutical compositions, manufacturing processes,
product configurations and methods of use related to the Licensed Patents.

         "VERSICOR RESPONSIBILITIES" shall have the meaning set forth in Section
2.4 hereof.

                                    SECTION 2

              GRANT OF LICENSES, TRANSFER OF TRANSFERRED ASSETS AND
                            ASSUMPTION OF LIABILITIES

         2.1 GRANT OF LICENSES. Upon the terms and subject to the conditions of
this Agreement:

                                      -10-
<PAGE>

                  (a) During the term of the Agreement, Lilly hereby grants to
Versicor an exclusive, even as to Lilly (except as expressly reserved by Lilly
herein), license under the Licensed Patents and Licensed Technology to make,
have made, use, sell, offer to sell and import the Product in the Territory.
Lilly shall retain a non-exclusive license under the Licensed Patents and
Licensed Technology to make and use the Product solely for internal research
purposes;

                  (b) Upon expiration of the Agreement in any country in the
Territory pursuant to Section 4.1, Versicor shall thereafter have a fully
paid-up, perpetual, irrevocable, non-exclusive license to the Licensed
Technology to make, have made, use, sell, offer to sell and import the Product
in such country; and

                  (c) Versicor hereby grants to Lilly a non-exclusive
royalty-free license, with a right to sublicense only to Affiliates, to make and
use Versicor Improvements in connection with the Licensed Patents and Licensed
Technology solely for internal research purposes.

         2.2 TRANSFERRED ASSETS. As of the Effective Date, Lilly hereby assigns,
transfers and conveys to Versicor all of Lilly's right, title and interest in
and to the Transferred Assets and Versicor hereby accepts such assignment,
transfer and conveyance. Within thirty (30) days following the Effective Date,
Lilly shall work with Versicor to transfer possession of the Product Data
Package to Versicor. Lilly shall be responsible for the initial shipment of the
Product Data Package F.O.B. to Versicor or its designee. In the event that
Versicor is unwilling or unable to assume physical possession of the Product
Data Package by the end of the initial thirty (30) day period, Lilly shall be
entitled to charge Versicor a reasonable fee for storage of the Product Data
Package beyond such thirty (30) day period. Except as otherwise provided in
Section 2.9 or 2.10 below, Lilly shall not be obligated to provide any
additional information or assistance to Versicor regarding the Product. Versicor
acknowledges that Lilly makes no representations or warranties with respect to
the Transferred Assets and that it accepts such Transferred Assets "as is."

         2.3      PRODUCT INVENTORY.

         (a) POSSESSION. Within ninety (90) days of the Effective Date, Versicor
shall arrange, at Versicor's expense, and with reasonable assistance of the
appropriate and necessary Lilly personnel, to take possession and control of all
Product Inventory,

                                      -11-
<PAGE>

including Start-Up Inventory and Reserve Inventory. In the event Versicor fails
to take possession of Product Inventory within the ninety (90) day period
referenced above, Versicor shall pay Lilly a storage fee of Two Thousand Dollars
($2,000.00) per day, plus any reasonable costs and expenses incurred by Lilly
(including without limitation the cost of personnel time) in maintaining the
Product Inventory, until the date upon which Versicor takes the required
possession.

         (b) MAINTENANCE OF RESERVE INVENTORY. Upon possession, Versicor shall
assume sole responsibility for and shall undertake commercially reasonable
efforts in the maintenance and periodic evaluations required to preserve and
maximize the utility, stability and value of all components of Reserve
Inventory, including, without limitation, timely maintenance and extension of
expiry dates when reasonable and appropriate. Versicor shall maintain the
Reserve Inventory in appropriate and secure storage facilities under appropriate
temperature conditions and controls and shall otherwise manage the Product
Inventory with the same care as Versicor would provide for its own property,
including without limitation proper insurance. Additionally, Versicor shall
provide Lilly with a quarterly report on the status of the Reserve Inventory,
setting forth the information described in EXHIBIT E. Lilly shall be entitled to
audit and inventory, at its expense and no more often that once per twelve (12)
month period, the Reserve Inventory at any time during normal business hours.

         (c) OWNERSHIP. Versicor shall be the title owner of the Start-Up
Inventory, for which Versicor has agreed to pay Lilly [ * ] in accordance
with Section 3.4 herein. With respect to the Reserve Inventory, Versicor
shall be a bailee for the mutual benefit of Versicor and Lilly, until such
time as Versicor either purchases such Reserve Inventory for itself or Lilly
reclaims possession.

           (d) RESERVE INVENTORY OPTION. Versicor shall have the right to
unilaterally purchase and use Reserve Inventory on an as needed, component by
component, and unit by unit basis at any time after the Effective Date and
without prior notice to Lilly, provided that Versicor shall pay Lilly the per
unit/component costs set forth in EXHIBIT D and such payment and a detailed
description of the inventory purchased/used is provided to Lilly within thirty
(30) days of the purchase/use. Except as specifically permitted herein with
respect to purchase or use of Reserve Inventory, Versicor shall have no right to
otherwise deplete, destroy, encumber or transfer the Reserve Inventory without
the prior written consent of Lilly.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                      -12-
<PAGE>

         2.4 VERSICOR UNDERTAKING. Except as otherwise provided in this
Agreement, Versicor hereby agrees that, commencing on the Effective Date,
Versicor is responsible for all aspects of the development and commercialization
of the Product in the Territory, including satisfying all obligations, claims,
liabilities, burdens and problems of any nature whatsoever (collectively, the
"Obligations") associated directly or indirectly with Versicor's licensing
and/or practice of the Licensed Patents from and after the Effective Date and
possession, use, ownership and transport of the Transferred Assets and the
Reserve Inventory from and after the Effective Date, as well as those associated
directly or indirectly with the manufacture, development, marketing and sale of
the Products by Versicor or its sublicensees from and after the Effective Date,
including, without limitation, all recalls, all warranty claims and all product
liability claims (without regard to the nature of the causes of action alleged
or theories of recovery asserted) arising in connection with Products On or
after the Effective Date, except for (1) those Obligations with respect to which
Lilly is providing indemnification pursuant to the provisions of Section 8.1 of
this Agreement, and (2) the hereinafter defined Excluded Liabilities, which
items shall remain the responsibility of Lilly as set forth herein. All of the
foregoing is hereinafter collectively referred to as the "Versicor
Responsibilities."

         2.5 LIABILITIES NOT ASSUMED BY VERSICOR. Anything herein to the
contrary notwithstanding, Lilly shall be responsible for, and Versicor shall not
be deemed to assume, any of the following (collectively, the "Excluded
Liabilities"):

                  (a) Any Obligations arising out of a claim of any third party
relating to the Product arising out of or relating to events occurring prior to
the Effective Date; or

                  (b) Any Obligations arising out of a claim by a government
entity or regulatory body that Lilly has failed to fulfill Lilly's regulatory
obligations under the Regulatory Documents prior to the Effective Date.

         2.6 SUBLICENSES. Subject to the terms and conditions herein, the Lilly
Development Option and the provisions in Section 2.8, Versicor shall have the
right to sublicense the licenses granted to it by Lilly. Any sublicenses granted
by Versicor under this Agreement shall provide for termination or assignment to
Lilly, at the option of Lilly, of Versicor's interest therein upon termination
of this Agreement and contain provisions

                                      -13-
<PAGE>

which obligate the sublicensee to Versicor to at least the same extent that
Versicor is obligated to Lilly under this Agreement.

         2.7 LILLY DEVELOPMENT OPTION: ORAL FORMULATION. Within thirty (30) days
of receiving the final results of the first Phase II Clinical Trial of the Oral
Formulation of the Product, Versicor shall provide to Lilly a written report
summarizing in reasonable detail such results (the "Phase II Report"). Within
sixty (60) days after receipt by Lilly from Versicor of the Phase II Report,
Lilly shall have the right, but not the obligation, to elect by written notice
to Versicor (the "Election") to exercise the Lilly Development Option for the
Oral Formulation. During the sixty (60) day period, Lilly shall have the right
to engage in a reasonable due diligence audit of Versicor's prior development
activities with respect to such Oral Formulation to assess whether Lilly desires
to exercise its Lilly Development Option. In the event Lilly makes the Election,
Lilly's Development Option shall take effect under the following terms and
conditions:

                  (a) The licenses granted to Versicor by Lilly under Section
2.1 shall automatically terminate with respect to the Oral Formulation of the
Product;

                  (b) Versicor shall grant, and hereby does grant, to Lilly
an exclusive, worldwide license, with a right to sublicense, to Versicor
Improvements solely to make, use, sell, promote, offer to sell, and import
the Oral Formulation of the Product, except to the extent such rights must be
retained by Versicor in connection with any Versicor Co-Promotion Right which
Versicor may obtain pursuant to subsection (g) below.

                  (c) Lilly shall pay to Versicor a royalty of [ * ] on Net
Sales of the Oral Formulation in the Territory for the Royalty Term, payment
of which shall be on terms equivalent to those set forth in Sections 3.5,
3.6, 3.7 and 3.8;

                  (d) Within ninety (90) days of the Election, Lilly shall
(i) reimburse to Versicor [ * ] of the Reimbursable Development Expenses
actually incurred by Versicor as of the date of the Election; (ii) reimburse
to Versicor [ * ] of any Oral Formulation milestone payments actually paid by
Versicor to Lilly pursuant to Section 3.3 of this Agreement; (iii) pay to
Versicor an additional fee of [ * ]; and (iv) reimburse to Versicor [ * ] of
the actual costs and expenses incurred by Versicor in filing,

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                      -14-
<PAGE>

prosecuting and/or maintaining the Licensed Patents that relate solely to the
Oral Formulation.

                  (e) As of the date of the Election, Lilly shall become solely
responsible for the development and commercialization of the Oral Formulation,
including, without limitation, the costs and expenses associated therewith.
Versicor shall have no further financial obligations to Lilly with respect to
the Oral Formulation, including, without limitation, no further obligation to
pay Royalty Payments or milestone payments under Section 3 of this Agreement.

                  (f) Within sixty (60) days of the Election, Versicor shall
promptly provide and make accessible to Lilly, as requested, all Versicor
Improvements in Versicor's or its agents' possession or control that is
reasonably useful or necessary for Lilly to proceed efficiently and effectively
with the further development and commercialization of the Oral Formulation,
including, without limitation, pre-clinical and clinical data, clinical research
regulatory files and filings, relevant technology and know-how, manufacturing
reports, sponsorship of all Regulatory Documents related to the Oral
Formulation, and relevant patents or patent applications encompassing Versicor
Improvements. Additionally, Versicor shall execute, acknowledge and deliver such
further instruments, and do all such other acts, consistent with the transition
support obligations described in Section 2.9 and 2.10, to enable and facilitate
an effective transition of development and commercialization responsibilities
and activities to Lilly for the Oral Formulation of the Product.

                  (g) Versicor shall have the right, subject to negotiation of a
mutually acceptable agreement between the Parties, to obtain from Lilly a
license to exclusively Co-Promote with Lilly the Oral Formulation in the
Hospital Market Sector (the "Versicor Co-Promotion Right"). Versicor may
exercise the Versicor Co-Promotion Right no later than ninety (90) days prior to
the anticipated completion of Phase III Clinical Trials by providing Lilly with
written notice of its desire to negotiate a Co-Promotion agreement. Upon
exercise of the Versicor Co-Promotion Right, the Parties shall mutually
negotiate in good faith the terms and conditions on a country-by-country basis
under which such Co-Promotion shall occur, which terms and conditions must be
consistent with the applicable terms of this Agreement and market comparables
and must include the following: (1) compensation to Versicor for its
Co-Promotion efforts in the Hospital Market Sector taking into account the
economic burdens assumed by Versicor; (2) a manner of defining

                                      -15-
<PAGE>

Versicor Co-Promotion efforts qualifying for compensation from Lilly, taking
into account the form, substance and delivery of such efforts; and (3) agreement
that Versicor's negotiated license to Co-Promote the Oral Formulation shall be
limited exclusively to Versicor, with no right to sublicense or use a third
party or Affiliate sales force without the prior written consent of Lilly. In
the event a Co-Promotion agreement is not fully executed by the Parties on or
before ninety (90) days after completion of the last Phase III Clinical Trial
necessary for preparing the first Application for Marketing Authorization for
the Oral Formulation, the Versicor Co-Promotion Right shall expire. Thereafter,
Versicor shall have a right to match Co-Promotion offers, similar to Lilly's
rights under Section 2.8 below.

         2.8 LILLY RIGHT TO FUTURE OPPORTUNITIES. Versicor recognizes that Lilly
has an interest in future royalties and milestone fees for the Product.
Therefore, in addition to Lilly's rights under Section 2.7 above, in the event
that Versicor seeks at any time to license a third party any rights with respect
to Product in the Territory ("License Opportunity"), whether together with or
independent of Versicor, Versicor shall in good faith consider Lilly for such
License Opportunity, subject to arms-length negotiations.

         2.9 TRANSITION SUPPORT. Subject to the other provisions of this Section
2.9 and Section 2.10, Lilly shall make available to Versicor the Licensed
Technology, either through access to documents and/or to personnel in possession
of such Licensed Technology. Lilly and Versicor shall establish a joint team of
personnel to coordinate transition of the Licensed Patents, Licensed Technology
and Transferred Assets. Lilly undertakes to work in good faith with Versicor to
complete an effective transition of the Licensed Patents, Licensed Technology
and Transferred Assets to Versicor within six (6) months of the Effective Date
("Transition Period"), subject to the limitations set forth herein. During the
Transition Period, Lilly shall provide, at no cost to Versicor, reasonable
access to appropriate and available personnel for up to two hundred (200) person
hours (during normal business hours) for reasonable regulatory, scientific,
medical, information technology, and patent assistance and consultation related
to the transition of the Licensed Patents, Licensed Technology and Transferred
Assets from Lilly to Versicor, not including Manufacturing Support which is
otherwise covered by Section 2.10 below, and shall execute, acknowledge and
deliver such further instruments as may be necessary to enable and facilitate an
effective transition for the Product. In the event the Parties mutually agree to
extend either the Transition Period or the total man hours of Lilly support,
Versicor shall reimburse Lilly for the cost of such additional time

                                      -16-
<PAGE>

or hours at a rate of Three Hundred Dollars ($300.00) per hour for Lilly patent
counsel hours and One Hundred Fifty Dollars ($150.00) per hour for all other
Lilly personnel hours. Notwithstanding the foregoing, all out-of-pocket expenses
or other costs associated with travel and related accommodations for Lilly
personnel involved in transition support shall be paid by Versicor.
Additionally, Lilly shall execute, acknowledge and deliver such further
instruments, and do all such other acts, consistent with the transition support
obligations described in Section 2.9 and 2.10, to enable and facilitate an
effective transition of development and commercialization responsibilities and
activities to Versicor for the Product.

         2.10 MANUFACTURING SUPPORT. Upon request by Versicor, Lilly shall
provide, at no cost to Versicor, reasonable access to appropriate and available
manufacturing and information technology personnel for up to three hundred (300)
person hours (during normal business hours) ("Manufacturing Support") for
reasonable manufacturing process technical assistance and consultation that
would enable Versicor and/or a third party manufacturer to reasonably employ the
Licensed Patents and/or Licensed Technology in the manufacture of the Product;
provided, however, that such Manufacturing Support shall be (i) provided over a
time period not exceeding two (2) months in duration, commencing with the first
date of engagement in such Manufacturing Support by Lilly personnel; and (ii)
completed no later than August 31, 2000.

         2.11 BIOLOGICAL MATERIALS. In connection with providing manufacturing
support under Section 2.10, Lilly shall transfer all the Biological Materials to
Versicor. Versicor shall not distribute or release the Biological Materials to
others except to further the purposes of this Agreement. All Biological
Materials, provided to Versicor and/or its sublicensee by Lilly under the terms
of this Agreement shall be maintained as a trade secret by Versicor and/or its
sublicensee and shall not be delivered or transmitted to any third party without
the express written consent of Lilly and then only upon enforceable written
assurances to Lilly by Versicor and the third party that the know-how and trade
secret rights in the Biological Materials will not be compromised by the
transaction. Versicor shall protect the Biological Materials at least as well as
it protects its own valuable tangible personal property and shall take measures
to protect the Biological Materials from any claims by third parties including
creditors and trustees in bankruptcy. Versicor's and/or its sublicensee's
obligation to safeguard the trade secret status of the Biological Materials
shall extend in perpetuity beyond the Royalty Term. Upon early termination of
this Agreement (but not expiration under Section 4.1), Versicor shall

                                      -17-
<PAGE>

return any remaining Biological Materials to Lilly or otherwise dispose of such
materials as instructed by Lilly.

                                    SECTION 3

                                    PAYMENTS

         In consideration of the exclusive license granted herein and the
transfer of ownership of the Transferred Assets, Versicor shall pay the
following amounts to Lilly:

         3.1 CASH PAYMENT UPON SIGNING. Within five (5) days of the execution
of this Agreement, in consideration for the Product Data Package, Versicor
shall pay to Lilly the non-refundable sum of [ * ] by Federal Reserve
electronic wire transfer in immediately available funds to an account
designated by Lilly.

         3.2 MILESTONE PAYMENTS FOR INTRAVENOUS FORMULATION. Within thirty (30)
days of Versicor and/or its sublicensees achieving a milestone event listed
below with respect to the Intravenous Formulation, Versicor shall pay the below
specified non-refundable fees to Lilly by Federal Reserve electronic wire
transfer in immediately available funds to an account designated by Lilly.
Except as otherwise provided in Section 2.7 such fees shall be non-refundable.

<TABLE>
<CAPTION>
             Intravenous Formulation Milestone                                     Fee
             ---------------------------------                                     ---
             <S>                                                                  <C>
             [ * ]                                                                [ * ]

             Total                                                                 $51 million

</TABLE>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                      -18-

<PAGE>

         3.3 MILESTONE PAYMENTS FOR ORAL FORMULATION. Within thirty (30) days of
achieving a milestone event listed below with respect to the Oral Formulation of
the Product, Versicor shall pay the below specified fee to Lilly by Federal
Reserve electronic wire transfer in immediately available funds to an account
designated by Lilly.

<TABLE>
<CAPTION>
                Oral Formulation Milestone                                         Cash
                --------------------------                                         ----
                <S>                                                                <C>
                [ * ]                                                              [ * ]

                Total                                                              $79 million

</TABLE>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                      -19-
<PAGE>

         3.4      PAYMENT FOR PRODUCT INVENTORY.

                  (a) START-UP INVENTORY. In consideration for the Start-Up
         Inventory, Versicor shall pay Lilly a total of [ * ] by Federal Reserve
         electronic wire transfer in immediately available funds to an account
         designated by Lilly as follows:

                       (1) [ * ] on or before the date which is twelve (12)
               months after the Effective Date;

                       (2) [ * ] on or before the date which is twenty-four
               (24) months after the Effective Date;

                       (3) [ * ] on or before the date which is thirty-six
               (36) months after the Effective Date;

                  (b) RESERVE INVENTORY. In the event Versicor elects to
         purchase any or all of the Reserve Inventory pursuant to Section
         2.3(d), Versicor shall pay Lilly for such inventory pursuant to the
         terms set forth in Section 2.3(d), by Federal Reserve

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                      -20-
<PAGE>

         electronic wire transfer in immediately  available funds to an account
         designated by Lilly.

         3.5      ROYALTIES.

                  (a) During the Royalty Term, Versicor shall pay to Lilly
running royalties ("Royalty Payments") for the Product as follows:

                       (1) [ * ] of Net Sales of all Intravenous Formulations
     and Other Formulations (excluding the Oral Formulation) of the Product in
     the North America and Europe during a Calendar Year;

                       (2) [ * ] of Net Sales in ROW of all Intravenous
     Formulations and Other Formulations of the Product (excluding the Oral
     Formulation); and

                       (3) [ * ] of Net Sales of the Oral Formulation of the
     Product in the Territory during a Calendar Year.

                  (b) In the event practice or use of the Licensed Patents or
Licensed Technology consistent with the terms of this Agreement results in
(i) an infringement claim by a third party or (ii) a desire on the part of
Versicor to enter into a third party license agreement based on its good
faith opinion that an infringement against such third party's patent(s) may
occur without such a license and notice to and concurrence by Lilly to such
third party license (which concurrence shall not be unreasonably withheld),
Versicor shall be entitled to credit, against royalties otherwise owed to
Lilly under Section 3.5 above, [ * ] of any amount actually paid by Versicor
to such third party for a license under a patent owned or controlled by such
third party; PROVIDED, HOWEVER, that Versicor may only credit against
royalties otherwise due in a Calendar Year such amounts that (i) are directly
attributable to the manufacture or sale of the Product (and not with respect
to any other uses or products); and (ii) that in total for such Calendar Year
do [ * ]. Except as set forth in this subsection (b), Versicor shall be
solely responsible for any royalties or other payments due a third party for
the Product.

                  (c) Royalty payments shall be made within sixty (60) days
after the end of each Calendar Quarter for which royalties are due. All payments
shall be made in U.S. Dollars and mailed to the attention of Lilly Royalty
Administration, Lilly Corporate Center, Indianapolis, Indiana 46285.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                      -21-
<PAGE>

                  (d) During the term of this Agreement and after the first sale
of the Product, Versicor shall furnish to Lilly on a quarterly basis a written
report covering each Calendar Quarter (each such Calendar Quarter being
sometimes referred to herein as a "reporting period") showing (1) the Net Sales
of Product in each country by Versicor or its Affiliates or sublicensees, and
(2) the Royalty Payments, which shall have accrued under this Section 3.5 in
respect of such sales and the basis for calculating those royalties. With
respect to sales of the Product invoiced in a currency other than U.S. Dollars,
the Net Sales and amounts due to Lilly hereunder shall be expressed in the U.S.
Dollar equivalent calculated on a monthly basis in the currency of the country
of sale and converted to their dollar equivalent using the official rate of
exchange as determined by the European American Bank (or such other bank as may
be regularly relied upon by Versicor with respect to official exchange rates) in
effect on the last business day of the applicable month of the Calendar Quarter
to which the report relates. Versicor will, at Lilly's reasonable request but
not more frequently than once a year, inform Lilly as to the specific exchange
rate translation methodology used for a particular country or countries. Each
quarterly report shall be due thirty (30) days following the close of each
reporting period. Amounts shown to have accrued by each sales report shall be
due and payable on the date such sales report is due.

                  (e) Versicor shall keep accurate records in sufficient detail
to enable the Royalty Payments due to be determined and verified by the audit
described in Section 3.6 for at least three years following the period in which
such obligation arose. Additionally, if laws or regulations require the
withholding of taxes, the taxes will be deducted by Versicor from the Royalty
Payments and remitted by Versicor to the proper tax authority. Proof of payment
shall be provided to Lilly within ninety (90) days after payment. Versicor will
cooperate in pursuing the refund of such tax, if such refund is appropriate in
Lilly's determination.

         3.6 AUDITS. Versicor and its Affiliates and sublicensees shall keep
full and accurate books and records relating to the performance of its payment
obligations required under this Agreement. During the term plus three (3) years
after termination or expiration of this Agreement, Lilly shall have the right,
during regular business hours and upon reasonable advance notice, no more often
than once every twelve (12) months to have such books and records audited so as
to verify the accuracy of the payments made to Lilly. The scope of such audits
shall be restricted to the review of not more than three (3) prior years. Such
information shall be Versicor Confidential Information and, as such, subject

                                      -22-
<PAGE>

to confidentiality pursuant to Section 6.3. The cost of such audit shall be
borne by Lilly; however, in the event such audit reveals that the Royalty
Payments to Lilly deviates by five percent (5%) or more from that revealed by
the audit to be actually owed, the cost of the audit shall be borne by Versicor.
Versicor shall include in all sublicenses granted as permitted under Section 2.6
an audit provision substantially similar to the foregoing requiring the
sublicensee to keep full and accurate books and records relating to the Product
and granting Lilly the right to audit the accuracy of the information reported
by the sublicensee in connection therewith on the same terms as apply to an
audit of Versicor's records hereunder.

         3.7 LATE PAYMENTS. Any amounts not paid by Versicor when due under this
Agreement shall be subject to interest from and including the date payment is
due through and including the date upon which Lilly has collected immediately
available funds in an account designated by Lilly at a rate equal five percent
(5%) plus the prime rate of interest quoted in the Money Rates section of THE
WALL STREET JOURNAL, calculated daily on the basis of a 360-day year, or similar
reputable data source.

         3.8 NO EXCUSE. Versicor shall not be excused from or relieved of its
obligations to pay the amounts actually owed as described in this Section 3 by
any claimed or actual event of force majeure, commercial or other
impracticability or impossibility, or frustration of essential purpose, except
to the extent otherwise provided in this Agreement.

                                    SECTION 4

                                TERM OF AGREEMENT

         4.1 TERM. The term of this Agreement shall begin upon the Effective
Date and, unless sooner terminated as hereinafter provided, shall continue in
full force and effect on a country-by-country basis until Versicor, its
Affiliates and sublicensees have no remaining royalty obligations in a country
as set forth in Section 3.5.

                                    SECTION 5

                         REPRESENTATIONS AND WARRANTIES

         5.1 CORPORATE EXISTENCE AND POWER. As of the Effective Date, each Party
represents and warrants to the other that it (a) is a corporation duly
organized, validly existing and in good standing under the laws of the state in
which it is incorporated, and

                                      -23-
<PAGE>

(b) has full corporate power and authority and the legal right to own and
operate its property and assets and to carry on its business as it is now being
conducted and is contemplated in this Agreement, including, without limitation,
the right to grant the licenses granted hereunder.

         5.2 AUTHORITY. As of the Effective Date, each Party represents and
warrants to the other that it (a) has the corporate power and authority and the
legal right to enter into this Agreement and perform its obligations hereunder;
(b) has taken all necessary corporate action on its part required to authorize
the execution and delivery of the Agreement and the performance of its
obligations hereunder; and (c) the Agreement has been duly executed and
delivered on behalf of such Party, and constitutes a legal, valid and binding
obligation of such Party and is enforceable against it in accordance with its
terms.

         5.3 ABSENCE OF LITIGATION. As of the Effective Date, Lilly represents
and warrants to Versicor that it is not aware of any pending or threatened
litigation (and has not received any communication relating thereto) which
alleges that Lilly's activities, with respect to the Product or the Licensed
Technology or otherwise related to this Agreement, have infringed or
misappropriated, or that by conducting the activities as contemplated herein by
Versicor would infringe or misappropriate, any of the intellectual property
rights of any other person. To the best Lilly's knowledge, there is no material
unauthorized use, infringement or misappropriation of any of its intellectual
property rights licensed hereunder.

         5.4 NO APPROVALS OR CONSENTS. Except as otherwise described in this
Agreement, each Party represents and warrants to the other that all necessary
consents, approvals and authorizations of all governmental authorities and other
persons or entities required to be obtained by such Party in connection with
entry into this Agreement have been obtained.

         5.5 PATENTS; PRIOR ART. Except as Lilly has otherwise advised Versicor
in writing prior to the Effective Date, Lilly represents and warrants to
Versicor that as of the Effective Date, (a) to the best of its knowledge, it has
sufficient legal and/or beneficial title and ownership under its intellectual
property rights necessary for it to fulfill its obligations under this
Agreement; (b) it has granted Versicor a license to all patents and patent
applications (with the exception of the "Cal-Tech Patent Application" defined in
the

                                      -24-
<PAGE>

Licensed Patent definition) which Lilly owns or controls in connection with the
Product as of the Effective Date; and (c) to the best of its knowledge, there is
no material unauthorized use, infringement or misappropriation of any of its
intellectual property rights by third parties relevant to the Product or other
rights granted under this Agreement. As used herein, "intellectual property
rights" shall mean all patent rights, copyrights, trademarks, trade secrets, and
confidential and/or proprietary chemical substances, Biological Materials,
technical information, data and assays necessary or useful to make, use or sell
the Product.

         5.6 NO CONFLICT. Each Party represents and warrants to the other that
the execution and delivery of the Agreement by such Party and the performance of
such Party's obligations hereunder (a) do not conflict with or violate any
requirement of applicable law or regulation or any provision of articles of
incorporation or bylaws of such Party in any material way, and (b) do not
conflict with, violate or breach or constitute a default or require any consent
under, any contractual obligation or court or administrative order by which such
Party is bound.

         5.7 REGULATORY DOCUMENTS. Lilly represents and warrants to Versicor
that: (a) Lilly has furnished Versicor with access to a complete copy of the
United States Regulatory Documents for the Product, including all material
amendments and supplements thereto; (b) Lilly is and was, at all times prior to
the Effective Date, the lawful holder of all rights under the Regulatory
Documents; (c) to the best of Lilly's knowledge, Lilly has complied in all
material respects with all applicable laws and regulations in connection with
the preparation and submission to the relevant regulatory authorities of the
Regulatory Documents; (d) the Regulatory Documents have been approved by, and
nothing has come to the attention of Lilly which has, or reasonably should have,
led Lilly to believe that the Regulatory Documents are not in good standing with
relevant regulatory authorities; (e) Lilly has filed with the relevant
regulatory authorities all required notices, supplemental applications and
annual or other reports, including adverse experience reports, with respect to
the Regulatory Documents which are material; and (f) there is no pending or
overtly threatened action by relevant regulatory authorities which will have a
material adverse effect on the Regulatory Documents. Except for the
representations contained in this Section 5.7, upon which Versicor is relying
(which Lilly hereby acknowledges), Versicor has had a reasonable opportunity to
review and evaluate the Regulatory Documents and Versicor is relying solely upon
its own judgment and experience in connection therewith.

                                      -25-
<PAGE>

         5.8 NO DEBARMENT. Each Party represents and warrants to the other that
it will comply at all times with the provisions of the Generic Drug Enforcement
Act of 1992 and will upon request certify in writing to the other that neither
it, its employees, nor any person has provided services to such Party in
connection with the Product have been debarred under the provisions of such Act.

         5.9 NO THIRD PARTY INFRINGEMENT. To the best of Lilly's knowledge,
there is no patent issued to a Third Party as of the Effective Date that would
be infringed by the manufacture, use or sale of Product.

         5.10 IMPLIED WARRANTIES. EXCEPT AS EXPRESSLY PROVIDED IN THIS SECTION
5, LILLY MAKES NO REPRESENTATION OR WARRANTY AS TO THE LICENSED PATENTS OR THE
TRANSFERRED ASSETS, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW,
BY STATUTE OR OTHERWISE, AND LILLY SPECIFICALLY DISCLAIMS ANY AND ALL IMPLIED OR
STATUTORY WARRANTIES. Without limiting the foregoing, Versicor acknowledges that
it has not and is not relying upon any implied warranty of merchantability,
fitness for a particular purpose or otherwise, or upon any representation or
warranty whatsoever as to the prospects (financial, regulatory or otherwise), or
the validity or likelihood of success, of the Product after the date of this
Agreement.

         5.11 NO PRIOR LICENSES. Lilly represents and warrants to Versicor that
prior to the Effective Date Lilly has not granted any licenses or
covenants-not-to-sue to Third Parties with respect to the Licensed Patents or
Licensed Technology.

                                    SECTION 6

               ADDITIONAL COVENANTS AND AGREEMENTS OF THE PARTIES

         6.1 GOVERNMENTAL FILINGS. Lilly and Versicor each agree to prepare and
file whatever filings, requests or applications are required to be filed with
any governmental authority in connection with this Agreement and to cooperate
with one another as reasonably necessary to accomplish the foregoing. Without
limiting the generality of the foregoing, prior to the assignment, transfer and
conveyance by Lilly to Versicor of the Transferred Assets pursuant to Section
2.2, Lilly shall have submitted to the relevant regulatory authorities the
information required of a former owner of regulatory filings with

                                      -26-
<PAGE>

respect to the Product, and Versicor shall submit to the relevant regulatory
authorities the information required of a new owner of regulatory filings with
respect to the Product.

         6.2 COMPLIANCE WITH LAW. Versicor shall comply with all federal, state
and local laws and regulations related to Versicor's manufacture, development,
marketing and selling of the Product. Without limiting the generality of the
foregoing sentence, Versicor shall not promote the Product in any manner in
conflict with any applicable laws or regulations.

         6.3 CONFIDENTIALITY. Except as provided elsewhere in this Agreement,
Lilly and Versicor each agree to maintain Confidential Information in confidence
and not use, transfer or disclose such Confidential Information to a third party
without the prior written approval of the other Party, except as is contemplated
by this Agreement, or as is required to be disclosed to recover Damages for a
breach of this Agreement, or as is required to comply with any order of a court
or any applicable rule, regulation, or law of any jurisdiction. In the event
that a Party is required by judicial or administrative process to disclose
Confidential Information of the other Party (except with respect to disclosures
to tax authorities), it shall promptly notify the other Party and allow the
other Party a reasonable time to oppose such process. For disclosures to tax
authorities, no prior notification to the other Party shall be required. The
foregoing obligations shall remain in force until ten (10) years following
termination of this Agreement by either Party, except with respect to trade
secrets for which such obligations shall continue in perpetuity.

         (a) Both Lilly and Versicor shall protect Confidential Information by
         using the same degree of care, but not less than a reasonable degree of
         care, to prevent the unauthorized disclosure or use of Confidential
         Information, as that Party uses to protect its own confidential
         information of like nature.

         (b) Any provision of this Agreement to the contrary notwithstanding,
         both Lilly and Versicor are entitled to disclose Confidential
         Information to the extent reasonably necessary for the purposes of this
         Agreement, to their respective Affiliates and their consultants,
         outside contractors and clinical investigators on the condition that
         such entities agree to be bound by this Agreement with respect to
         nondisclosure and/or non-use of such information.

                                      -27-
<PAGE>

         6.4 PUBLICITY AND DISCLOSURE OF AGREEMENT. Within ten (10) days of the
Effective Date, the Parties shall agree in good faith on a form of press release
which Versicor may release after June 6, 1999. The Parties agree that no future
publicity release or announcement concerning the transactions contemplated
hereby shall be issued without the advance written consent of the other Party to
the extent such release or announcement includes statements concerning terms of
this Agreement and/or explicitly includes either Parties' trademark(s) or
name(s), except to the extent such release or announcement may be required by
law. For releases or announcements required by law, the Party making the release
or announcement shall, before making any such release or announcement, afford
the other Party a reasonable opportunity to review and comment. Any copy of this
to be filed with the Securities and Exchange Commission shall be redacted to the
reasonable satisfaction of both Parties; provided, however, in the event that
the Securities and Exchange Commission objects to the redaction of any portion
of the Agreement after the initial submission, the filing Party shall inform the
other Party of the objections and shall in good faith respond to the objections
in an effort to limit the disclosure required by the Securities and Exchange
Agreement, but in any event the filing Party shall be free to include any
portions of the Agreement it deems necessary to respond to the objections in any
future filings. Further, Versicor shall have the right to disclose the Agreement
in confidence to existing or prospective investors or acquirers and investment
bankers and related financial service providers.

         6.5 USE OF NAMES, LOGOS OR SYMBOLS. No Party hereto shall use the name,
trademarks, logos, physical likeness, employee names or owner symbol of the
other Party hereto for any purpose, including, without limitation, in connection
with any private or public securities placements, without the prior written
consent of the affected Party, such consent not to be unreasonably withheld or
delayed so long as such use of name is limited to objective statements of fact,
rather than for endorsement purposes. Nothing contained herein shall be
construed as granting either Party any rights or license to use any of the other
Party's trademarks or tradenames without separate, express written permission of
the owner of such trademark or tradename.

         6.6 EXPENSES. Lilly and Versicor shall each bear their own direct and
indirect expenses incurred in connection with the negotiation and preparation of
this Agreement and, except as set forth in this Agreement, the performance of
the obligations contemplated hereby.

                                      -28-
<PAGE>

         6.7 EFFORTS. Versicor shall use Reasonable Diligence to develop and
obtain Regulatory Approval in the Territory for both the Intravenous and Oral
Formulations of the Product. On or before January 1,2000, Versicor shall
prepare and submit to Lilly a detailed plan for development of the Oral
Formulation, setting forth a description of the efforts Versicor intends to
make in connection with its Reasonable Diligence obligations for the Oral
Formulation, which plan shall include at least one animal study ("Oral
Formulation Development Plan"). Versicor shall provide Lilly with a
reasonable opportunity to review and comment on the Oral Formulation
Development Plan. Except as otherwise provided in Section 2.7, Versicor shall
be solely responsible for all development efforts and costs associated with
developing and obtaining Regulatory Approval of both the Intravenous and Oral
Formulations of the Product. Lilly and Versicor each hereby agree to use all
reasonable efforts to take, or cause to be taken, all actions and to do, or
cause to be done, all things necessary or proper to make effective the
transactions contemplated by this Agreement, including such actions as may be
reasonably necessary to obtain approvals and consents of governmental Persons
and other Persons (including, without limitation, all applicable drug listing
and notifications to the relevant regulatory authorities identifying Versicor
as a licensee of the Product); PROVIDED that no Party shall be required in
connection with such activities to (1) make any payments (other than as
expressly required pursuant to this Agreement), or (2) assume any other
material obligation not otherwise required to be assumed by this Agreement.
In the event Versicor or its sublicensees fail to undertake Reasonable
Diligence in developing and/or obtaining Regulatory Approval of the
Intravenous Formulation and/or the Oral Formulation of the Product in a
particular country in the Territory, such failure shall be considered a
material default of this Agreement for which Lilly shall be entitled to
terminate this Agreement under Section 9.1 (b) solely with respect to such
particular country and only as to the affected formulation (I.E., IV or oral)
(but may not terminate the entire Agreement under Section 9.1 (d) for any
such default), PROVIDED THAT Versicor (or its sublicensee) does not cure such
failure within sixty (60) days of written notice from Lilly specifying its
belief that such failure has occurred and the reasons therefor. However,
Lilly shall not be entitled to exercise the foregoing termination rights if
Versicor reasonably disputes Lilly's contention that Versicor has failed in
such Reasonable Diligence until after the Parties have first pursued dispute
resolution discussions and procedures as required under Section 10.14 with
respect to such dispute. In the event of an uncured default by Versicor of
its obligations to use Reasonable Diligence for the Oral Formulation prior to
first human dose on an Oral Formulation, Lilly shall be entitled to terminate
Versicor's license under Section 2.1 (a) in the Territory only with respect
to the Oral Formulation, after first

                                      -29-
<PAGE>

pursuing dispute resolution discussions and procedures as required under Section
10.14 (if Versicor disputes Lilly's claim that Versicor defaulted on such
obligation), and Versicor shall, and hereby does, grant to Lilly the license
described in Section 2. l(c) with respect to such Oral Formulation.

         6.8 COOPERATION. If either Party shall become engaged in or participate
in any investigation, claim, litigation, interference or other proceeding with
any third party, including any proceeding before a relevant regulatory
authority, relating in any way to the Product or any of the Licensed Patents the
other Party shall cooperate in all reasonable respects with such Party in
connection therewith, including, without limitation, using its reasonable
efforts to make available to the other Party such party's employees who may be
helpful with respect to such investigation, claim, litigation, interference or
other proceeding, provided that, for purposes of this provision, reasonable
efforts to make available any employee shall be deemed to mean providing a Party
with reasonable access to any such employee at no cost for a period of time not
to exceed 24 hours (e.g., three 8-hour business days). Thereafter, any such
employee shall be made available for such time and upon such terms and
conditions (including, but not limited to, compensation) as the Parties may
mutually agree.

         6.9 CONFLICTING RIGHTS. Lilly shall not grant any right to any third
party relating to the Licensed Patents or Licensed Technology that would violate
the terms of or conflict with the rights granted to Versicor pursuant to this
Agreement.

         6.10 MANUFACTURING. After the Effective Date, Versicor shall be solely
responsible for the manufacture of the Product, including without limitation for
clinical trials and commercialization. In the event Lilly exercises the Lilly
Development Option, Lilly shall assume manufacturing responsibilities for the
Oral Formulation.

         6.11 DEEMED BREACH OF COVENANT. Neither Lilly nor Versicor shall be
deemed to be in breach of any covenant contained in this Section 6 if such
Party's deemed breach is the result of any action or inaction on the part of the
other Party.

                                      -30-
<PAGE>

                                    SECTION 7

                        INTELLECTUAL PROPERTY MANAGEMENT

          7.1 PATENT PROSECUTION AND MAINTENANCE. Except to the extent otherwise
agreed by the Parties pursuant to subsection (f) and Section 7.3 below, Versicor
shall be responsible for the preparation, filing, prosecution and maintenance of
the Licensed Patents including all payment obligations and shall on an ongoing
basis promptly furnish copies of all related documents to Lilly within thirty
(30) days of receipt or deposition.

                  a) Versicor shall, subject to the prior approval of Lilly (not
         to be unreasonably withheld), select registered patent attorneys or
         patent agents to provide services for preparing, filing, prosecuting
         and maintaining the Licensed Patents on behalf of Versicor and Lilly.
         Versicor shall directly pay such attorneys or agents and provide Lilly
         copies of each invoice associated with such services, as well as
         documentation that such invoices have been paid.

                  b) Lilly shall provide appropriate powers of attorney and
        other documents necessary to undertake such actions to the patent
        attorneys or patent agents providing such services.

                  c) Versicor and its attorneys or agents shall consult with
        Lilly in all aspects of the preparation, filing, prosecution and
        maintenance of the Licensed Patents and shall provide Lilly sufficient
        opportunity to comment on any document that Versicor intends to file or
        to cause to be filed with the relevant intellectual property or patent
        office.

                  d) Each Party shall promptly inform the other as to all
        matters that come to its attention that may affect the preparation,
        filing, prosecution, or maintenance of the Licensed Patents and permit
        each other to provide comments and suggestions with respect to such
        activities, which comments and suggestions shall be reasonably
        considered by the other Party.

                  e) Upon receipt of approval to market Product in a country of
         a Territory, Lilly shall provide assistance to Versicor in obtaining
         patent extensions, supplementary protection certificates, and the like
         for the Licensed Patents to the

                                      -31-
<PAGE>

         extent the laws of the country provide it. It is understood that
         Versicor is responsible for promptly notifying Lilly of receipt of
         Regulatory Approval. Versicor shall provide Lilly with at least sixty
         (60) days prior written notice before surrendering or abandoning any
         Licensed Patent in any country of the Territory.

                  f) Except with respect to those patents and patent
        applications listed on List A-1 ("core patents and patent applications")
        in EXHIBIT A that are filed in a country in the Major Market Countries,
        upon ninety (90) days written notice to Lilly, Versicor may elect to
        surrender its rights under any particular Licensed Patent in any country
        in the Territory and owe no payment or other obligation under this
        section for patent-related expenses incurred in that country as to such
        Licensed Patent as of the effective date of such written notice. To the
        extent that Lilly desires to continue maintenance and/or prosecution of
        such Licensed Patents in such countries which Versicor has elected to
        surrender rights, Versicor shall cooperate fully with Lilly, its
        attorneys, and agents in assuming such responsibilities and provide
        Lilly with complete copies of any and all documents or other materials
        that Lilly deems necessary to undertake such responsibilities.

         7.2 RIGHT TO RECLAIM PATENT MANAGEMENT RESPONSIBILITIES. In the event
that Lilly exercises the Lilly Development Option, Lilly may provide Versicor
with written notice that Lilly wishes to assume control as of a certain date of
the preparation, filing, prosecution and maintenance of any or all patent
applications and patents ("Selected Patents") included in the Licensed Patents.

                  a) If Lilly elects to assume responsibilities for Selected
         Patents, Versicor agrees to cooperate fully with Lilly, its attorneys,
         and agents in the preparation, filing, prosecution and maintenance
         related to the Selected Patents and, upon request, to provide Lilly
         with complete copies of any and all documents or other materials that
         Lilly deems necessary to undertake such responsibilities. Lilly shall
         assume responsibility for all costs associated with the Selected
         Patents, including costs associated with transferring patent
         prosecution responsibilities to an attorney or agent of Lilly's choice,
         as of the date specified by Lilly in its election notice.

                  b) Lilly and its attorneys or agents shall consult with
         Versicor in all aspects of the preparation, filing, prosecution and
         maintenance of the Selected

                                      -32-
<PAGE>

         Patents and shall provide Versicor sufficient opportunity to comment on
         any document related thereto that Lilly intends to file or to cause to
         be filed with the relevant intellectual property or patent office.

                  c) Each Party shall promptly inform the other as to all
         matters that come to its attention that may affect the preparation,
         filing, prosecution, or maintenance of the Selected Patents and permit
         each other to provide comments and suggestions with respect to such
         activities, which comments and suggestions shall be reasonably
         considered by the other Party.

                  d) Lilly shall provide ninety (90) days prior written notice
         to Versicor prior to any abandonment or surrender of rights by Lilly
         related to any or all of the Selected Patents, and Versicor shall have
         the right to notify Lilly of its election as of a certain date during
         such ninety (90) day period to resume responsibilities for such
         Selected Patents. If Versicor elects to resume responsibility of any or
         all of such Selected Patents, Lilly shall cooperate fully with
         Versicor, its attorneys, and agents in assuming the responsibilities of
         such related patent applications and patents and to provide Versicor
         with complete copies of any and all documents or other materials that
         Versicor deems necessary to undertake such responsibilities. Versicor
         shall assume responsibility for all costs associated with the Selected
         Patents for which it elects to resume responsibility under this
         subsection (d), including costs associated with transferring patent
         prosecution responsibilities to an attorney or agent of Versicor's
         choice, as of the date specified by Versicor in its election notice.

         7.3      INFRINGEMENT AND MISAPPROPRIATION.

                  (a) NOTICE. Each Party shall promptly notify the other in
writing of any alleged infringement or misappropriation by third parties of any
Licensed Patent or Licensed Technology and provide any information available to
that Party relating to such alleged infringement or misappropriation.

                  (b) ENFORCEMENT OF LICENSED PATENTS. Versicor shall have the
primary right, but not the obligation, to take action in its own name to secure
the cessation of any infringement or misappropriation or to enter suit against
the infringer. Any such action will be at Versicor's expense, employing counsel
of its own choosing. If Versicor elects

                                      -33-
<PAGE>

not to exercise its right to prosecute or take other appropriate action in
connection with an infringement or misappropriation of the Licensed Patents or
fails to take any such action within sixty (60) days of first receiving of such
infringement or misappropriation, Lilly may do so at its own expense,
controlling such action. In the event of any infringement or misappropriation
suit against a third party brought by either Party pursuant to this Section, the
Party so proceeding shall pay to the other Party all of its costs and expenses
(but not attorney's fees) in connection with such action and such other Party
shall join in and reasonably cooperate with respect to such action to the extent
necessary to initiate and maintain it (e.g., by providing relevant documents,
witnesses and testimony, etc.).

                  (c) ALLOCATION OF DAMAGES OR OTHER MONETARY AWARDS. If
Versicor brings action, any Damages or other monetary awards recovered by
Versicor shall be applied proportionately first to defray the unreimbursed costs
and expenses (including reasonable attorneys' fees) incurred by either or both
Parties in the action. If any balance remains, Versicor shall second pay to
Lilly an amount equal to the royalty that Lilly would otherwise be entitled to
under this Agreement if such remaining balance was treated as Net Sales. If any
balance remains after payment to Lilly, such balance shall be the property of
Versicor. If Versicor fails to bring action and Lilly brings action, any Damages
or other monetary awards recovered by Lilly shall be applied first to defray the
costs and expenses (including reasonable attorneys' fees) incurred in the action
by either or both of the Parties. If any balance remains, Lilly shall second
retain as its own property an amount equal to the royalty that Lilly would
otherwise be entitled to under this Agreement if such remaining balance was
treated as Net Sales. If any balance remains, such balance shall be the property
of Versicor.

                  (d) SETTLEMENT PROCEDURES. No settlement, consent judgment or
other voluntary final disposition of a suit being prosecuted by a Party under
this Section 7.3 may be entered into without the consent of the other Party if
such settlement, consent judgment or other voluntary final disposition would
alter, derogate or diminish such other Party's rights under the Agreement or
otherwise materially adversely affect such other Party, which consent shall not
be unreasonably withheld or delayed.

                                   SECTION 8

                                 INDEMNIFICATION

         8.1      INDEMNIFICATION.

                                      -34-
<PAGE>

               (a) Lilly shall indemnify, defend and hold Versicor (and its
directors, officers, employees, and Affiliates) harmless from and against any
and all Damages incurred or suffered by Versicor (and its directors,
officers, employees, and Affiliates) (excluding incidental or consequential
Damages suffered or incurred by Versicor directly (as opposed to incidental
or consequential Damages suffered or incurred by third parties who are, in
turn, seeking the same from Versicor, which shall be covered by the indemnity
set forth herein)) as a consequence of third party claims or actions based
upon:

                    (1) any breach of any representation or warranty made by
Lilly in this Agreement;

                    (2) any failure to perform duly and punctually any covenant,
agreement or undertaking on the part of Lilly contained in this Agreement;

                    (3) any Excluded Liabilities.

               (b) Versicor shall indemnify, defend and hold Lilly (and its
directors, officers, employees, and Affiliates) harmless from and against any
and all Damages incurred or suffered by Lilly (and its directors, officers,
employees, and Affiliates) (excluding incidental or consequential Damages
suffered or incurred by Lilly directly (as opposed to incidental or
consequential Damages suffered or incurred by third parties who are, in turn,
seeking the same from Lilly, which shall be covered by the indemnity set
forth herein)) as a consequence of third party claims or actions based on:

                    (1) any breach of any representation or warranty made by
Versicor in this Agreement;

                    (2) any failure to perform duly and punctually any covenant,
agreement or undertaking on the part of Versicor contained in this Agreement;

                    (3) and the Versicor Responsibilities, including; any action
or inaction by Versicor (and its agents, directors, officers, employees,
Affiliates and sublicensees) related to the making, using, selling, offering to
sell, or importing of the Product or Transferred Assets after the Effective
Date, except to the extent such action or inaction is caused by the misconduct
or negligence of Lilly.

                                      -35-
<PAGE>

         8.2 NOTICE AND OPPORTUNITY TO DEFEND. Promptly after receipt by a Party
hereto of notice of any claim which could give rise to a right to
indemnification pursuant to Section 8.1, such Party (the "Indemnified Party")
shall give the other Party (the "Indemnifying Party") written notice describing
the claim in reasonable detail. The failure of an Indemnified Party to give
notice in the manner provided herein shall not relieve the Indemnifying Party of
its obligations under this Section, except to the extent that such failure to
give notice materially prejudices the Indemnifying Party's ability to defend
such claim. The Indemnifying Party shall have the right, at its option, either
to compromise or defend, at its own expense and by its own counsel, any such
matter involving the asserted liability of the Party seeking such
indemnification, except as provided below. The Indemnifying Party shall promptly
(and in any event not less than twenty (20) days after receipt of the
Indemnified Party's original notice) notify the Indemnified Party in writing of
its intention to either compromise or defend such matter, and the Indemnified
Party agrees to cooperate fully with the Indemnifying Party and its counsel in
the compromise or defense against any such asserted liability. All reasonable
costs and expenses incurred in connection with such cooperation shall be borne
by the Indemnifying Party. If the Indemnifying Party elects in writing not to
compromise or defend the asserted liability, fails to notify the Indemnified
Party of its election to compromise or defend as herein provided, fails to admit
its obligation to indemnify under this Agreement with respect to the claim
following a written request of the Indemnified Party (except in the case where
the Indemnifying Party denies, on reasonable grounds, that it has such an
obligation (which dispute shall be resolved under Section 10.14)), or, if in the
reasonable opinion of counsel to the Indemnified Party, the claim could result
in the Indemnified Party becoming subject to injunctive relief or relief other
than the payment of money Damages that could materially adversely affect the
ongoing business of the Indemnified Party in any manner, the Indemnified Party
shall have the right, at its option, to pay, compromise or defend such asserted
liability by its own counsel and its reasonable costs and expenses shall be
included as part of the indemnification obligation of the Indemnifying Party
hereunder; provided, however, in the event the Indemnifying Party intends to
compromise or settle a claim under this Section 8.2, the Indemnifying Party
shall provide at least ten (10) business days prior written notice to the
Indemnified Party describing the proposed compromise or settlement in order that
the Indemnified Party may comment and/or object. Notwithstanding the foregoing,
neither the Indemnifying Party nor the Indemnified Party may settle or
compromise any claim under this Section 8.2 over the written objection of the
other Party if such settlement or compromise could reasonably result in a
material adverse effect on the other Party or otherwise alter, diminish or
derogate the other Party's

                                      -36-
<PAGE>

rights under this Agreement. In any event, the Indemnified Party and the
Indemnifying Party may participate, at their own expense, in the defense of such
asserted liability. If the Indemnifying Party defends any claim, the Indemnified
Party shall make available to the Indemnifying Party any books, records or other
documents within its control that are necessary or appropriate for such defense.
Notwithstanding anything to the contrary in this Section 8.2, (1) the Party
conducting the defense of a claim shall (A) keep the other Party informed on a
reasonable and timely basis as to the status of the defense of such claim (but
only to the extent such other Party is not participating jointly in the defense
of such claim), and (B) conduct the defense of such claim in a prudent manner,
and (2) the Indemnifying Party shall not cease to defend any claim (except
pursuant to a permitted settlement or compromise thereof) without the prior
written consent of the Indemnified Party (which consent shall not be
unreasonably withheld).

         8.3 INDEMNIFICATION PAYMENT OBLIGATION. No Indemnifying Party will have
any obligations under Sections 8.1(a) or 8.1(b) until the cumulative aggregate
amount of Damages incurred or suffered by the Indemnified Party (or which likely
would be incurred or suffered if the relevant claim were successful) which the
Indemnifying Party is otherwise subject to under this Agreement exceeds
$100,000, at which time the entire cumulative aggregate amount of such Damages
shall be covered. The provisions of this Section 8.3 shall not limit or
otherwise affect the obligations of any Indemnifying Party under any other
Section of this Agreement.

         8.4 INDEMNIFICATION PAYMENT ADJUSTMENTS. The amount of any Damages for
which indemnification is provided under this Section 8 shall be reduced to take
account of any net tax benefit and shall be increased to take account of any net
tax detriment arising from the incurrence or payment of any such Damages or from
the receipt of any such indemnification payment and shall be reduced by the
insurance proceeds received and any other amount recovered, if any, by the
Indemnified Party with respect to any Damages; provided, however, that an
Indemnified Party shall not be subject to an obligation to pursue an insurance
claim relating to any Damages for which indemnification is sought hereunder. If
any Indemnified Party shall have received any payment pursuant to this Section 8
with respect to any Damages and shall subsequently have received insurance
proceeds or other amounts with respect to such Damages, then such Indemnified
Party shall pay to the Indemnifying Party an amount equal to the difference (if
any) between (1) the sum of the amount of those insurance proceeds or other
amounts received and the amount of the payment by such Indemnifying Party
pursuant to this Section 8 with respect

                                      -37-
<PAGE>

to such Damages and (2) the amount necessary to fully and completely indemnify
and hold harmless such Indemnified Party from and against such Damages;
PROVIDED, HOWEVER, in no event will such Indemnified Party have any obligation
pursuant to this sentence to pay to such Indemnifying Party an amount greater
than the amount of the payment by such Indemnifying Party pursuant to this
Section 8 with respect to such Damages.

         8.5 INDEMNIFICATION PAYMENT. Upon the final determination of liability
and the amount of the indemnification payment under this Section 8, the
appropriate Party shall pay to the other in immediately available funds, within
thirty (30) business days after such determination, the amount of any claim for
indemnification made hereunder.

         8.6 SURVIVAL. The provisions of this Section 8 shall survive any
termination of this Agreement with respect to actions of the Parties during the
term of this Agreement. Each Indemnified Party's rights under this Section 8
shall not be deemed to have been waived or otherwise affected by such
Indemnified Party's waiver of the breach of any representation, warranty,
agreement or covenant contained in or made pursuant this Agreement, unless such
waiver expressly and in writing also waives any or all of the Indemnified
Party's right under this Section 8.

                                   SECTION 9

                                   TERMINATION

         9.1 TERMINATION. Anything herein to the contrary notwithstanding, this
Agreement may be terminated as follows:

                    (a) VERSICOR VOLUNTARY TERMINATION. Versicor may terminate
this Agreement at any time by giving ninety (90) days written notice of its
intention to terminate.

                    (b) LILLY TERMINATION FOR CAUSE. Lilly may terminate this
Agreement solely with respect to a particular country and as to the applicable
formulation (I.E., IV or oral) for Versicor's uncured breach of its obligations
of Reasonable Diligence in such country with respect to such formulation of the
Product as provided in Section 6.7.

                                      -38-
<PAGE>

                  (c) TERMINATION FOR BANKRUPTCY. If either Versicor or
Lilly (1) makes a general assignment for the benefit of creditors; (2) files
an insolvency petition in bankruptcy; (3) petitions for or acquiesces in the
appointment of any receiver, trustee or similar officer to liquidate or
conserve its business or any substantial part of its assets; (4) commences
under the laws of any jurisdiction any proceeding involving its insolvency,
bankruptcy, reorganization, adjustment of debt, dissolution, liquidation or
any other similar proceeding for the release of financially distressed
debtors; or (5) becomes a Party to any proceeding or action of the type
described above in (3) or (4) and such proceeding or action remains
undismissed or unstayed for a period of more than sixty (60) days, then the
other Party may by written notice terminate this Agreement in its entirety
with immediate effect.

                  (d) TERMINATION FOR DEFAULT.

                  (1) Versicor and Lilly each shall have the right (except as
otherwise provided in Section 6.7) to terminate this Agreement with respect
to the Product for default upon the other Party's uncured failure to comply
in any material respect with the terms and conditions of this Agreement. At
least sixty (60) days prior to any such termination for default, the Party
seeking to so terminate shall give the other written notice of its intention
to terminate this Agreement in accordance with the provisions of this Section
9.1(d), which notice shall set forth the default(s) which form the basis for
such termination. If the defaulting Party fails to correct such default(s)
within sixty (60) days after receipt of notification, or if the same cannot
reasonably be corrected or remedied within sixty (60) days, then if the
defaulting Party has not commenced curing said default(s) within said sixty
(60) days and is not diligently pursuing completion of same, then such Party
immediately may terminate this Agreement with respect to such Product.

                  (2) This Section 9.1 (d) shall not be an exclusive remedy
and shall not be in lieu of any other remedies available to a Party hereto for
any default hereunder on the part of the other Party.

                  (e) RIGHTS UPON TERMINATION.

                  (1) LILLY RIGHTS UPON TERMINATION. In the event of
termination of the entire Agreement by Lilly under Sections 9.1(b) or 9.1(d)
or termination by

                                      -39-
<PAGE>

Versicor under Section 9.1(a), payment by Versicor to Lilly of all amounts
actually earned and accrued by Lilly but remaining unpaid as of the effective
date of such termination shall be immediately accelerated and all such amounts
shall be immediately due and payable by Versicor to Lilly on the date of
termination. Additionally, the license granted by Lilly to Versicor shall
immediately terminate and the ownership of the Product Data Package shall
immediately revert back to Lilly with no further notice required on Lilly's
behalf. Consequently, notwithstanding anything else contained in this Agreement
to the contrary, (A) Lilly shall have the right, directly or indirectly, to
make, use, sell, offer to sell and import the Product in the Territory and (B)
Versicor shall have no further rights in the Product whatsoever.

                    (2) VERSICOR RIGHTS UPON TERMINATION UPON DEFAULT BY LILLY.
In the event of termination of this Agreement by Versicor under Section 9.1(d),
Versicor shall (A) have no further obligation to make any payments under
Sections 3.2 and 3.3 of the Agreement as of the effective date of the
termination, and (B) retain all of the rights under the licenses granted by
Lilly to Versicor hereunder with respect to the Product.

                    (3) ASSISTANCE FOLLOWING TERMINATION. In the event of
termination of this Agreement pursuant to Section 9.1(b), 9.1(c) or 9.1(d)
and if Lilly so requests, Versicor shall provide reasonable assistance to
Lilly for a period of ninety (90) days following the date of notice of
termination. Additionally, Versicor shall (and shall cause any subcontractors
under contract with Versicor) grant to Lilly an exclusive license (but solely
in the country or countries where such termination occurred) to all Versicor
Improvements related to Product, including but not limited to, all applicable
regulatory files and filings related to the Product and any patents or patent
applications encompassing Versicor Improvements, solely to develop, make,
have made, use, sell, offer to sell and import the Product in such countries.

                  (f) CONTINUING OBLIGATIONS. Except as otherwise provided
above, termination of this Agreement for any reason shall not relieve the
Parties of any obligation accruing prior thereto and shall be without
prejudice to the rights and remedies of either Party with respect to any
antecedent breach of the provisions of this Agreement. Without limiting the
generality of the foregoing, no termination of this Agreement, whether by
lapse of time or otherwise, shall serve to terminate the obligations of the
Parties hereto under Sections 2.1(b), 3.4, 3.5 (only in the event Versicor
terminates under Section 9.1(d)), 3.6, 3.7, 6.3, 6.4, 6.5, 7.1 (only in the
event Versicor terminates under Section

                                      -40-
<PAGE>

9.1(d), 7.2 (only in the event Versicor terminates under Section 9.1(d)), all
of Section 8, subsections 9.1, 9.2, all of Section 10 and such other Sections
as by their nature should survive, and such obligations shall survive any
such termination.

         9.2 BIOLOGICAL MATERIAL. Upon termination of this Agreement, whether by
Lilly or Versicor, Versicor shall cease all use of any Biological Materials and
shall, upon request, return or destroy (at Lilly's option) all Biological
Materials under its control or in its possession within sixty (60) days and
provide a written warranty by an Officer of Versicor that the Biological
Materials have been returned or destroyed.

                                   SECTION 10

                                  MISCELLANEOUS

         10.1 SUCCESSORS AND ASSIGNS. This Agreement shall be binding upon and
shall inure to the benefit of the Parties hereto and their respective successors
and assigns. No assignment of this Agreement or Of any rights hereunder shall
relieve the assigning Party of any of its obligations or liability hereunder. In
the event Versicor assigns this Agreement to a third party or a third party
acquires substantially all of the assets or greater than forty percent (40%)
outstanding shares of, or merges with, Versicor ("Change of Control"), as the
case may be, Lilly shall have the right, in its sole discretion, to terminate
the Versicor Co-Promotion Right in Section 2.7(g). Notwithstanding the
foregoing, Lilly may assign its rights and obligations under this Agreement to
an Affiliate.

         10.2 NOTICES. All notices or other communications required or permitted
to be given hereunder shall be in writing and shall be deemed to have been duly
given if delivered by hand, facsimile and confirmed in writing or mailed first
class, postage prepaid, by registered or certified mail, return receipt
requested (mailed notices shall be deemed to have been given three (3) days
after mailing; notices sent by facsimile and confirmed in writing shall be
deemed given on the date sent) as follows:

         If to Lilly, as follows:

              Eli Lilly and Company
              Lilly Corporate Center
              Indianapolis, Indiana 46285
              Facsimile: (317) 276-6221
              Attn: General Counsel

         If to Versicor, as follows:

                                      -41-
<PAGE>

                  Versicor Inc.
                  Two Corporate Drive
                  South San Francisco, California 94080
                  Facsimile: (650) 829-4303
                  Attn: Chief Executive Officer

or in any case to such other address or addresses as hereafter shall be
furnished as provided in this Section 10.2 by any Party hereto to the other
Party.

         10.3 WAIVER; REMEDIES. Any term or provision of this Agreement may be
waived at any time by the Party entitled to the benefit thereof by a written
instrument executed by such Party. No delay on the part of Lilly or Versicor in
exercising any right, power or privilege hereunder shall operate as a waiver
thereof, nor shall any waiver on the part of either Lilly or Versicor of any
right, power or privilege hereunder operate as a waiver of any other right,
power or privilege hereunder nor shall any single or partial exercise of any
right, power or privilege hereunder preclude any other or further exercise
thereof or the exercise of any other right, power or privilege hereunder. The
indemnification provided in Section 8 shall be the sole remedy available for any
Damages arising out of or in connection with this Agreement except for any
rights or remedies which the Parties hereto may otherwise have in equity.

         10.4 ENTIRE AGREEMENT. This Agreement constitutes the entire agreement
between the Parties with respect to the subject matter hereof and supersedes all
prior communications, agreements or understandings, written or oral, of the
Parties relating thereto.

         10.5 AMENDMENT. This Agreement may be modified or amended only by
written agreement of the Parties hereto.

         10.6 COUNTERPARTS. This Agreement may be executed in any number of
counterparts, each of which shall be deemed an original but all of which
together shall constitute a single instrument.

         10.7 GOVERNING LAW. This Agreement shall be governed and construed in
accordance with the laws of the State of Indiana, excluding any choice of law
rules that may direct the application of the law of another state.

                                      -42-
<PAGE>

         10.8 CAPTIONS. All section titles or captions contained in this
Agreement, in any Exhibit referred to herein and the table of contents, if any,
to this Agreement are for convenience only, shall not be deemed a part of this
Agreement and shall not affect the meaning or interpretation of this Agreement.

         10.9 NO THIRD PARTY RIGHTS OR OBLIGATIONS. No provision of this
Agreement shall be deemed or construed in any way to result in the creation of
any rights or obligation in any Person not a Party to this Agreement.

         10.10 SEVERABILITY. If any provision of this Agreement is found or
declared to be invalid or unenforceable by any court or other competent
authority having jurisdiction, such finding or declaration shall not invalidate
any other provision hereof, and this Agreement shall thereafter continue in full
force and effect.

         10.11 ATTACHMENTS. All Exhibits and other attachments to this Agreement
are by this reference incorporated herein and made a part of this Agreement.

         10.12 DISCLAIMER OF AGENCY. This Agreement shall not constitute any
Party the legal representative or agent of another, nor shall any Party have the
right or authority to assume, create, or incur any third party liability or
obligation of any kind, express or implied, against or in the name of or on
behalf of another except as expressly set forth in this Agreement.

         10.13 INTERPRETATION. This Agreement has been jointly prepared by the
Parties and their respective legal counsel and shall not be strictly construed
against either Party.

         10.14 DISPUTE RESOLUTION. In the event of any dispute relating to this
Agreement, prior to instituting any lawsuit, arbitration or other dispute
resolution process on account of such dispute, the Parties shall attempt in good
faith to settle such dispute first by negotiation and consultation between
themselves, including referral of such dispute to the Chief Executive Officer of
Versicor and Group Vice President of Lilly Research Laboratories. In the event
said executives are unable to resolve such dispute or agree upon a mechanism to
resolve such dispute within sixty (60) days of the first written request for
dispute resolution under this Section 10.14, the Parties shall then consider
other forms of alternative dispute resolution as a means of resolving any such
dispute. Thereafter, either Party shall be free to institute litigation and seek
such remedies as may be available.

                                      -43-
<PAGE>

Notwithstanding anything in this Agreement to the contrary, either Party shall
be entitled to institute litigation immediately if the same shall be necessary
to prevent irreparable harm to either Party.

         IN WITNESS WHEREOF, the parties have caused this Agreement to be duly
executed and delivered on the day and year first above written.

ELI LILLY AND COMPANY                       VERSICOR, INC.

By:      /s/ August M. Watanabe             By:    /s/ George E. Horner III
    ---------------------------------           ------------------------------
         August M. Watanabe, M.D                     George E. Horner III
         Executive Vice President                    President and CEO

Versicor/License Agreement

                                      -44-
<PAGE>

                                    EXHIBIT A

LIST A-1 ("CORE PATENTS AND PATENT APPLICATIONS")

                            PENDING U.S. APPLICATIONS

<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------------
              TITLE                       U.S.           FILING DATE       FIRST NAMED INVENTOR
                                      APPLICATION #

-----------------------------------------------------------------------------------------------------
<S>                                   <C>                <C>           <C>
 Cyclic Peptide Antifungal Agents       08/449056         5/24/1995    Burkhardt, Frederick J.
         and Process for
       Preparation Thereof
-----------------------------------------------------------------------------------------------------
    Cyclic Peptide Antifungal           09/291900         4/14/1999    Burkhardt, Frederick J.
      Agents and Process for
       Preparation Thereof
-----------------------------------------------------------------------------------------------------
        Echinocandin/Carbo-             60/122692          3/3/1999    Larew, Larry A.
        hydrate Complexes
-----------------------------------------------------------------------------------------------------
           Echinocandin                 60/122623          3/3/1999    Milton, Nathaniel
          Pharmaceutical
     Formulations Containing
         Micelle-Forming
           Surfactants
-----------------------------------------------------------------------------------------------------
       Processes for Making             60/122693          3/3/1999    Schwier, John R.
     Pharmaceutical Oral ECB
         Formulations and
           Compositions
-----------------------------------------------------------------------------------------------------
 Formation and Anion-Exchange of        60/123073          3/3/1999    Dalder, Brian W.
           Crystalline
      Echinocandin Ammonium
              Salts
-----------------------------------------------------------------------------------------------------
</TABLE>

                                       1
<PAGE>

                                    EXHIBIT A

LIST A-2 ("NON-CORE PATENTS AND PATENT APPLICATIONS")

                                 ISSUED PATENTS
<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------------------
                                                              DATE OF
               TITLE                     PATENT #             ISSUANCE      FIRST NAMED INVENTOR
-----------------------------------------------------------------------------------------------------------
<S>                                    <C>                    <C>           <C>
     Derivatives of S31794/F-1         US 4,287,120           9/1/1981      Abbott, Bernard J.
              Nucleus
-----------------------------------------------------------------------------------------------------------
    Method of Producing the A-         US 4,288,549           9/8/1981      Boeck, LaVerne D.
         30912 Antibiotics
-----------------------------------------------------------------------------------------------------------
      Derivatives of A-30912B          US 5,293,488          10/6/1981      Debono, Manuel
              Nucleus
-----------------------------------------------------------------------------------------------------------
      Derivatives of A-30912A          US 4,293,489          10/6/1981      Debono, Manuel
              Nucleus
-----------------------------------------------------------------------------------------------------------
        A-30912B Nucleus &             US 4,299,763          11/10/1981     Abbott, Bernard J.
        Deacylation Process
-----------------------------------------------------------------------------------------------------------
  Derivatives of A-30912D Nucleus      US 4,320,053          3/16/1982      Abbott, Bernard J.
-----------------------------------------------------------------------------------------------------------
      Derivatives of A-30912B          US 4,322,338          3/10/1982      Abbott, Bernard J.
              Nucleus
-----------------------------------------------------------------------------------------------------------
      Process for Purifying            US 5,573,936         11/12/1996      Kreuzman, Adam J.
     Echinocandin B Deacylase
-----------------------------------------------------------------------------------------------------------
     Cyclic Peptide Antifungal         US 5,629,289          5/13/1997      Rodriguez, Micahel J.
              Agents
-----------------------------------------------------------------------------------------------------------
     Cyclic Peptide Antifungal         US 5,652,213          7/29/1997      Jamison, James A.
              Agents
-----------------------------------------------------------------------------------------------------------
     Cyclic Peptide Antifungal         US 5,629,290          5/13/1997      Lagrandeur, Lisa A.
              Agents
-----------------------------------------------------------------------------------------------------------
     Cyclic Peptide Antifungal         US 5,786,325          7/28/1998      Borromeo, Peter S.
       Agents and Methods of
         Making and Using
-----------------------------------------------------------------------------------------------------------
 Cyclic Peptide Antifungal Agents      US 5,693,611          12/2/1997      Henle, Stacy K.
-----------------------------------------------------------------------------------------------------------
 Cyclic Peptide Antifungal Agents      US 5,618,787           4/8/1997      Jamison, James A.
-----------------------------------------------------------------------------------------------------------
     Cyclic Peptide Antifungal         US 5,646,111           7/8/1997      Borromeo, Peter S.
              Agents
-----------------------------------------------------------------------------------------------------------
 Method For Treating Pneumocysits  South African Patent      11/25/1992     Current, William L.
                                          91-1447
-----------------------------------------------------------------------------------------------------------
</TABLE>

                                       2

<PAGE>

                                    EXHIBIT A

LIST A-2 (CONTINUED)

                            PENDING U.S. APPLICATIONS

<TABLE>
<CAPTION>
----------------------------------------------------------------------------------------------------
             TITLE                       U.S.            FILING DATE   FIRST NAMED INVENTOR
                                    APPLICATION #

----------------------------------------------------------------------------------------------------
<S>                                 <C>                   <C>          <C>
   Cyclic Peptide Antifungal          08/032228           3/17/1993    Burkhardt, Frederick J.
    Agents and Process for
      Preparation Thereof
----------------------------------------------------------------------------------------------------
   Cyclic Peptide Antifungal          08/873480           6/12/1997    Burkhardt, Frederick J.
    Agents and Process for
      Preparation Thereof                                              .
----------------------------------------------------------------------------------------------------
   Cyclic Peptide Antifungal          09/129062            8/4/1998    Grutsch, John L., Jr
            Agents
----------------------------------------------------------------------------------------------------
   Cyclic Peptide Antifungal          09/245572            2/5/1999    Jamison, James A.
            Agents
----------------------------------------------------------------------------------------------------
     Echinocandin Binding             09/217272           12/21/1998   Ma, Doreen
   Domain of 1,3-Bta-Glucan
           Synthase
----------------------------------------------------------------------------------------------------
      Reversible Boronate             60/098267           8/28/1998    Moser, Brian A.
   Complexes of 1,2-C/S Diol
        Cyclic Peptides
----------------------------------------------------------------------------------------------------
 Ring Modified Cyclic Peptide         60/097228           8/20/1998    Borromeo, Peter S.
            Analogs
----------------------------------------------------------------------------------------------------
Cyclic Peptide Antifungal Agent       60/112434           12/16/1998   Rodriguez, Micahel J.
----------------------------------------------------------------------------------------------------
   Cyclic Peptide Antifungal          60/112433           12/16/1998   Rodriguez, Micahel J.
            Agents
----------------------------------------------------------------------------------------------------
        Purification of               60/111524           12/9/1998    Kroeff, Eugene P.
   Echinocandin Cyclopeptide
           Compounds
----------------------------------------------------------------------------------------------------
   Photochemical Process for          60/105936           10/28/1998   Hitchcock, Stephen A.
     Making 1-Deoxy-2-Keto
          Derivatives
----------------------------------------------------------------------------------------------------
</TABLE>

                                       3

<PAGE>

                        EXHIBIT C - PRODUCT DATA PACKAGE

REGULATORY

1.   United States investigational new drug application (IND) #51,111, dated
     July 15, 1996;
2.   United States IND #54,597, dated November 20, 1997;
3.   Spain CTA #PEI97-06 dated August 17, 1998;
4.   Canada IND ##044571, 056065 and 056082, approved September 25, 1996, June
     16, 1998, June 16, 1998, respectively;
5.   Japan IND # 10-2469, dated August 3, 1998;
6.   Equivalent filings, authorizations and/or applications in the countries of
     France, United Kingdom CTX 6/350/A #61292; Italy, Belgium, Finland (KLN nro
     130/98), Germany (4013536), Argentina (2345/98)and Brazil;
7.   All amendments and reports related to the aforementioned documents.
8.   Annual Reports with the FDA;
9.   Existing correspondence with relevant regulatory authorities;
10.  Serious Adverse Event reports

MEDICAL

11.  Investigator's files, clinical trial AS400 system data, final study
     reports(1) clinical investigator brochures, and protocols (each to the
     extent of Lilly's existing rights) from the following clinical studies:

     XBAA-Single dose safety and PK study (oral)
     XBAB-Multiple dose safety and PK (oral)
     XBAE-Single dose safety and PK (IV)
     XBAU-Multiple dose safety and PK (IV)
     XBAC-Phase II study of LY (oral) vs. fluconazole in the therapy of OPC.
     XBAW-Phase I comparative study of safety PK in HIV-infected and uninfected
              volunteers (oral).
     XBAI-Phase II open label study of LY (oral) in the treatment of OPC.
     XBAF-Phase II pilot efficacy study of LY in treatment of candida
              esophagitis.
     XBAG-Phase II/III study of LY (IV) vs. fluconazole in the treatment of
               candidemia and systemic candidiasis in non-neutropenic patients.

12.  Toxicology Reports
13.  Pharmacokinetics reports

--------
(1) Final study reports for XBAI, XBAF, and XBAG are currently being prepared
and will not be completed and made available to Versicor in approximately
July/August, 1999.

<PAGE>

PRECLINICAL

14.  Protocols and data for LY303366 and control compounds from preclinical
     studies listed in Attachment I hereto.

CM&C

15.  290 grams of reference standard lot 185EM6 (reevaluation date July 2000).
16.  Process development technical reports
17.  Formulation development technical reports
18.  Analytical development technical reports
19.  Pilot plant campaign summaries
20.  Certificate of Analysis for API and drug product in Start-Up Inventory
21.  Batch release data for API and drug product (contained in IND)
22.  Analytical methods for API and drug product(contained in IND)
23.  Existing stability information (contained in IND)

<PAGE>

ATTACHMENT I - EXHIBIT C
<TABLE>
<CAPTION>
----------------------------------------------------------------------------------------------------
 Title of Study  (All Contain 303366 Studies)                                     Notebook
----------------------------------------------------------------------------------------------------
<S>                                                                       <C>
 Linoleic Acid and Cremaphor Formulation (From Jerry Mosher--Oral         H97-5QX-56
 Emulsion Formulation)
----------------------------------------------------------------------------------------------------
 Oral Bioavailability of 303366 in Rats at Various Time Intervals         H97-5QX-91-98
----------------------------------------------------------------------------------------------------
 Oral Bioavailability of ECB Analogs at Various Time Intervals            H97-5QX-99-130
----------------------------------------------------------------------------------------------------
 Renal Recovery of Aspergillus From Mice Treated With LY295337, ECB       H97-5QX-134-143
 Analogs, Fluconazole or Fungizone
----------------------------------------------------------------------------------------------------
 Renal Recovery OF ASPERGILLUS FUMIGATUS From Mice Treated With ECB       H97-5QX-152-160
 Finalists and Controls (IP and Oral)
----------------------------------------------------------------------------------------------------
 Oral Bioavailability of 280949 and 303366 in Rats                        H97-5QX-170-173
----------------------------------------------------------------------------------------------------
 IN VITRO Resistance Development of LY303366, Fluconazole &               H97-LPU-3-4
 Amphotericin B
----------------------------------------------------------------------------------------------------
 IN VITRO Susceptibility of Clinical Isolates of CANDIDA ALBICANS to      H97-LPU-9-22
 LY303366 and Ampho B in Antibiotic 3 or RPMI & MOPs Using a Microbroth
 Dilution, Assay
---------------------------------------------------------------------------------------------------
 LY303366 Fungicidal Activity vs. CANDIDA spp.                            H97-LPU-23-26
----------------------------------------------------------------------------------------------------
 Efficacy of LY303366 versus Murine systemic Candidiasis When Treated IP  H97-LPU-38-41
(4,24,48); (6,24,48); or (24,48,72) Hr Post-Infection
----------------------------------------------------------------------------------------------------
 IN VIVO Antifungal Efficacies of LY303366 & Amphotericin B Against a     H97-LPU-47-52
 Disseminated C. ALBICANS Infection in ICR Mice (Renel Recovery)
----------------------------------------------------------------------------------------------------
 Efficacy of LY303366 Versus Murine Systemic Candidiasis When Treated IV  H97-LPU-53-56
 (4,24,48); (6,24,48) or (24,48,72) Hr Post-Infection
----------------------------------------------------------------------------------------------------
 Oral Pharyngeal Candidiasis in Rats                                      H97-LPU-91-93
----------------------------------------------------------------------------------------------------
 Target Oragan Recovey of Candida albicans From Mice Treated With         H97-LPU-133-142
 LY303366, Amphotercin B or Fluconazole
----------------------------------------------------------------------------------------------------

----------------------------------------------------------------------------------------------------
 Pharmacokinetic Study of 303366 and 307853                               H97-CKX-28-29
----------------------------------------------------------------------------------------------------
 Renal Recovery of CANDIDA ALBICANS From Mice Treated With ECB Finalists  H97-CKX-3l-39
 and Controls
----------------------------------------------------------------------------------------------------
 Pharmacokinetic Study of 303366 Prodrug 25 mg/kg Orally in H2O or        H97-CKX-45-50
 Cremophro/Linoleic Acid and 303366 25 mg/kg Orally in Cremophor/Linoleic
 Acid in Rat Plasma
----------------------------------------------------------------------------------------------------
 Pharmacokinetic Study of 303366 Prodrug 5.0 mg/kg IV in H20 and 303366   H97-CKX-51-52
 5.0 mg/kg IV in 33% PEG 300 and 0.05 M Phosphate Buffer, pH 7.0
 in Rat Plasma
----------------------------------------------------------------------------------------------------
 Chemotherapy of Rat Vaginal Candidiasis (Miconazole, Fluconazole,        H97-CKX-72-78
 LY303366)
----------------------------------------------------------------------------------------------------
 Monoclonal Antibody Plus Candida albicans A26 and LY303366               H97-CKX-79-82
----------------------------------------------------------------------------------------------------
 Checkerboard Synergism Assay                                             H97-CKX-83-84
----------------------------------------------------------------------------------------------------
 Submission of Plasma From Rats Treated Orally Via Gavage With 303366     H97-CKX-85-86
 and Acacia w/wo Ethanol for HPLC Analysis
----------------------------------------------------------------------------------------------------
 Renal Recovery of CANDIDA ALBICANS From Mice Treated with ECB Finalists  H97-CKX-87-93
 (329960,333006,303366, 311725) and Controls
----------------------------------------------------------------------------------------------------
 Renal Recovery OF CANDIDA spp. (C. GLABRATA, C. PARAPSILOSIS, C.         H97-CKX-98-107
 TROPICALIS) From Mice Treated with ECB Finalists (329960, 333006,
 303366, 311725) and Controls
----------------------------------------------------------------------------------------------------
 Renal Recovery of CANDIDA ALBICANS From Mice Treated With ECB Finalists  H97-CKX-108-115
 and Controls for 10 Days-Cidal Activity Determination
----------------------------------------------------------------------------------------------------
 Renal Recovery of CANDIDA spp. (C. GLABRATA, C. PARAPSILOSIS, C.         H97-CKX-116-123
 TROPICALIS) From Mice Treated With ECB Finalists (329960, 333006,
 303366, 311725) and Controls
----------------------------------------------------------------------------------------------------
 Chemotherapy of Rat Vaginal Candidiasis (LY303366, Fluconazole PO and    H97-CKX-124-134
 Clotrimazole, Miconazole Topically)
----------------------------------------------------------------------------------------------------
 LY303366 Parenteral (IV) Formulations Comparison Study in Rats           H97-CKX-135-141
----------------------------------------------------------------------------------------------------
 Agar Dilution Assay of Candida spp. Isolates Versus ECB Analogs          H97-CKX-142-149
----------------------------------------------------------------------------------------------------
 Effect of Delaying Initial Treatment on the ED50 of 303366 in            H97-CKX-150-151
 Immunocompromised Mice Infected With CANDIDA ALBICANS A26
----------------------------------------------------------------------------------------------------
</TABLE>

<PAGE>

ATTACHMENT I - EXHIBIT C
<TABLE>
<S>                                                                       <C>
----------------------------------------------------------------------------------------------------
Renal Recovery of CANDIDA spp. (C. GLABRATA. C. TROPICALIS. C.            H97-CKX-152-158
PARAPSILOSIS) From Mice Treated With ECB Prodrugs and Parents
----------------------------------------------------------------------------------------------------
Renal Recovery of CANDIDA spp. (C. GLABRATA. C. TROPICALIS. C.            H97-CKX-159-175
PARAPSILOSIS) From Mice at Various Time Intervals (Days 4,7,10)
----------------------------------------------------------------------------------------------------
IN VITRO Activity of LY303366, Amphotericin B and Azoles Versus Azole     H97-CKX-177-181
Resistant CANDIDA ALBICANS Isolates
----------------------------------------------------------------------------------------------------
Antifungal Activity of LY303366 Against CANDIDA ALBICANS by               H97-CKX-182-183
Agar Dilution Assay
----------------------------------------------------------------------------------------------------
Chemotherapy of HISTOPLAMSA CAPSULATUM ATCC 26032-24 (LY303366, LY295337  H97-CKX-184
& Fungizone)
----------------------------------------------------------------------------------------------------
Comparison of the IN VITRO Activities of LY303366 and other Antifungal    H97-CKX-185-189
Agents Against CANDIDA spp.
----------------------------------------------------------------------------------------------------
Oral Pharmacokinetci Mouse Study 303366 in Acacia                         H97-CKX-190-192
----------------------------------------------------------------------------------------------------

----------------------------------------------------------------------------------------------------
Comparison of the IN VITRO Activities of LY303366 and other Antifungal    H97-JBN-1-7
Agents (303366, Fluconazole, Amphotericin B) Against CANDIDA spp.
(C. KRUSEI, C. ALBICANS, C. PARAPSILOSIS, C. GLABRATA, C. TROPICALIS)
----------------------------------------------------------------------------------------------------
Renal Recovery of CANDIDA spp. (10(5) or 10(6)) From Mice                 H97-JBN-8-24
(x-ray or non x-ray) Treated with 303366 and Controls
----------------------------------------------------------------------------------------------------
Effect of Delaying Initial Treatment on the ED(50) of LY303366 in         H97-JBN-25-27
Immunocompromised Mice Infected With CANDIDA ALBICANS A26
----------------------------------------------------------------------------------------------------
Antimicrobial Susceptibilities of CANDIDA ALBICANS Isolates (107) to      H97-JBN-31-42
LY303366 and Amphotericin B in an Agar Dilution Assay
----------------------------------------------------------------------------------------------------
Growth Inhibition of C. ALBICANS by LY303366 in Antibiotic 3-Growth       H97-JBN-43-46
Curve
----------------------------------------------------------------------------------------------------
Effect of Delaying Initial Treatment on the ED(50) of LY303366 in         H97-JBN-49-50
Immunocompromised Mice Infected with CANDIDA ALBICANS A26
----------------------------------------------------------------------------------------------------
Effect of Delaying Initial Treatment on the ED(50) of LY303366 in         H97-JBN-51
Immunocompromised Mice Infected with CANDIDA ALBICANS A26
----------------------------------------------------------------------------------------------------
Pharmacokinetic Study of LY303366 Administered Orally via Gavage in       H97-JBN-55-57
ICR Mice
----------------------------------------------------------------------------------------------------
Notes for the Preparation of the Dose solution of 085R94-LY303366         H97-JBN-74
and (14)C-LY303366
----------------------------------------------------------------------------------------------------
Antifungal Susceptibility Testing of Filamentous Fungal Dermatophytes     H97-JBN-75-78
Versus LY303366
----------------------------------------------------------------------------------------------------
Chemotherapy of Rat Vaginal Candidiasis (LY303366 and Fluconazole PO)     H97-JBN-79-87
----------------------------------------------------------------------------------------------------
Email Message discussing lack of PO activity in vaginal model possibly    H97-JBN-87 bottom of page
predicting failure versus esophygeal candidiasis when
LY303366 administered orally
----------------------------------------------------------------------------------------------------
Susceptibility of CANDIDA spp. Grown on Sabourauds Agar by the Agar       H97-JBN-88-97
Dilutlion Test LY303366 and Ampho B
----------------------------------------------------------------------------------------------------
IN VITRO Resistance Development vs. C. ALBICANS for LY303366 and          H97-JBN-98
Fluconazole
----------------------------------------------------------------------------------------------------
Gastrointestinal Candidiasis--LY303366 and Fluconazole                    H97-JBN-99-106
----------------------------------------------------------------------------------------------------
Renal Recovery of C. ALBICANS From Mice Treated IV with LY303366 in an    H97-JBN-107-113
Bio-Pharm Formulation, PEG or Cyclodextran for 7 Day Post-Infection
----------------------------------------------------------------------------------------------------
IN VITRO Antifungal Testing of 303366, Fluconazole and Amphotericin B     H97-JBN-116
----------------------------------------------------------------------------------------------------
Chemotherapy of HISTOPLASMA CAPSULATUM and BLASTOMYCES DERMATITIDIS vs.   H97-JBN-121
ECB Analogs (303366)
----------------------------------------------------------------------------------------------------
Gastrointestinal Candidiasis (303366 and Fluconazole)                     H97-JBN- 143-152
----------------------------------------------------------------------------------------------------
Various Broth and Methods for MIC Determination of 303366, Fluconazole    H97-JBN-165-173
and Ampho B
----------------------------------------------------------------------------------------------------
Oral Pharyngeal Candidiasis in Rats Procedure                             H97-JBN- 174-175
----------------------------------------------------------------------------------------------------
Efficacy of a Microemulsion Formulation of LY303366 vs. Murine            H97-JBN-185-186
Candidiasis When Treated IV at 4,24 & 48 hr Post-Infection
----------------------------------------------------------------------------------------------------
Recovery of C. ALBICANS From Kidney and Liver Homogenates of Mice         H97-JBN- 187-192
Treated IP With LY303366 (4,24); (4,24,48); or (4,24,72) hr
Post-Infection
----------------------------------------------------------------------------------------------------
</TABLE>

<PAGE>

ATTACHMENT I - EXHIBIT C

<TABLE>
<CAPTION>
Anti-pneumocystis Activity of 280949 and LY303366                          Study
----------------------------------------------------------------------------------------------------

----------------------------------------------------------------------------------------------------
<S>                                                                       <C>
PC Cyst-Reduction Model (4 days therapy) oral dose LY303366 in rats       PT9211
(280949 included in study as a positive control drug).
----------------------------------------------------------------------------------------------------
Oral Prophylaxis of PCP with LY303366                                     PT9212
----------------------------------------------------------------------------------------------------
Oral Prophylaxis of PCP with LY303366 and 280949                          PT9301
----------------------------------------------------------------------------------------------------
Oral Prophylaxis of PCP with 303366 and Oral dose ranging Cyst Reduction  PT9302
Study of PCP with LY303366: IV and oral single dose vs. IV/Oral combined
therapy
----------------------------------------------------------------------------------------------------
Parenteral Prophylaxis of PCP with 1,2 and 3 x weekly dosing of LY303366  PT9303
----------------------------------------------------------------------------------------------------
Parenteral Prophylaxis of PCP with 1 x weekly dosing of LY303366          PT9304
----------------------------------------------------------------------------------------------------
Cyst-Reduction Study-single IV dose vs. 4 days oral therapy of PCP        PT9401
LY303366
----------------------------------------------------------------------------------------------------
Oral Therapy of PCP with LY303366                                         PT9402
----------------------------------------------------------------------------------------------------
Oral Prophylaxis of PCP: once a week VS. QD dosing LY303366               PT9403
----------------------------------------------------------------------------------------------------
Oral Cyst Reduction Study comparing 303366 Biopharm formulation with      PT9503
LY303388 in 17.5% PEG
----------------------------------------------------------------------------------------------------
</TABLE>

303366 Only Study Locations

                                ECB SAR DATABASE

ECB SAR data is included in a FileMaker Pro database. This database contains
records for approximately 604 analogs. The majority of MIC, ED(50) and glucan
synthase data can be found here. This information can be provided on a CD due
to its large size (7.7 MB). The following information can be found in this
database:

1.   Serial numbers
2.   Lot numbers
3.   Structure drawings
4.   ClogP values
5.   MIC's for CANDIDA ALBICANS, CANDIDA PARAPSILOSIS, ASPERGILLUS FUMIGATUS,
     CRYPTOCOCCUS NEOFORMANS, HISTOPLASMA CAPSULATUM in Antibiotic 3,
     Sabouaruads and/or RPMI & MOPS broths.
6.   Glucan synthase % inhibition + control values for CANDIDA ALBICANS and
     ASPERGILLUS FUMIGATUS.
7.   Murine candidiasis ED(50) values (IP and/or PO)
8.   Murine cryptococcosis ED(50) values (IP and/or PO)
9.   Murine aspergillosis ED(50) values (IP and/or PO)
10.  PNEUMOCYSITIS CARINII IN VIVO evaluation
11.  Pharmacokinetic data (plasma levels following IV or PO dosing)

<PAGE>

                                    EXHIBIT D

                               START UP INVENTORY
<TABLE>
<CAPTION>
-------------------------------------- --------------- --------------- --------------- -----------------
NAME                                      QUANTITY          UOM          UNIT COST        TOTAL COST

-------------------------------------- --------------- --------------- --------------- -----------------
<S>                                    <C>             <C>             <C>             <C>
ECB Nucleus HCI                         [ * ]          Kg               [ * ]           [ * ]
-------------------------------------- --------------- --------------- --------------- -----------------
Terphenyl Acid                          [ * ]          Kg               [ * ]           [ * ]
-------------------------------------- --------------- --------------- --------------- -----------------
HOBT                                    [ * ]          Kg               [ * ]           [ * ]
-------------------------------------- --------------- --------------- --------------- -----------------
ECB fructose complex API                [ * ]          Kg               [ * ]           [ * ]
-------------------------------------- --------------- --------------- --------------- -----------------
ECB vials for injection 25 mg           [ * ]          Vials            [ * ]           [ * ]
-------------------------------------- --------------- --------------- --------------- -----------------
ECB vials for injection 35 mg           [ * ]          Vials            [ * ]           [ * ]
-------------------------------------- --------------- --------------- --------------- -----------------

                                                     Grand Total:                       [ * ]
</TABLE>

                                    RESERVE INVENTORY
<TABLE>
<CAPTION>
-------------------------------------- --------------- --------------- --------------- -----------------
NAME                                      QUANTITY          UOM          UNIT COST        TOTAL COST
-------------------------------------- --------------- --------------- --------------- -----------------
<S>                                    <C>             <C>             <C>             <C>
ECB Nucleus HCI                         [ * ]          Kg               [ * ]           [ * ]
-------------------------------------- --------------- --------------- --------------- -----------------
Terphenyl Acid                          [ * ]          Kg               [ * ]           [ * ]
-------------------------------------- --------------- --------------- --------------- -----------------
HOBT                                    [ * ]          Kg               [ * ]           [ * ]
-------------------------------------- --------------- --------------- --------------- -----------------
ECB fructose complex API                [ * ]          Kg               [ * ]           [ * ]
-------------------------------------- --------------- --------------- --------------- -----------------
ECB vials for injection 25 mg           [ * ]          Vials            [ * ]           [ * ]
-------------------------------------- --------------- --------------- --------------- -----------------
ECB vials for injection 35 mg           [ * ]          Vials            [ * ]           [ * ]
-------------------------------------- --------------- --------------- --------------- -----------------

                                                     Grand Total:                       [ * ]

</TABLE>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

<PAGE>

                                    EXHIBIT E

                 QUARTERLY REPORTING OF RESERVE INVENTORY STATUS

Date of Report:

Period of Time Covered by this Report:

PART 1: INVENTORY USED
<TABLE>
<CAPTION>
-------------------------------- --------------- ------------ ---------------- ------------------
NAME                             AMOUNT USED         UOM      UNIT COST        TOTAL COST OWED
                                 SINCE LAST                   (FROM EXHIBIT    TO LILLY
                                 REPORT                       D)
-------------------------------- --------------- ------------ ---------------- ------------------
<S>                              <C>             <C>          <C>              <C>
ECB Nucleus HCI                                  Kg            [ * ]
-------------------------------- --------------- ------------ ---------------- ------------------
Terphenyl Acid                                   Kg            [ * ]
-------------------------------- --------------- ------------ ---------------- ------------------
HOBT                                             Kg            [ * ]
-------------------------------- --------------- ------------ ---------------- ------------------
ECB fructose complex API                         Kg            [ * ]
-------------------------------- --------------- ------------ ---------------- ------------------
ECB vials for injection 25 mg                    Vials         [ * ]
-------------------------------- --------------- ------------ ---------------- ------------------
ECB vials for injection 35 mg                    Vials         [ * ]
-------------------------------- --------------- ------------ ---------------- ------------------

                                                     Grand Total:

</TABLE>

PART 2: INVENTORY REMAINING IN RESERVE STATUS
<TABLE>
<CAPTION>
-------------------------------- ------------ ------------- ------------ ------------------------
NAME                               AMOUNT         UOM        UNIT COST   COMMENTS
-------------------------------- ------------ ------------- ------------ ------------------------
<S>                              <C>          <C>           <C>          <C>
ECB Nucleus HCI                               Kg
-------------------------------- ------------ ------------- ------------ ------------------------
Terphenyl Acid                                Kg
-------------------------------- ------------ ------------- ------------ ------------------------
HOBT                                          Kg
-------------------------------- ------------ ------------- ------------ ------------------------
ECB fructose complex API                      Kg
-------------------------------- ------------ ------------- ------------ ------------------------
ECB vials for injection 25 mg                 Vials
-------------------------------- ------------ ------------- ------------ ------------------------
ECB vials for injection 35 mg                 Vials
-------------------------------- ------------ ------------- ------------ ------------------------
</TABLE>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

<PAGE>

                          EXHIBIT F- BIOLOGIC MATERIAL

<TABLE>
<CAPTION>
STRAIN                                                QUANTITY
<S>                                                   <C>
ASPERGILLUS NIDULANS E00382-02-73                     70 straws
ASPERGILLUS NIDULANS E00560-03-57                     10 straws
STREPTOMYCES LIVIDANS PSHP150-2                       80 straws
</TABLE><PAGE>

                                                                    Exhibit 10.9

                  COLLABORATIVE RESEARCH AND LICENSE AGREEMENT

      THIS COLLABORATION AND LICENSE AGREEMENT (the "Agreement"), effective the
31st day of March, 1999 (the "Effective Date") is by and between NOVARTIS PHARMA
AG ("Novartis"), a corporation organized under the laws of Switzerland, having
its principal place of business at Lichtstrasse 35, CH-4000 Basel, Switzerland,
and VERSICOR, INC., a Delaware corporation having its principal place of
business at 34790 Ardentech Court, Fremont, CA 94555, U.S.A. ("Versicor").

                                    RECITALS

      WHEREAS, Versicor has developed expertise and acquired proprietary rights
relating to the discovery and development of pharmaceutical products in the area
of infectious diseases;

      WHEREAS, Novartis is engaged in the research, development, marketing,
manufacture and distribution of pharmaceutical compounds useful in treating or
preventing human diseases and conditions; and

      WHEREAS, Novartis and Versicor desire to engage in a joint research and
development effort to discover and/or design compounds which act as peptidyl
deformylase inhibitors and MUR pathway inhibitors to develop pharmaceutical
products from such compounds in all fields of diagnosis, prophylaxis and
therapeutics for human and veterinary use;

      WHEREAS, in conjunction with such joint research and development, Novartis
desires to sponsor certain research and development activities to be carried out
by Versicor and Versicor and Novartis desire that Novartis commercialize
products resulting from the joint research and development.

      NOW, THEREFORE, in consideration of the foregoing premises and the mutual
covenants herein contained, Novartis and Versicor agree as follows:

1. DEFINITIONS

      For the purposes of this Agreement, the terms defined in this Article I,
whether used in their singular or plural form, shall have the respective
meanings set forth below:

      1.1 "Affiliate" shall mean, with respect to a Party to this Agreement, any
other entity, whether de jure or de facto, which directly or indirectly
controls, is controlled by, or is under common control with, such Party. A
business entity or Party shall be regarded as in control of another business
entity if it owns, or directly or indirectly controls, at least fifty percent
(50%) (or such lesser percentage which is the maximum allowed to be owned by a
foreign entity in a particular jurisdiction) of the voting stock or other
ownership interest of the other entity, or if it directly or indirectly
possesses the power to direct or cause the direction of the management and
policies of the other entity by any lawful means whatsoever.

                                       1
<PAGE>

      1.2 "Back-Up Compound" shall mean a Research Compound having a similar
level of activity as another Research Compound in the same Target Assay, and
which Novartis may develop to a certain early stage of development (usually to
an EDC) which is then parked at this stage as possible replacements for more
advanced EDCs or CDCs whose development and/or commercialization efforts are
abandoned.

      1.3 "Clinical Development Compound" or "CDC" shall mean an Early
Development Compound for which an IND has been filed for clinical development,
designed to obtain approval by the appropriate regulatory authorities to market
such Research Compound or Product.

      1.4 "Contract Year" shall mean the twelve (12) month period from the
Effective Date and each subsequent twelve (12) month period during the Research
Program Term.

      1.5 "Co-Promotion Agreement" shall have the meaning set forth in Section
5.2.

      1.6 "Co-Promotion Option Product" shall have the meaning set forth in
Section 5.1.

      1.7 "Co-Promotion Profit" shall have the meaning set forth in Exhibit C.

      1.8 "Detail" shall have the meaning set forth in Exhibit C.

      1.9 "Early Development Compound" or "EDC" shall mean a Research Compound
which has been declared, following Novartis' standard compound development
procedures, an Early Development Compound (EDC) or equivalent status by Novartis
Innovation Management Board or some similar body, authorizing the completion of
the preclinical development program thereby allowing the filing of an IND.

      1.10 "FDA" shall mean the United States Food and Drug Administration.

      1.11 "Field of Cooperation" shall mean deformylase inhibitors and MUR
Pathway inhibitors.

      1.12 "Field of Use" shall mean all fields of use including, but not
limited to, diagnostics, therapeutics and prophylaxis in human and veterinary
health.

      1.13 "First Commercial Sale" shall mean, with respect to a Product, the
first sale, for payment in cash or in kind (but excluding sales or transfers of
a Product that is used in a clinical trial,) to a Third Party in a country after
such time as any required marketing approval has been granted by the governing
health authority of such country.

      1.14 "Gene-to-Screen" shall mean Versicor's technology with which it can
be established if a gene product is essential for bacterial growth and with
which a screening strain can be created that is selectively hypersusceptible to
inhibitors of that gene product.

      1.15 "IND" shall mean an investigational new drug application filed with
the FDA (pursuant to 21 CFR ss.312.3) prior to beginning clinical trials in
humans or any comparable application filed with the regulatory authorities of a
country other than the United States prior to beginning clinical trials in
humans in that country.

                                       2
<PAGE>

      1.16 "Invention" shall have the meaning set forth in Section 6.1.

      1.17 "Information" shall mean all tangible and intangible (i) techniques,
technology, practices, trade secrets, inventions (whether or not patentable),
methods, knowledge, Know-How, skill, experience, test data and results
(including pharmacological, toxicological and clinical test data and results),
analytical and quality control data, results or descriptions, software and (ii)
compounds, compositions of matter, cells, cell lines, assays, and physical,
biological or chemical material.

      1.18 "Joint Invention" shall have the meaning set forth in Section 6.1

      1.19 "Joint Patent Rights" shall mean any United States or foreign patent
applications, provisional patent applications, patents, patent extensions,
certificates of invention and applications for certificates of invention,
together with any divisions, continuations or continuations-in-part, reissues,
renewals, or additions claiming a Joint Invention.

      1.20 "Joint Research Steering Committee" or "JRSC" shall mean the research
management committee composed of representatives of Versicor and Novartis
described more fully in Section 2.1 hereof.

      1.21 "Know-How" shall mean all Information that is necessary or reasonably
useful to the discovery, identification, synthesis, development, manufacture or
use of Research Compounds and/or Products

      1.22 "Major Country" shall mean any of the United States, Canada, France,
Germany, Italy, Japan, and the United Kingdom.

      1.23 "MUR Pathway" shall mean the pathway of bacterial cell-wall
polysaccharide-chain synthesis, as generally described by the schematic
illustration attached hereto as Exhibit A and shall include MUR A, B, C, D, E
and F.

      1.24 "NDA" shall mean a New Drug Application and all amendments and
supplements thereto filed with the FDA (as more fully defined in 21 C.F.R. 314.5
et seq.), or the equivalent application filed with any equivalent agency or
governmental authority outside the United States (including any supra-national
agency such as in the European Union) requiring such filing, including all
documents, data, and other information concerning a Product which are necessary
for gaining Regulatory Approval to market and sell such Product.

      1.25 "Net Sales" shall mean the actual amount invoiced for sale of a
Product by a Party or its Affiliate(s) or the sublicensee to a Third Party after
deducting the following, to the extent actually incurred or allowed with respect
to such sale: (i) discounts, rebates (including government-mandated rebates),
retroactive price reductions, samples and/or allowances actually allowed or
granted from the billed amount, (ii) credits or allowances actually granted upon
claims, rejections or returns of such Products in amounts not in excess of those
customary in the industry, including recalls, and (iii) taxes, duties or other
governmental charges levied on or measured by the billing amount when included
in billing, as adjusted for rebates and refunds; all in accordance with standard
allocation procedures and

                                       3
<PAGE>

accounting methods consistently applied, which methods are in accordance with
generally accepted accounting principles.

      In the event a Party is receiving royalties under this Agreement from any
Product sold in the form of a "Combination Product" (a product containing a
Research Compound, including one or more additional active ingredients other
than a Research Compound), Net Sales for such Combination Product will be
calculated by multiplying actual Net Sales by the fraction A/(A+B) where A is
the fair market value of the portion of the Combination Product that contains
the Research Compound and B is the fair market value of the other active
ingredients included in such Combination Product, as determined by market prices
of such portions if separately priced and sold, or if not so priced and sold, as
determined by mutual agreement of the Parties. As used herein, the term "active
ingredient" does not include ingredients the primary effect of which is the
enhancement of drug delivery, even if such ingredients have pharmacological
activity.

      1.26 "Novartis Compounds" shall mean any compound owned or controlled by
and synthesized at Novartis or which originated from a Novartis library, or any
derivative, isomer, analog or homolog thereof.

      1.27 "Novartis Invention" shall have the meaning set forth in Section 6.1.

      1.28 "Novartis Patent Rights" shall mean any United States or foreign
patent applications, provisional patent applications, patents, patent
extensions, certificates of invention and applications for certificates of
invention, together with any divisions, continuations-in-part, reissues,
renewals, or additions owned or controlled by Novartis as of the Effective Date
or covering any Novartis Invention.

      1.29 "Party" shall mean either Versicor or Novartis.

      1.30 "Patent Rights" shall have the meaning set forth in Section 7.1.

      1.31 "Phase I Clinical Trials" shall mean studies in human subjects
designed to demonstrate the safety of a Product.

      1.32 "Phase III Clinical Trials" shall mean studies in human subjects
intended to gather additional information about the effectiveness and safety of
a Product, and which are intended to serve as a basis of the marketing approval
of the Product by the FDA or its equivalent governmental authorities in any
other country.

      1.33 "Product" shall mean a product, whether in development or
commercialized, containing any formulation or dosage of a Research Compound.

      1.34 "Project Contact Persons" shall have the meaning set forth in Section
2.7.

      1.35 "Research Compound" shall mean a Novartis Compound or a Versicor
Compound, which, during the term of the Research Program, has been identified or
confirmed as being active against a Target.

                                       4
<PAGE>

      1.36 "Research Plan" shall mean the detailed description of the research
activities to be performed by the Parties under the Research Program set forth
in Exhibit B hereto, as revised from time to time by the JRSC pursuant to
Section 2.6.

      1.37 "Research Program" shall mean the program of research in the Field of
Cooperation in which Versicor and Novartis will participate under this Agreement
and which is described generally in the Research Plan.

      1.38 "Research Program Term" shall mean the period of three (3) years from
the Effective Date, unless terminated earlier pursuant to Article 16.

      1.39 "Stock Purchase Agreement" shall have the meaning set forth in
Section 10.4.

      1.40 "Target" shall mean a specific bacterial protein (including, without
limitation, a glycoprotein, a lipoprotein, etc.) selected by the Joint Research
Steering Committee to undergo research for target validation and/or development
of a Target Assay.

      1.41 "Target Assay" shall mean the primary compound screening assays
incorporating a Target or Targets.

      1.42 "Target Audience" shall have the meaning set forth in Exhibit C.

      1.43 "Territory" shall mean the entire world.

      1.44 "Third Party" shall mean a party other than a Party including its
Affiliates, to this Agreement.

      1.45 "Valid Claim" shall mean either (a) a claim of an issued and
unexpired patent included within the Versicor Patent Rights or the Joint Patent
Rights, which has not been held permanently revoked, unenforceable or invalid by
a decision Of a court or other governmental agency of competent jurisdiction,
unappealable or unappealed within the time allowed for appeal, and which has not
been admitted to be invalid or unenforceable through reissue or disclaimer or
otherwise or (b) a claim of a pending patent application included within the
Versicor Patent Rights or the Joint Patent Rights, which claim was filed in good
faith and has not been abandoned or finally disallowed without the possibility
of appeal or refiling of said application.

      1.46 "Versicor Compounds" shall mean any compound owned or controlled by
and synthesized at Versicor or which originated from a Versicor library, or any
derivative, isomer, analog or homolog thereof.

      1.47 "Versicor Invention" shall have the meaning set forth in Section 6.1.

      1.48 "Versicor Patent Rights" shall mean any United States or foreign
patent applications, provisional patent applications or patents owned or
controlled by Versicor as of the Effective Date, as set out in Exhibit D, or
coveting any Versicor Inventions, or any patent extensions, certificates of
invention and applications for certificates of invention, together with any
divisions, continuations or continuations-in-part, reissues, renewals, or
additions thereof.

                                       5
<PAGE>

2. RESEARCH PROGRAM GOVERNANCE.

      2.1 Joint Research Steering Committee. The Research Program established by
this Agreement shall be overseen by a committee composed of three (3)
representatives of Novartis and three (3) representatives of Versicor (the
"Joint Research Steering Committee" or "JRSC"). The Parties shall designate
their representatives on the JRSC within ten business (10) days after the
Effective Date. A Party may change one or more of its representatives to the
JRSC at any time. The Parties shall agree upon the appropriate qualifications
for members of the JRSC and mechanisms for making substitutions for JRSC
members. An alternate member designated by a Party may serve temporarily in the
absence of a permanent member of the JRSC for such Party. Each Party shall
designate one of its representatives as a Co-Chair of the JRSC. Each Co-Chair of
the JRSC will be responsible for the agenda and the minutes of alternating JRSC
meetings.

      2.2 Meetings of the JRSC. The JRSC shall hold meetings at such times and
places as shall be determined by the JRSC, and may conduct meetings in person or
by video conference or telephone conference. Face-to-face meetings shall
alternate between the research offices of each Party, and shall be held not less
frequently than once every three (3) months. Either Party may permit additional
employees and consultants to attend and participate (on a non-voting basis) in
the JRSC meetings, subject to the confidentiality provisions of Article 13.

      2.3 Minutes. At each meeting, the JRSC shall elect a secretary who will
prepare, within ten (10) business days after each meeting (whether held in
person or be telecommunication), the minutes reporting in reasonable detail the
actions taken by the JRSC, the status of the Research Program, issues requiring
resolution and resolutions of previously reported issues, which minutes are to
be signed by the Co-Chairs of the JRSC from each of the Parties.

      2.4 JRSC Actions. Actions by the JRSC pursuant to this Agreement shall be
taken, in person or by proxy, only with unanimous consent of all of the
representatives of the JRSC. Any disagreement among members of the JRSC will be
resolved within the JRSC based on the efficient achievement of the objectives of
this Agreement. In the event that the JRSC cannot reach agreement as to any
matter that is subject to its decision-making authority, Novartis shall cast the
deciding vote in good faith. Notwithstanding the foregoing, the Parties agree
that Novartis shall not cast the deciding vote against Versicor's position on
matters related to resource allocation by Versicor for the Research Program or
have the right to cast the deciding vote hereunder with respect to the
resolution of technical obstacles which arise in the Research Program which
require Versicor's expertise to resolve. In all matters outside Novartis' right
to cast the deciding vote, if after such deliberation, the JRSC fails to reach
unanimity on a matter before it, the matter shall be referred for resolution to
the Chief Executive Officer of Versicor and the Head of Global Research of
Novartis.

      2.5 Subcommittees. The JRSC may establish subcommittees as necessary for
an effective management of the Research Program. Each subcommittee shall have
appropriate representation of each Party and may include representatives of a
Party who are not members of the JRSC. Any such subcommittee shall be subject to
the JRSC and shall report its actions to the JRSC. At the request of either
Party at any time, any such committee shall be dissolved and its powers and
functions returned to the JRSC.

                                       6
<PAGE>

      2.6 JRSC Functions and Powers. The JRSC shall be responsible for the
overall supervision and management of the Research Program. The principal
functions of the JRSC will be inter alia, to foster the collaborative
relationship between the Parties, and shall in particular:

            (a) develop the Research Plan for each year of the Research Program
Term determining in detail the activities to be performed by the Parties under
the Research Program;

            (b) facilitate and monitor the technology transfer from Versicor to
Novartis;

            (c) designate the activity levels required for selection of a
compound as an EDC;

            (d) monitor the progress of the Research Program and the Parties'
diligence in carrying out their responsibilities thereunder;

            (e) review and allocate annual FTEs within the framework of the
contractually agreed funding level;

            (f) review scientific publications, subject to the review and
approval process described in Article 13.

            (g) encourage and facilitate ongoing cooperation and information
exchange between the Parties;

            (h) schedule routine visits by Versicor personnel to Novartis and
oversee training of Novartis personnel;

            (i) review patent issues related to Joint Inventions;

            (j) perform such other functions as appropriate to further the
purposes of this Agreement as mutually determined by the Parties.

      2.7 Project Contact Persons. The day-to-day interactions and project
management of the Research Program will be performed by a pair of "Project
Contact Persons", one to be appointed by each Party.

      2.8 Obligations of Parties. Novartis and Versicor shall provide the JRSC
and its authorized representatives with reasonable access during regular
business hours to all records and documents of the respective Parties specific
to the Research Program that the JRSC may reasonably require in order to perform
its obligations hereunder, subject to any bona fide obligations of
confidentiality to a Third Party.

      2.9 Limitations of Powers of the JRSC. The JRSC shall have no power to
amend this Agreement and shall have only such powers as are specifically
delegated to it hereunder.

                                       7
<PAGE>

3. CONDUCT OF THE RESEARCH PROGRAM

      3.1 Research Commitment. During the Research Program Term, the Parties
shall diligently conduct the Research Program in accordance with the Research
Plan as revised from time to time by the JRSC. The Research Plan shall provide,
inter alia, for tasks to be performed by Versicor with ten (10) FTEs during each
year of the Research Program Term. Each Party shall conduct its activities under
the Research Program in good scientific manner, and in compliance in all
material respects with all requirements of applicable laws and regulations and
with all applicable good laboratory practices and good manufacturing practices
to attempt to achieve its objectives efficiently and expeditiously.

      3.2 Funding of the Research Program. In consideration for Versicor's
performance of the Research Plan in accordance with Section 3.1, Novartis shall
pay to Versicor per Contract Year during the Research Program Term. Payments
shall be made in advance of Versicor's performance and in quarterly installments
equal to twenty-five percent (25%) of the total amount due for each such year,
the first payment being due on the Effective Date, and payable upon presentation
of an invoice by Versicor and subsequent payments being due at the beginning of
each calendar quarter thereafter and payable upon presentation of an invoice by
Versicor. If the Effective Date does not coincide with the beginning of a
calendar quarter, the payment for the quarter in which the Effective Date occurs
and the quarter in which the Research Program Term ends will be pro-rated by the
quarter. All payments due under this Section 3.2 shall be made by Novartis no
later than (a) by each due-date or (b) thirty (30) days after receipt of the
corresponding invoice from Versicor, whichever is the later. The research
funding for the second and third year of the Research Program Term,
respectively, shall be increased over the above amount by an inflation factor
equal to the percentage rise in the Greater San Francisco Consumer Price Index
between the Effective Date and the first and second anniversary of the Effective
Date, respectively.

      3.3 Subcontracts. Neither Versicor nor Novartis shall subcontract to Third
Parties portions of the Research program to be performed by it without the prior
consent of the JRSC, provided, however, that a Party shall have the right to
contract for custom synthesis and other routinely used outside services in
accordance with its standard procurement practices. Any subcontractor shall
enter into a confidentiality agreement with the contracting Party with terms not
less stringent than those contained herein, and shall be in compliance in all
material respects with all requirements of applicable laws and regulations,
together with all applicable good laboratory practices and good manufacturing
practices. The contracting Party shall supervise and be responsible under this
Agreement for such subcontract work.

      3.4 Technology Transfer. In order to ensure a successful transfer of
Target Assays and related materials from Versicor to Novartis and to further a
close working relationship, the Parties will provide offices and support to each
other at each other's facilities for the personnel of the other Party, as needed
and as provided herein. All details with respect to the timing of training, its
duration, its location and the number of participating scientists from either
Party will be arranged by the JRSC. It is, inter alia, tentatively foreseen that
up to two (2) Novartis scientists shall be trained for one week during the first
three months of the Research Program at Versicor's facilities to familiarize
themselves with the Target Assays to be transferred under this Agreement, and
that one (1) of Versicor's FTEs dedicated to the Research Program pursuant to
Section 3.1 shall visit Novartis, at a time to be set by the

                                       8
<PAGE>

JRSC, to assist in the establishment of the Target Assays. In addition, the JRSC
shall arrange visits by such personnel to each Party's facilities as is needed
for the successful implementation of transferred Target Assays and for further
technology transfer as provided herein.

      Under the direction of the JRSC, Versicor shall supply to Novartis, at no
extra charge to Novartis, all not commercially available materials needed for
use in the Research Program according to the Research Plan and the successful
implementation of the Target Assays at Novartis including, but not limited to,
the following materials:

                  (i) reagents required for the Target Assays for the term of
the Research Program

                  (ii) bacterial constructs and enzyme purification protocols
required to carry out high-throughput screening with the Target Assays

                  (iii) enzymes for testing the inhibition spectrum of lead
compounds

                  (iv) Gene-to-Screen technology constructs involving
regulatable deformylase and the MUR pathway

                  (v) chemical structures, organic synthesis and combinatorial
methodologies; Know-How of proprietary leads in the deformylase program

                  (vi) chemical structures of its proprietary leads in the MUR
Pathway program

                  (vii) access to its current patent applications in the
deformylase and MUR pathway programs

      3.5 Exclusivity. During the Research Program Term, Versicor shall not
engage in any activity, alone or with any Third Party, to research, develop or
commercialize pharmaceutical products in the Field of Cooperation.

      3.6 Records. Versicor and Novartis each shall generate and maintain
records which shall fully and properly reflect all work done and results
achieved in the performance of the Research Program (including without
limitation all data in the form required under all applicable laws and
regulations). Such records may consist of lab books, reports, research notes,
charts, graphs, comments, computations, analyses, recordings, photographs, in
paper or electronic form.

      3.7 Research Reports. Versicor and Novartis each shall keep the other
Party fully informed as to all discoveries and technical developments made under
the Research Program. In particular, Versicor and Novartis each shall prepare,
and distribute to all members of the JRSC, no later than twenty (20) business
days prior to the next JRSC meeting, a reasonably detailed written summary
report, in such form and format and setting forth such information regarding the
Research Program as determined from time to time by the JRSC.

4. PRODUCT DEVELOPMENT AND COMMERCIALIZATION

                                       9
<PAGE>

      4.1 Identification and Development of Research Compounds.

            (a) Versicor and Novartis shall screen compounds of their respective
libraries in the Target Assays developed by the Parties in the course of the
Research Program. The JRSC shall select from any compounds which show activity
in those assays those Research Compounds which meet the criteria set by the JRSC
for further optimization and characterization under the Research Program. Any
compounds which do not show activity or which are not selected by the JRSC
shall, subject to the provisions of Sections 4.3 and 4.4, revert to the Party
from whose library it was drawn.

            (b) Research Compounds shall be optimized and characterized as
provided in the Research Plan or as determined by the JRSC in order to develop
compounds which meet the EDC criteria established by the JRSC. Any Research
Compound which is deemed by the JRSC to be of no interest for further
development shall, subject to the provisions of Sections 4.3 and 4.4, be
returned to the Party from whose library the compound was drawn.

      4.2 Selection and Development of Early Development Compounds. Novartis
shall select from the number of Research Compounds which meet the EDC criteria
those compounds which Novartis intends to further develop or which will become
Back-Up Compounds. Those EDCs selected by Novartis pursuant to Section 4.3 shall
be developed in order to determine whether one more of such compounds meet the
criteria Novartis applies to compounds to qualify for development as Clinical
Development Compounds. Any Research Compounds which are Versicor Compounds and
which are not selected by Novartis either for development to a CDC or as a
Back-Up Compound shall, subject to the provisions of Section 4.4, revert to
Versicor.

      4.3 Selection and Development of CDC Compounds.

            (a) Novartis shall select from the number of EDCs those compounds
which Novartis desires to develop as CDCs, and shall give prompt notice to
Versicor of each compound which has been promoted to a CDC. Novartis shall use
its commercially reasonable best efforts to conduct such preclinical and human
clinical trials with CDCs as Novartis determines are necessary or desirable to
obtain regulatory approvals to manufacture and market Products incorporating
such CDCs in the Territory. Novartis shall diligently seek all necessary
regulatory approvals required for marketing a Product in the Major Countries and
such other countries where Novartis markets its own products of similar
commercial potential.

            (b) Novartis shall keep Versicor informed as to the progress of the
development of all CDCs by providing to Versicor a reasonably detailed written
half-yearly report which shall describe the progress of the development and
regulatory filings of CDCs. In the event that Novartis discontinues the
development of a CDC which is a Versicor Compound for a period of more than one
(1) year (provided that discontinuation of development is not due to force
majeure, government regulation or intervention or institution of a lawsuit by a
Third Party) and does not replace such discontinued CDC with a Back-Up Compound,
such CDC shall revert to Versicor, subject to the provisions of Section 4.4. For
the avoidance of doubt, the provisions of this sub-paragraph will explicitly not
apply to any CDCs which are Novartis Compounds; any CDCs which are Novartis
Compounds and whose development or commercialization Novartis discontinues for
any period of time or in what

                                       10
<PAGE>

territory and for whatever reason whatsoever, will stay Novartis' sole property,
and will not be transferred to Versicor unless explicitly otherwise agreed by
the Parties.

      4.4 Rights to Targets

            (a) As long as Novartis is using commercially reasonable efforts to
diligently develop and/or commercialize at least one MUR Pathway inhibitor
Product, (i) the licenses granted to Novartis in Section 9.2 shall continue to
be effective with respect to any Versicor Compound showing a MUR Pathway
inhibitor activity in a Target Assay licensed to Novartis under this Agreement,
subject to the milestone and royalty payment obligations of Novartis described
in Sections 10.2 and 10.3, and (ii) Versicor shall not develop, make, have made,
use and sell itself or license to a Third Party any Versicor Compound showing a
MUR Pathway inhibitor activity in a Target Assay licensed to Novartis under this
Agreement for use within the Field of Use.

            (b) As long as Novartis is using commercially reasonable efforts to
diligently develop and/or commercialize at least one dipeptidyl deformylase
inhibitor Product, (i) the licenses granted to Novartis in Section 9.2 shall
continue to be effective with respect to any Versicor Compound showing a
dipeptidyl deformylase inhibitor activity in a Target Assay licensed to Novartis
under this Agreement, subject to the milestone and royalty payment obligations
of Novartis described in Sections 10.2 and 10.3, and (ii) Versicor shall not
develop, make, have made, use and sell itself or license to a Third Party any
Versicor Compound showing a dipeptidyl deformylase inhibitor activity in a
Target Assay licensed to Novartis under this Agreement for use within the Field
of Use.

            (c) Novartis shall be deemed to be using commercially reasonable
efforts with respect to the provisions of Section 4.4(a) and (b) above if
Novartis is actively undertaking diligent, commercially reasonable efforts,
similar to those used for other Novartis products of comparable commercial
potential, for the continuing development and the commercialization of a Product
including, without limitation, the development and/or optimization and/or
further characterization of Research Compounds and/or Products to which it is
licensed under Section 9.2, the performance of an active derivatisation and lead
optimization program with respect to Research Compounds, the designation of EDC
Status, initiation of clinical trials, submission of regulatory filings and
commercial launch of a Product.

            (d) In the event Novartis fails to use commercially reasonable
efforts as provided in Section 4.4(a) and (B) above, as such efforts are defined
in Section 4.4(c), or if Novartis notifies Versicor that it is not interested in
maintaining a diligent program with respect to any such Target, then Novartis'
licenses to such Target shall terminate and Versicor shall be free to use such
Target, and to research, develop and commercialize compounds against such Target
alone or with a Third Party.

            (e) During the term of the Research Program, Novartis shall provide
information regarding its commercially reasonable efforts to the JRSC on a
quarterly basis. Thereafter, during the remainder of the term of this Agreement,
Novartis shall on a not less than six-monthly basis provide documentation to the
reasonable satisfaction of Versicor that Novartis is using commercially
reasonable efforts with respect to all Research Compounds, EDCs, CDCs and
Products.

                                       11
<PAGE>

5. CO-PROMOTION OF PRODUCTS

      5.1 Versicor has the option to co-promote with Novartis in the hospitals
in the U.S. and Canada intravenous antimicrobial formulations of any Products
which contain Versicor Compounds as active ingredient (a "Co-Promotion Option
Product").

      5.2 Novartis will give notice to Versicor not later than nine (9) months
before it plans to submit an NDA to the U.S. FDA or an equivalent application to
the equivalent Canadian agency for a given Co-Promotion Option Product of the
anticipated submission date. Versicor will have to inform Novartis not later
than six (6) months prior to the indicated submission date whether, and in which
of the two countries if not in both, it will execute its co-promotion right to
the Co-Promotion Option Product. If Versicor gives notice to Novartis that it
wishes to co-promote the Co-Promotion Option Product, the Parties and/or their
local Affiliates will within three (3) months after such notice has been given,
enter into (a) co-promotion agreement(s) ("Co-Promotion Agreement") which shall
at least cover and include the provisions as set forth in Exhibit C, attached
hereto and made a part of this Agreement, and such other provisions the Parties
may agree upon in good faith.

      5.3 If Versicor has not given notice to Novartis that it exercises its
right to co-promote the Co-Promotion Option Product by six months before the
anticipated date for submission of an NDA, or if Versicor has given notice to
Novartis of its decision not to exercise its co-promotion right to the
Co-Promotion Option Product in either the U.S. and/or Canada, Novartis will have
an exclusive, royalty-bearing commercial license pursuant to Section 9.2 also in
the U.S. and/or in Canada, as the case may be.

6. INVENTIONS AND PATENTS.

      6.1 Ownership of Inventions.

            (a) The entire right, title and interest in all patentable
inventions and discoveries within the Field of Cooperation, and any patent
applications, or patents based thereon (collectively, the "Inventions") that are
made or conceived (i) solely by employees of Versicor or others acting on behalf
of Versicor ("Versicor Inventions") shall be owned by Versicor (ii) solely by
employees of Novartis or others acting on behalf of Novartis ("Novartis
Inventions") shall be owned by Novartis and (iii) jointly by employees or others
acting on behalf of Versicor and Novartis ("Joint Inventions") shall be owned
jointly by Novartis and Versicor.

            (b) Each Party shall promptly disclose to the other Party the
Inventions made by employees or others acting on behalf of such Party to the
extent that the other Party has a license thereto under this Agreement. Each
Party represents and agrees that all employees and other persons acting on its
behalf in performing its obligations under this Agreement shall be obligated
under a binding written agreement to assign to such Party. In the case of
non-employees working for other companies or institutions on behalf of Versicor
or Novartis and using Novartis research funding, Versicor or Novartis, as
applicable, shall have the right to license all Inventions made by such
non-employees on behalf of Versicor or Novartis, as applicable, in accordance
with the policies of said company or institution. Versicor and Novartis agree to
undertake to such agreements (including, where appropriate, by legal action)
considering, among other things, the commercial value of such Inventions.

                                       12
<PAGE>

      6.2 Patent Applications.

            (a) Priority filings. When a Versicor Invention or a Joint Invention
has been made which may reasonably be considered to be patentable and as to
which Novartis is licensed under this Agreement, a priority patent application
shall be filed by Versicor in the United States as soon as reasonably possible
with a patent counsel selected by Novartis in the case of a Joint Invention.
Versicor shall give Novartis an opportunity to review the text of any
application for a Joint Invention before filing and shall supply Novartis with a
copy of the application as filed, together with a note of its filing date and
serial number. The costs of such priority filings for Versicor Inventions and
Joint Inventions shall be borne by Novartis.

            (b) Foreign Filing Decisions. No later than nine (9) months
following the filing date of a priority patent application filed according to
Section 6.2(a), the Parties shall consult together, through the JRSC or
otherwise, and agree whether such priority application should be abandoned
without replacement; abandoned and refiled; proceeded with in the country of
filing only; or used as the basis for a claim of priority under the Paris
Convention for corresponding applications in other countries. The same shall
apply to any priority patent application which, as of the Effective Date, is
part of the Versicor Patent Rights and for which no corresponding foreign
applications have been filed.

            (c) Versicor Patent Rights. Any patent application filed in any
country in respect of a Versicor Invention as to which Novartis is licensed
under this Agreement shall be added to the Versicor Patent Rights.

            (d) Prosecution and Maintenance. Versicor shall bear cost and
responsibility for foreign filing, prosecution and maintenance of the Versicor
Patent Rights. At regular intervals, or upon request, Versicor shall provide
Novartis with updated information on its patent portfolio as to which Novartis
is licensed under this Agreement, and Exhibit D hereto shall be amended
accordingly. Novartis shall bear the cost for foreign filing, prosecution and
maintenance of the Joint Patent Rights with Versicor having responsibility
therefor in the United States and Novartis in the rest of the world. Novartis
and Versicor shall consult with each other as to the prosecution and maintenance
of such patent applications and patents. If at any time Novartis or Versicor
shall elect not to continue to prosecute or maintain any patent application or
patent included in the Joint Patent Rights or the Versicor Patent Rights
respectively, the Party making such election shall so notify the other Party
within thirty (30) days of such determination. If Novartis shall elect not to
continue to prosecute or maintain any patent application or patent included in
the Joint Patent Rights, then that patent application or patent shall be
transferred to the sole ownership of Versicor, and shall be excluded from the
licensed Versicor Patent Rights. If Versicor shall elect not to continue to
prosecute or maintain any patent application or patent included in the Versicor
Patent Rights, then Versicor shall give Novartis the timely opportunity to
direct Versicor to continue to prosecute or maintain the patent application or
patent in Versicor's name and at Novartis' expense.

      6.3 Notification of Patent Term. Versicor shall notify Novartis of the
issuance of each patent included within the Versicor Patent Rights as to which
Novartis is licensed under this Agreement, giving the date of issue, patent
number and normal expiry date for each such patent. Versicor shall notify
Novartis of each filing for patent term restoration under the United States Drug
Price Competition and Patent Term Restoration Act of 1984, any

                                       13
<PAGE>

allegations of failure to show due diligence, and all awards of patent term
restoration in the United States with respect to the Versicor Patent Rights as
to which Novartis is licensed under this Agreement. Novartis shall make
corresponding notifications to Versicor in respect of any patent included within
the Joint Patent Rights.

      6.4 Patent Term Extension. Versicor shall cooperate with Novartis in
obtaining patent term extension or supplemental protection certificates and the
like with respect to the Versicor Patent Rights and Joint Patent rights as to
which Novartis is licensed under this Agreement, in each country and region
where it is possible to do so. Novartis shall have the right to make the
election and Versicor agrees to abide by such election.

7. PATENT INFRINGEMENT.

      7.1 Enforcement.

            (a) Each Party shall promptly notify the other of its knowledge of
any actual or potential infringement of the Versicor Patent Rights or the Joint
Patent Rights (collectively, the "Patent Rights") by a Third Party with respect
to a Product as to which Novartis is licensed under this Agreement.

            (b) Novartis shall have the right to enforce the Patent Rights in
the Territory in its discretion with respect to a Product as to which Novartis
is licensed under this Agreement. If within six (6) months following receipt of
notice from Versicor, Novartis falls to take action to halt infringement,
Versicor shall, in its sole discretion, have the right, at its expense, to take
such action in its own name or jointly with Novartis. Each Party agrees to
render such reasonable assistance as the prosecuting Party may request.

            (c) Costs of maintaining any such action therefrom shall be paid by
the Party or Parties bringing the action. Neither Party shall enter into any
settlement which admits or concedes that any aspect of the Patent Rights is
invalid or unenforceable without the prior written consent of the other Party.
Notwithstanding the foregoing, in the event either Party receives notice of a
Third Party who has filed an Abbreviated NDA ("ANDA") or paper NDA with respect
to a Product as to which Novartis is licensed under this Agreement containing a
certification of patent invalidity or noninfringement of one or more of the
Versicor Patent Rights in the United States, the notified Party shall notify the
other Party within ten (10) days thereof. Novartis shall have the right, but not
the obligation, to bring an action for infringement within twenty (20) days from
the date it receives notice, or if Novartis falls to bring such action, Versicor
shall, in its sole discretion, have the right, at its expense, to take such
action in its own name or jointly with Novartis. Any recovery achieved as a
result of an action brought by either Party shall belong to the Party bringing
the action. If it is decided that both Parties take enforcement action together
and split the costs 50/50, then any rewards will likewise be split 50/50.

      7.2 Infringement Claims. If the manufacture, sale or use of Product
pursuant to this Agreement results in any claim, suit or proceeding lodged by a
Third Party alleging patent infringement by Versicor or Novartis (or its
licensees or sublicensees), or by an Affiliate of Versicor or Novartis, such
Party shall promptly notify the other Party hereto in writing. The Party subject
to such claim shall have the exclusive right to defend and control the defense
of any such claim, suit or proceeding, at its own expense, using counsel of its
own

                                       14
<PAGE>

choice; provided, however, that Novartis shall not enter into any settlement
which admits or concedes that any aspect of the Versicor Patent Rights or Joint
Patent Rights is invalid or unenforceable without the prior written consent of
Versicor. The Party subject to the claim shall keep the other Party hereto
reasonably informed of all material developments in connection with any such
claim, suit or proceeding.

8. TRADEMARKS.

      Novartis shall be free to use and to register in any trademark office in
the Territory any trademark for use with Product it desires in its sole
discretion. Novartis shall own all right, title and interest in and to any
trademark in its own name during and after the term of this Agreement. Nothing
in this Article 8 is to be construed as granting any rights to Novartis with
respect to any trademark owned by Versicor.

9. LICENSE GRANTS

      9.1 Research License Grants.

            (a) Grant by Versicor. Versicor hereby grants to Novartis and its
Affiliates a worldwide, nonexclusive, non-transferable, royalty-free research
license during the Research Program Term under Versicor's interest in Versicor
Patent Rights, Joint Patent Rights, Research Compounds and Know-How of Versicor,
subject to the terms of this Agreement, solely for the purpose of carrying out
Novartis' responsibilities under the Research Program.

            (b) Grant by Novartis. Novartis hereby grants to Versicor and its
Affiliates a worldwide, nonexclusive, non-transferable, royalty-free research
license during the Research Program Term under Novartis' interest in Patent
Rights of Novartis, Joint Patent Rights, Research Compounds and Know-How of
Novartis, subject to the terms of this Agreement, solely for the purpose of
carrying out Versicor's responsibilities under the Research Program.

      9.2 Commercial License Grants. Subject to the terms and conditions of this
Agreement, Versicor hereby grants to Novartis and its Affiliates an exclusive,
royalty-bearing license in the Territory, with the right to sublicense pursuant
to Section 9.4, under Versicor Patent Rights and Versicor's interest in Joint
Patent Rights and Versicor's Know-How (pursuant to this Agreement) to develop,
make, have made, use, sell, offer for sale and import Products in the Field of
Use, subject to Versicor's right to co-promote the Co-Promotion Option Products
in the U.S. and Canada in accordance with Article 5 hereof.

      9.3 Commercial Due Diligence. The rights granted under Section 9.2 shall
be subject to Novartis' obligation to develop and commercially exploit Products
using the same degree of diligence it would for its own products of comparable
commercial potential. If Novartis fails to use such diligence (provided that
Novartis is not prevented in meeting its obligation to develop and commercially
exploit Products by force majeure, government regulation or intervention or
institution of a lawsuit by a Third Party), Versicor may notify Novartis of such
failure and, if not cured within six (6) months of such notice, terminate the
license with respect to such Product, except if Novartis replaces Products for
which it is thus

                                       15
<PAGE>

prevented to meet its obligation for development and commercial exploitation
with a Back-Up Compound.

      9.4 Sublicensing. Novartis shall have the right to grant sublicenses in
the Territory under the license granted in Section 9.2 above. Novartis shall
inform Versicor of each sublicense promptly after granting such sublicense. No
sublicense shall relieve Novartis of any obligations under this Agreement.
Novartis will guarantee that the rights of Versicor are not adversely affected
by any sublicense granted pursuant to this Section 9.4.

      9.5 Limited Research License after Research Program Term. After the
expiration or termination of the Research Program Term, the license granted to
Novartis under Section 9.1(a) with respect to Targets and Target Assays shall be
limited to the use of Target Assays in the course of derivatisation and
optimization of Research Compounds, but not for the de novo screening of
compounds by Novartis.

10. FINANCIAL TERMS

      10.1 Technology Transfer Milestone Payments.

      In consideration of Versicor's work on the Research Program and the
license and option rights granted to Novartis hereunder, Novartis shall pay the
following amounts to Versicor upon the achievement of each of the applicable
milestones.

--------------------------------------------------------------------------------
            Milestone                                Milestone Payment
--------------------------------------------------------------------------------

             [ * ]                                        [ * ]

--------------------------------------------------------------------------------

provided, however, that in no event shall Novartis be required to pay
Versicor under this Section 10.1 more than One Million Five Hundred Thousand
U.S. dollars ($1,500,000). Payments made to Versicor pursuant to this Section
10.1 will be non-refundable and not be creditable against any other payments
payable by Novartis to Versicor under this Agreement.

      10.2 Development Milestone Payments.

            (a) Versicor Compounds. For the first EDC, and for each CDC and each
Product being or containing a Versicor Compound, Novartis shall pay Versicor
each of the milestone payments set forth below at the time of their first
achievement:

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                       16
<PAGE>

--------------------------------------------------------------------------------
            Milestone                                Milestone Payment
--------------------------------------------------------------------------------

             [ * ]                                        [ * ]

             Total                                    $13,000,000

provided, however, that if a Versicor Compound pursuant to this subsection (a)
is abandoned during development after one or more of the milestone payments B.,
C., or D. above has been made, and if a Back-Up Compound is developed to replace
such abandoned Versicor Compound, then no milestone payment B., C. or D. shall
be made in respect of the Back-Up Compound which milestone payment, has already
been made in respect of the abandoned Versicor Compound.

All payments made under this subsection (a) shall be creditable in the amount of
50% against royalty payments on Net Sales of the EDC, CDC and Product for which
such milestone payment was made, provided, however, that any one royalty payment
shall not be reduced by more than 50% of the total royalty payment due.

            (b) Novartis Compounds. For the first EDC, and for each CDC and each
Product being or containing a Novartis Compound, Novartis shall pay Versicor
each of the milestone payments set forth below at the time of their first
achievement:

--------------------------------------------------------------------------------
            Milestone                                Milestone Payment
--------------------------------------------------------------------------------

             [ * ]                                        [ * ]

             Total                                     $7,250,000

provided, however, that if a Novartis Compound pursuant to this subsection (b)
is abandoned during development after one or more of the milestone payments B.,
C., or D. above has been made, and if a Back-Up Compound is developed to replace
such abandoned Novartis Compound, then no milestone payment B., C. or D. shall
be made in respect of the Back-Up Compound which milestone payment has already
been made in respect of the abandoned Novartis Compound.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                       17
<PAGE>

All payments made under this subsection (b) shall be creditable in the amount of
25% against royalty payments on Net Sales of the EDC, FDC and Product for which
such milestone payment was made, provided, however, that any one royalty payment
shall not be reduced by more than 50% of the total royalty payment due.

      10.3 Royalties.

            (a) Versicor Compounds. Except in countries where Versicor elects to
co-promote a Product pursuant to Article 5, Novartis will pay royalties per
Product being or containing a Versicor Compound, based on the annual Net Sales
of each Product, which royalties will be calculated by multiplying Net Sales by
the royalty rate set forth in the following schedule:

<TABLE>
<S>                                                                <C>
------------------------------------------------------------------------------
On annual Net Sales less than $300 million                         [ * ]
------------------------------------------------------------------------------
On the portion of annual Net Sales equal to or greater
than $300 million but less than $500 million                       [ * ]
------------------------------------------------------------------------------
On the portion of annual Net Sales equal to or greater
than $500 million but less than $1,000 million                     [ * ]
------------------------------------------------------------------------------
On the portion of annual Net Sales equal to or greater
than $1,000 million                                                [ * ]
------------------------------------------------------------------------------
</TABLE>

provided, however, that royalties under this Section 10.3(a) shall be payable on
a country-by-country basis for the longer of (i) the period that such Product,
its manufacture, use or sale is covered by a Valid Claim in such country or (ii)
ten (10) years from the date of First Commercial Sale of each Product in such
country;

provided, furthermore, that if after expiry of the relevant Valid Claim in a
country, substantial competition in the sale of a Product being or containing a
Versicor Compound is created by any independent Third Party entering the market
with such a Product, then with respect solely to such country any royalty still
payable shall be reduced by of the amounts set forth above, commencing with the
first full calendar quarter following written notice to Versicor of such
substantial competition and continuing for only so long as such substantial
competition exists. As used in this Section, "substantial competition" shall
mean a market share of an independent Third Party entering the market of greater
than twenty percent (20%) of the Novartis sales of the respective Product as
shown by IMS Panel data or, if not available, such market research data mutually
agreed upon by the Parties.

            (b) Novartis Compounds. Novartis will pay royalties per Product
being or containing a Novartis Compound based on the annual Net Sales of each
Product, which royalties will be calculated by multiplying Net Sales by the
royalty rate set forth in the following schedule:

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                       18
<PAGE>

<TABLE>
<S>                                                                <C>
------------------------------------------------------------------------------
On annual Net Sales less than $300 million                         [ * ]
------------------------------------------------------------------------------
On the portion of annual Net Sales equal to or greater
than $300 million but less than $500 million                       [ * ]
------------------------------------------------------------------------------
On the portion of annual Net Sales equal to or greater
than $500 million but less than $1,000 million                     [ * ]
------------------------------------------------------------------------------
On the portion of annual Net Sales equal to or greater
than $1,000 million                                                [ * ]
------------------------------------------------------------------------------
</TABLE>

provided, however, that royalties under this Section 10.3(b) shall be payable on
a country-by-country basis for ten (10) years from the date of First Commercial
Sale of each Product in such country.

      10.4 Equity Investment by Novartis. On the terms and subject to the
conditions set forth in the Stock Purchase Agreement entered into as of the date
hereof between the Parties (the "Stock Purchase Agreement"), a copy of which is
attached hereto as Exhibit E, Novartis shall make an investment in Versicor's
stock in the aggregate amount of five million U.S. dollars ($5,000,000),
three million dollars ($3,000,000) upon the execution of this Agreement and
two million dollars ($2,000,000) on the first anniversary of the execution of
this Agreement. Payments made to Versicor pursuant to the Stock Purchase
Agreement are solely for the purchase of Versicor stock, and will not be
credited against any payments due Versicor under this Agreement.

11. ROYALTY REPORTS AND ACCOUNTING

      11.1 Reports and Records. During the term of the Agreement following the
First Commercial Sale of a Product, Novartis shall furnish to Versicor a written
report for each calendar quarter showing, on a country by country basis, (a) the
gross sales of all Products sold by Novartis and its sublicensees during the
reporting period, the deductions made from gross sales in the calculation of Net
Sales, (b) the calculation and amount of royalties payable under this Agreement,
in U.S. dollars; and (c) the exchange rates used in determining the amount of
U.S. dollars. Novartis shall keep complete and accurate records in sufficient
detail to properly reflect all gross sales and Net Sales and to enable the
royalties payable hereunder to be determined.

      11.2 Currency Conversion. With respect to sales of Products invoiced in
U.S. dollars, the gross sales, Net Sales, and royalties payable shall be
expressed in U.S. dollars. With respect to sales of Products invoiced in a
currency other than U.S. dollars, the gross sales, Net Sales and royalties
payable shall be expressed in the domestic currency of the Party making the sale
together with the U.S. dollar equivalent of the royalty payable, calculated
using the average closing buying rate for such currency quoted in the
continental terms method of quoting exchange rates (local currency per U.S. $1)
of Citibank N.A., New York, or, in the absence of quoted exchange rates from
Citibank N.A., a comparable bank or financial institution, on the last business
day of the quarter for which the payment is being

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                       19
<PAGE>

made. Reports shall be due on the sixtieth (60th) day following the close of
each calendar quarter.

      11.3 Audits. Upon the written request of Versicor and not more than once
in each calendar year, Novartis shall permit an independent certified accounting
firm of nationally recognized standing, selected by Versicor and reasonably
acceptable to Novartis, at Versicor's expense, to have access during normal
business hours to such of the records of Novartis as may be reasonably necessary
to verify the accuracy of the royalty reports hereunder for any year of the
previous five (5) year period. The accounting firm shall disclose to Versicor
only whether the records are correct or not and the specific details concerning
any discrepancies. No other information shall be shared.

      If such accounting firm concludes that additional royalties were owed
during such period, Novartis shall pay the additional royalties within thirty
(30) days of the date Versicor delivers to Novartis such accounting firm's
written report so concluding. If the audit discloses a discrepancy between
royalties paid and royalties owed of more than 5%, then Novartis shall pay
interest at the prime rate on the additional royalties owed, and shall pay the
fees charged by the accounting firm.

12. METHOD OF PAYMENTS

      12.1 Payment Terms.

            (a) Milestone Payments. All payments to be made by Novartis to
Versicor pursuant to Sections I0.1 and 10.2 above shall be made within thirty
(30) days of receipt of an invoice from Versicor. Novartis shall promptly report
to Versicor the occurrence of any event triggering a milestone payment.

            (b) Royalty Payments. Royalty reports pursuant to Section 11.1 above
together with the royalty payable for the periods to which the reports relate
shall be due on the sixtieth (60th) day following the close of each calendar
quarter.

      12.2 Payment Method. Except as otherwise agreed between the Parties, all
royalties and other payments due hereunder shall be paid in U.S. dollars. All
royalties and other payments by Novartis to Versicor under the Agreement shall
be originated from a United States bank located in the United States and shall
be made by bank wire transfer in immediately available funds to such account as
Versicor shall designate before such payment is due. If at any time legal
restrictions in any country in the Territory prevent the prompt remittance in
the manner set forth in this Section 12.2 of part or all royalties owing with
respect to Product sales in such country, then the Parties shall meet and
mutually determine a lawful of such royalty payments so long as such legal
restrictions exist.

      12.3 Withholding Taxes. All royalty amounts required to be paid to
Versicor pursuant to this Agreement shall be paid with deduction for withholding
for or on account of any taxes (other than taxes imposed or measured by net
income) or similar governmental charge imposed by a jurisdiction other than the
US on Versicor ("Withholding Taxes"). Novartis shall provide Versicor a
certificate evidencing payment of any Withholding Taxes hereunder and provide
reasonable assistance to recover such taxes.

                                       20
<PAGE>

13. CONFIDENTIALITY

      13.1 Confidentiality. Except to the extent expressly authorized by this
Agreement or otherwise agreed in writing by the Parties, the Parties agree that,
for the term of this Agreement and for five (5) years thereafter, the receiving
Party (the "Receiving Party") shall keep confidential and shall not publish or
otherwise disclose and shall not use for any purpose other than as provided for
in this Agreement any Information furnished to it by the other Party (the
"Disclosing Party") pursuant to this Agreement (the "Confidential Information")
unless the Receiving Party can demonstrate by contemporaneous, competent written
proof that such Confidential Information:

            (a) was already known to the Receiving Party, other than under an
obligation of confidentiality, at the time of disclosure by the Disclosing
Party;

            (b) was generally available to the public or otherwise part of the
public domain at the time of its disclosure to the Receiving Party;

            (c) became generally available to the public or otherwise part of
the public domain after its disclosure and other than through any act or
omission of the Receiving Party in breach of the Agreement;

            (d) was disclosed to the Receiving Party, other than under an
obligation of confidentiality to a Third Party, by a Third Party who had no
obligation to the Disclosing Party or any Third Party not to disclose such
information to others; or

            (e) was independently discovered or developed by the Receiving Party
without the use of Confidential Information belonging to the Disclosing Party.

      13.2 Authorized Disclosure. Each Party may disclose Confidential
Information belonging to the other Party to the extent such disclosure is
reasonably necessary in the following instances:

            (a) filing or prosecuting patent applications under this Agreement;

            (b) regulatory filings;

            (c) prosecuting or defending litigation;

            (d) complying with applicable governmental regulations;

            (e) conducting pre-clinical or clinical trials of Products; and

            (f) disclosure to Affiliates, sublicensees, employees, consultants
or agents who agree to be bound by similar terms of confidentiality and non-use
at least equivalent in scope to those set forth in this Article 13.

      Notwithstanding the foregoing, in the event a Party is required to make a
disclosure of the other Party's Confidential Information pursuant to this
Section 13.2 it will, except where impracticable, give reasonable advance notice
to the other Party of such disclosure and use best efforts to secure
confidential treatment of such information. In any event, the Parties

                                       21
<PAGE>

agree to take all reasonable action to avoid disclosure of Confidential
Information hereunder. The Parties will consult with each other and agree on the
provisions of this Agreement to be redacted in any filings made by the Parties
with the Securities and Exchange Commission or as otherwise required by law.

      13.3 Samples. Samples of compounds provided by one Party (the "Supplying
Party") to the other Party (the "Receiving Party") during the Research Program
shall not be supplied or sent by the Receiving Party to any Third Party without
the written consent of the Supplying Party.

14. SCIENTIFIC AND OTHER PUBLICATIONS

      14.1 Scientific Publications.

            (a) Review and Approval. Each Party to this Agreement recognizes
that the publication of papers, including oral presentations and abstracts,
regarding the Research Program or results generated in the course thereof,
subject to reasonable controls to protect Confidential Information, can be
beneficial to both Parties. However, each Party shall have the right to review
and approve any paper proposed for publication by the other Party, including
oral presentations and abstracts, which utilizes data generated from the
Research Program or includes Confidential Information of the reviewing Party.

            (b) Review and Approval Process. At least forty-five (45) days
before any such paper, oral presentation or abstract is presented or submitted
for publication, the Party proposing publication shall deliver a complete copy
to the other Party. The receiving Party shall review any such paper, oral
presentation or abstract and give its comments to the publishing Party within
thirty (30) days of the delivery of such paper to the receiving Party. With
respect to papers, oral presentation materials and abstracts, the Parties shall
make reasonable efforts to expedite review of such materials and abstracts, and
shall return such items as soon as practicable to the publishing Party with
appropriate comments, if any, but in no event later than thirty (30) days from
the delivery date thereof to the receiving Party. The publishing Party shall
comply with the other Party's request to delete references to such other Party's
Confidential Information in any such paper and agrees to withhold publication of
same an additional ninety (90) days in order to permit the Parties to obtain
patent protection, if either of the Parties deem it necessary, in accordance
with the terms of this Agreement.

      14.2 Terms of this Agreement/Use of Name/Press Releases. Except as
required by applicable law or regulation, neither Party shall use the name of
the other Party in any publicity or advertising without the prior written
approval of the other Party, except that either Party may disclose the existence
of the collaboration. Versicor and Novartis each agrees not to disclose any
terms or conditions of this Agreement to any Third Party without the prior
consent of the other Party, except as required by applicable law or to persons
with whom Novartis or Versicor has entered into or proposes to enter into a
business relationship related to the subject matter hereof or to potential
financial investors of Versicor, and provided that such persons are subject to
appropriate confidentiality agreements.

      Notwithstanding the foregoing, Novartis and Versicor agree that the
information contained in a press release mutually agreed by the Parties may be
used to describe the nature

                                       22
<PAGE>

of this transaction, and Novartis and Versicor may disclose such information, as
modified by mutual agreement from time to time, without the other Party's
consent.

15. REPRESENTATIONS AND WARRANTIES

      15.1 Representations and Warranties. Each Party represents and warrants to
the other that:

            (a) Corporate Power. It is duly organized and validly existing under
the laws of its state or country of incorporation, and has full corporate power
and authority to enter into this Agreement and to carry out the provisions
hereof.

            (b) Due Authorization. It is duly authorized to execute and deliver
this Agreement and to perform its obligations hereunder, and the person or
persons executing this Agreement on its behalf has been duly authorized to do so
by all requisite corporate action.

            (c) Binding Agreement. This Agreemento is legally binding upon it
and enforceable in accordance with its terms. The execution, delivery and
performance of this Agreement by it does not conflict with any agreement,
instrument or understanding, oral or written, to which it is a Party or by which
it may be bound, nor violate any material law or regulation of any court,
governmental body or administrative or other agency having jurisdiction over it.

            (d) Grant of Rights; Maintenance of Agreements. It has not, and will
not during the term of this Agreement, grant any right to any Third Party which
would conflict with the rights granted to the other Party hereunder. It has (or
will have at the time performance is due) maintained and will maintain and keep
in full force and effect all agreements necessary to perform its obligations
hereunder.

            (e) Validity. It is aware of no action, suit or inquiry or
investigation instituted by any governmental agency which questions or threatens
the validity of this Agreement.

            (f) Employee Obligations. All of its employees, officers and
consultants have executed agreements requiring in the case of employees and
officers, assignment to the Party of all inventions made during the course of
and as a result of their association with such Party and obligating the
individual to maintain as confidential the confidential information of the
Party, as well as the confidential information of a Third Party which such Party
may receive.

      15.2 Disclaimer Concerning Technology. THE TECHNOLOGY PROVIDED BY EACH
PARTY HEREUNDER IS PROVIDED "AS IS" AND EACH PARTY EXPRESSLY DISCLAIMS ANY AND
ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION THE
WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE,
NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES OR ARISING
FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES, IN ALL CASES WITH RESPECT
THERETO. Without limiting the generality of the foregoing, each Party expressly
does not warrant (i) the success of any

                                       23
<PAGE>

research commenced under the Research Program or (ii) the safety or usefulness
for any purpose of the technology it provides hereunder.

16. TERM AND TERMINATION

      16.1 Expiration. Unless terminated earlier pursuant to Section 16.4 or
16.5 below, the Agreement shall expire on the expiration of Novartis' obligation
to pay royalties under the Agreement, and the licenses granted by Versicor to
Novartis hereunder shall become fully paid-up and royalty-free, on a
country-by-country basis.

      16.2 Abbreviation of the Research Program Term. Novartis shall have the
right to terminate the Research Program at the end of the second year of the
Research Program Term with three month's prior written notice to Versicor. If
Novartis so terminates, Novartis will keep all rights and licenses accrued
before such early termination, subject to the milestone and royalty payment
obligations of Novartis described in Sections 10.2 and 10.3.

      16.3 Effect of Expiration or Termination. Upon expiration or termination
of this Agreement, the obligations which by their nature are intended to survive
expiration or termination of the Agreement, shall survive.

      16.4 Termination In Case of Bankruptcy.

            (a) Either Party may terminate this Agreement if, at any time, the
other Party shall file in any court or agency pursuant to any statute or
regulation of any state or country, a petition in bankruptcy or insolvency or
for reorganization or for an arrangement or for the appointment of a receiver or
trustee of the Party or of its assets, or if the other Party proposes a written
agreement of composition or extension of its debts, or if the other Party shall
be served with an involuntary petition against it, filed in any insolvency
proceeding, and such petition shall not be dismissed within sixty (60) days
after the filing thereof, or if the other Party shall propose or be a Party to
any dissolution or liquidation, or if the other Party shall make an assignment
for the benefit of creditors.

            (b) Notwithstanding the bankruptcy of Versicor, or the impairment of
performance by Versicor of its obligations under this Agreement as a result of
bankruptcy or insolvency of Versicor, Novartis shall be entitled to retain the
licenses granted herein, subject to Versicor's rights to terminate this
Agreement for reasons other than bankruptcy or insolvency as expressly provided
in this Agreement, and subject to performance by Novartis of its preexisting
obligations under this Agreement. Notwithstanding the bankruptcy of Novartis, or
the impairment of performance by Novartis of its obligations under this
Agreement as a result of bankruptcy or insolvency of Novartis, Versicor shall be
entitled to retain the licenses granted herein, subject to Novartis' rights to
terminate this Agreement for reasons other than bankruptcy or insolvency as
expressly provided in this Agreement, and subject to performance by Versicor of
its preexisting obligations under this Agreement.

            (c) All rights and licenses granted under or pursuant to this
Agreement by Versicor to Novartis, and by Novartis to Versicor, are, and shall
otherwise be deemed to be, for purposes of Section 365(n)of the U.S. Bankruptcy
Code, licenses of rights to "intellectual property" as defined under Section
101(52) of the U.S. Bankruptcy Code. The Parties agree that each Party, as a
licensee of such rights under this Agreement, shall retain and may fully

                                       24
<PAGE>

exercise all of its rights and elections under the U.S. Bankruptcy Code, subject
to performance by the licensee of its preexisting obligations under this
Agreement. The Parties further agree that, in the event of the commencement of a
bankruptcy proceeding by or against the licensor under the U.S. Bankruptcy Code,
the licensee shall be entitled to a complete duplicate of (or complete access
to, as appropriate) any such intellectual property and all embodiments of such
intellectual property, and same, if not already in its possession, shall be
promptly delivered to the licensee (a) upon any such commencement of a
bankruptcy proceeding upon written request therefor by the licensee, unless the
licensor elects to continue to perform all of its obligations under this
Agreement, or (b) if not delivered under (a) above, upon the rejection of this
Agreement by or on behalf of the licensor upon written request therefor by the
licensee, provided, however, that upon the licensor's (or its successor's)
written notification to the licensee that it is again willing and able to
perform all of its obligations under this Agreement, the licensee shall promptly
return all such tangible materials to the licensor, but only to the extent that
the licensee does not require continued access to such materials to enable the
licensee to perform its obligations under this Agreement.

      16.5 Termination for Material Breach. Either Party may terminate the
Research Program in the case of a material breach of the Agreement by the other
which is not cured after sixty (60) days from the giving of notice of such
breach.

17. LIABILITY/INDEMNITY

      17.1 Indemnification by Novartis. Novartis shall defend, indemnify and
hold harmless Versicor, Affiliates of Versicor, licensors of Versicor, and their
respective directors, officers, shareholders, agents and employees (each an
"Versicor Indemnified Party"), from and against any and all liability, loss,
damages and expenses (including attorneys' fees) as the result of claims,
demands, costs or judgments which may be made or instituted against any of them
arising out of the manufacture, possession, distribution, use, testing, sale or
other disposition of Products by or through Novartis or its Affiliates,
licensees or sublicensees. Novartis' obligation to defend, indemnify and hold
harmless shall include claims, demands, costs or judgments, whether for money
damages or equitable relief by reason of alleged personal injury (including
death) to any person or alleged property damage, provided, however, the
indemnity shall not extend to any claims against a Versicor Indemnified Party
which result from the gross negligence or willful misconduct of a Versicor
Indemnified Party.

      17.2 Indemnification by Versicor. Versicor shall defend, indemnify and
hold harmless Novartis and its Affiliates, licensors of Novartis, and their
respective directors, officers, shareholders, agents and employees (each a
"Novartis Indemnified Party"), from and against any and all liability, loss,
damages and expenses (including attorneys' fees) as the result of claims,
demands, costs or judgments which may be made or instituted against any of them
arising out of the promotion of Product by or through Versicor or its Affiliates
(or their licensees or sublicensees) pursuant to the Co-Promotion Agreement.
Versicor's obligation to defend, indemnify and hold harmless shall include
claims, demands, costs or judgments, whether for money damages or equitable
relief by reason of alleged personal injury (including death) to any person or
alleged property damage; provided, however, the indemnity shall not extend to
any claims against an indemnified party which result from the gross negligence
or willful misconduct of a Novartis Indemnified Party.

                                       25
<PAGE>

      17.3 Procedure in Event of Claim. Any Versicor Indemnified Party or
Novartis Indemnified Party that intends to claim indemnification under this
Article 17 (the "Indemnitee") shall promptly notify the other Party (the
"Indemnitor") of any loss, claim, damage, liability or action in respect of
which the Indemnitee intends to claim such indemnification, and the Indemnitor
shall assume the defense thereof with counsel mutually satisfactory to the
Parties; provided, however, that an Indemnitee shall have the right to retain
its own counsel, with the fees and expenses to be paid by the Indemnitor if
Indemnitor does not assume the defense; or, if representation of such Indemnitee
by the counsel retained by the Indemnitor would be inappropriate due to actual
or potential differing interests between such Indemnitee and any other Party
represented by such counsel in such proceedings. The indemnity agreement in this
Article 17 shall not apply to amounts paid in settlement of any loss, claim,
damage, liability or action if such settlement is effected without the consent
of the Indemnitor, which consent shall not be withheld unreasonably. Without the
written consent of the Indemnitee (which consent shall not be unreasonably
withheld), the Indemnitor shall not agree to settle any claim against the
Indemnitee to the extent that such claim has a material adverse effect on the
Indemnitee. The failure to deliver notice to the Indemnitor within a reasonable
time after the commencement of any such action, if prejudicial to its ability to
defend such action, shall relieve such Indemnitor of any liability to the
Indemnitee under this Article 17, but the omission to deliver notice to the
Indemnitor will not relieve it of any liability that it may have to the
Indemnitee otherwise than under this Article 17. The Indemnitee under this
Article 17, its employees and agents, shall cooperate fully with the Indemnitor
and its legal representatives in the investigation of any action, claim or
liability covered by this indemnification. In the event that each Party claims
indemnity from the other and one Party is finally held liable to indemnify the
other, the Indemnitor shall additionally be liable to pay the reasonable legal
costs and attorneys' fees incurred by the Indemnitee in establishing its claim
for indemnity.

      17.4 Reporting. Each Party hereto agrees to report promptly to the other
Party any information concerning serious or unexpected side effects, in jury,
toxicity, reactions or any unexpected event associated with clinical,
investigational or commercial use whether or not finally attributable to
Product. Such information shall also include preexisting diseases, syndromes, or
abnormal diagnostic tests results which reappear or are exacerbated by use of
Product. Upon receipt of such information by either Party hereto, both Parties
shall promptly consult each other and use best efforts to arrive at a mutually
acceptable procedure for taking the appropriate actions under the circumstances;
pro vided, however, that nothing contained herein shall restrict the right of
either Party to make a submission to a regulatory authority or take other
actions it deems to be appropriate or necessary.

      17.5 Insurance. Novartis shall maintain, through self-insurance or
otherwise, Product liability insurance with respect to the development,
manufacture and sale of Products in such amount as Novartis customarily
maintains with respect to its other Products. Novartis shall maintain such
insurance for so long as it continues to develop, manufacture or sell any
Products, and thereafter for so long as Novartis maintains insurance for itself
covering such manufacture or sales. In case Versicor will co-promote in the U.S.
and/or Canada pursuant to the provisions of Article 5, the provisions of this
Section 17.5 will, mutatis mutandis, apply also to Versicor.

                                       26
<PAGE>

      17.6 Survival. The provisions of this Article 17 shall survive and remain
in full force and effect after any termination, expiration or cancellation of
this Agreement and the Indemnitor's obligation hereunder shall apply whether or
not such claims are rightfully brought.

18. MISCELLANEOUS

      18.1 Force Majeure. Neither Party shall be held liable or responsible to
the other Party nor be deemed to have defaulted under or breached this Agreement
for failure or delay in fulfilling or performing any term of this Agreement when
such failure or delay is caused by or results from causes beyond the reasonable
Control of the affected Party including but not limited to fire, floods,
embargoes, war, acts of war (whether war be declared or not), insurrections,
riots, civil commotions, strikes, lockouts or other labor disturbances, acts of
God or acts, omissions or delays in acting by any governmental authority or the
other Party.

      18.2 Assignment. This Agreement may not be assigned or otherwise
transferred, nor, except as expressly provided hereunder, may any right or
obligations hereunder be assigned or transferred by either Party without the
consent of the other Party; provided, however, that Versicor may, without such
consent, assign this Agreement and its rights and obligations hereunder in
connection with the transfer or sale of all or substantially all of its business
pertaining to this Agreement, or in the event of its merger or consolidation
with another entity or a change in control or similar transaction. Any permitted
assignee shall assume all obligations of its assignor under this Agreement.

      18.3 Severability. Each Party hereby agrees that it does not intend to
violate any public policy, statutory or common laws, rules, regulations, treaty
or decision of any government agency or executive body thereof of any country or
community or association of countries. In any term or provision of this
Agreement is held to be invalid, illegal or unenforceable by a court or other
governmental authority of competent jurisdiction, such invalidity, illegality or
unenforceability shall not affect any other term or provision of this Agreement,
which shall remain in full force and effect. The holding of a term or provision
to be invalid, illegal or unenforceable in a jurisdiction shall not have any
effect on the application of the term or provision in any other jurisdiction.

      18.4 Notices. Any consent, notice or report required or permitted to be
given or made under this Agreement by one of the Parties hereto to the other
shall be in writing, delivered personally or by facsimile transmission effective
upon such delivery and, in the case of facsimile transmission, confirmation of
receipt by the recipient (and promptly confirmed by personal delivery, first
class mail or courier), first class mail or courier, postage prepaid (where
applicable), addressed to such other Party at its address first set forth above,
or to such other address as the addressee shall have last furnished in writing
to the addressor and (except as otherwise provided in this Agreement) shall be
effective upon receipt by the addressee.

      18.5 Applicable Law. The Agreement shall be governed by and construed in
accordance with the laws of Delaware, as it applies to Delaware residents and a
transaction to be performed within Delaware.

                                       27
<PAGE>

      18.6 Entire Agreement. This Agreement contains the entire understanding of
the Parties with respect to the subject matter hereof and shall supersede all
express or implied agreements and under-standings, either oral or written,
heretofore made. This Agreement may be amended, or any term hereof modified,
only by a written instrument duly executed by both Parties hereto.

      18.7 Headings. The captions to the several Articles and Sections hereof
are not a part of this Agreement, but are merely guides or labels to assist in
locating and reading the several Articles and Sections hereof.

      18.8 Independent Contractors. It is expressly agreed that Versicor and
Novartis shall be independent contractors and that the relationship between the
two Parties shall not constitute a partnership, joint venture or agency. Neither
Versicor nor Novartis shall have the authority to make any statements,
representations or commitments of any kind, or to take any action, which shall
be binding on the other, without the prior consent of the Party to do so.

      18.9 U.S. Export Laws and Regulations. Each Party warrants and represents
to the other that it does not intend to, nor will it export from the United
States or re-export from any foreign country, or permit a Third Party to export
or re-export technology or technical information of the other Party, to a
Country where such export or re-export would be in violation of U.S. Export
Administration Regulations.

      18.10 Waiver. The waiver by either Party hereto of any right hereunder or
the failure to perform or of a breach by the other Party shall not be deemed a
waiver of any other right hereunder or of any other breach or failure by said
other Party whether of a similar nature or otherwise.

      18.11 Dispute Resolution. In the event of any dispute, the Parties shall
refer such dispute to a designated executive of Versicor and a designated
executive of Novartis for attempted resolution by good faith negotiations within
thirty (30) days after such referral is made. In the event such executives are
unable to resolve such dispute within such thirty (30) day period, either Party
may invoke the provisions of subsection (b) below.

      Any claim or controversy arising out of or related to this Agreement or
any breach hereof shall be adjudicated in the state and federal courts having
jurisdiction over disputes arising in the State of Delaware, and the Parties
hereby consent to the jurisdiction and venue of such court.

      18.12 Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

                                       28
<PAGE>

            IN WITNESS WHEREOF, the Parties have executed this Agreement as of
      the date first set forth above.

VERSICOR, INC.                         NOVARTIS PHARMA AG

By:    /s/ G. F. Horner III               By:    /s/ Dr. F. Harling   XXX
   ----------------------------               ----------------------------------
                                                 Head of Research
                                                 Novartis Pharma AG
Title: President & CEO                    Title: WSJ 3861306   Auth. Sign.
                                                 CH-4002 Barel/Switzerland

EXHIBITS

A     MUR Pathway
B     Research Plan
C     Co-Production Terms U.S./Canada
D     Versicor Patent Rights
E     Stock Purchase Agreement

<PAGE>

                             EXHIBIT A: MUR Pathway

<PAGE>

                                    EXHIBIT B

                                  RESEARCH PLAN

<PAGE>

                                    Exhibit B
                                  Research Plan

                                Mur Pathway Plan

                                Executive Summary

Current Status at Versicor:

The Escherichia coli genes for the Mur enzymes A through F, which catalyse the
synthesis UDP-MurNAc-pentapeptide (a critical cell wall precursor) have been
cloned and expressed. A proprietary pathway assay has been developed which
allows the simultaneous assay of all six enzymes in a single incubation. The mur
homologues in Streptococcus pneumoniae and Staphylococcus aureus have been
identified. Methodology has also been developed to deconvolute any hits
identified and identify the specific step that is inhibited. Construction of
Gene to Screen assays has been initiated in which the regulation of individual
mur genes will provide evidence on the mechanism of hits active against whole
cells. Based on a knowledge of the unusual biochemical reaction catalysed by the
ligases, a series of mechanism based pharmacophoric scaffolds have been designed
and the corresponding building blocks have been synthesized. These novel
chemical entities have been utilized in the construction of focused libraries
and their testing for ligase inhibition using the pathway screen has led to the
identification of several hits.

Proposed collaboration with Novartis:

Versicor will supply to Novartis all reagents that are not commercially
available, together with the protocols and training necessary to carry out high
throughput screening with the mur pathway assay using the enzymes from E. coli
Key tour enzymes from S aureus and S pneumoniae will be provided to test the
enzyme inhibition spectrum of any leads found. A set of Gene to Screen strains
based on murA through murF constructs in E. coli for lead charecterisation will
also be supplied. Versicor will grant Novartis exclusive licenses for using
their proprietary DASA and Gene to Screen technologies on the enzymes of the Mur
pathway. Using a mechanism and structure based design approach, and utilizing
the information derived from early hits, Versicor chemists will design and
synthesize multi-substrate and transition-state analog pharmacophore building
blocks, and incorporate these in the preparation of potential mur pathway
inhibitor libraries. These libraries will be screened and characterized at
Versicor. Progress of the collaboration will be monitored by periodic meetings
of a jointly chaired Research Management Committee with equal representation
from Novartis and Versicor. The option of putting any lead(s) discovered at
Novartis into the Versicor chemistry program in place of existing Versicor leads
would be welcome and decided by the Research Management Council.

                       Bacterial Peptidyl DeformylasePlan

                                                                               1
<PAGE>

                                Executive Summary

Current Status of Program at Versicor:

The genes defA and defB for the essential bacterial enzyme Peptidyl Deformylase
have been cloned and expressed from Escherichia coli, Streptococcus pneumonia
and Staphylococcus aureus. Based on a knowledge of the enzyme's mechanism and
substrate requirements, a number of potential inhibitors have been designed and
tested using a high throughput coupled enzyme assay. This has resulted in the
discovery of several "hits" which have subsequently formed the basis for the
design of focussed combinatorial libraries. After two generations of library
synthesis, a number of highly potent Peptidyl Deformylase inhibitors (IC50's in
the low nanomolar range) have been obtained. Importantly, several of these lead
structures have significant activity (MIC's in the low micrograms/ml, range)
against intact clinically relevant bacteria. Biochemical and genetic evidence
has been obtained demonstrating that the mechanism of this whole cell activity
is through inhibition of Peptidyl Deformylase.

Proposed Collaboration with Novartis:

Versicor will transfer all the reagents and protocols required to carry out high
throughput screening at-Novartis, using deformylase from Escherichia coli Enzyme
from Streptococcus pneumoniae and Staphylococcus aureus will also be provided
for the purpose of secondary testing. Training of Novartis scientists, first at
Versicor and then at Novartis, will be provided to facilitate technology
transfer. The Gene to Screen constructs involving regulatable deformylase will
also be provided for screening and validating whether whole cell inhibition by
any hits discovered is due to deformylase inhibition. Versicor will continue
with its existing "in house" mechanism-based combinatorial chemistry program to
discover new lead structures and further develop its existing leads with the
objective of improving antibacterial potency, spectrum, and selectivity.
Versicor libraries and compounds will be characterized and screened at its site.
Progress of the collaboration will be monitored by periodic meetings of a
Research Management Committee with equal representation from Novartis and
Versicor scientific management, and jointly chaired. The option of putting any
lead(s) discovered at Novartis into the Versicor chemistry program would be
welcome and decided by the Research Management Council.

                                                                               2
<PAGE>

                                    EXHIBIT C

                         CO-PROMOTION TERMS U.S./CANADA

Co-Promotion Products and Market Segment

Versicor shall co-promote with Novartis I.V. antimicrobial formulations of the
Co-Promotion Option Products in the hospital markets of the U.S. and Canada to
key physicians and other medical personnel with the highest potential for
prescribing the Co-Promotion Option Product to in-patients and out-patients
("Target Audience"). Novartis shall be primarily responsible for the overall
marketing strategy and promotional activities, and shall manufacture, sell, book
sales of, and distribute the Co-Promotion Option Products. All Co-Promotion
Option Products shall be sold under a Novartis trademark.

Co-Promotion Profit

Versicor shall be compensated for its co-promotion efforts by receiving a
percentage of Co-Promotion Profit which shall equal Versicor's share of combined
Details of the Parties to the Target Audience, provided, however, that
Versicor's share of such Details shall be no less than 20% of total Details, and
no more than 40% of total Details. Such participation in Co-Promotion Profit
shall be in place of any royalty obligation of Novartis for sales of the
Co-Promotion Option Product in the U.S. and/or Canadian hospital market.

As used herein, "Co-Promotion Profit" shall mean the Net Sales of a Co-Promotion
Option Product, less COGS (as per U.S. GAAP) and advertising/promotion expenses.

As used herein, "Details" shall mean a first-position sales presentation made by
a Novartis or Versicor sales representative to a member of the Target Audience.

<PAGE>

                                    EXHIBIT D

                             VERSICOR PATENT RIGHTS

1.    Title:. Methods for Solid-Phase Synthesis of Hydroxylamine Compounds and
      Derivatives and Combinatorial Libraries Thereof

      U.S. Serial No.: 08/958,638
      Filed: October 27, 1997
      Priority Claimed: October 28, 1996 Ser. No 60/029,788; and May 23, 1997
      Ser. No. 60/047,468
      Status: Pending
      and
      U.S. Serial No.: 09/074,035
      Filed: May 6, 1998
      Priority Claimed: October 28, 1996; May 23, 1997; October 27, 1997
      Status: Pending

      WO 98/18754
      Filed: October 27, 1997
      Status: Preliminary Examination Filed

2.    Title: Direct Adsorption Scintillation Assay for Measuring Enzyme Activity
      and Assaying Biochemical Processes U.S. Serial No.: to be assigned Filed:
      February 9, 1999
      Priority Claimed: February 10, 1998
      Status: Pending

This application discloses methods for performing scintillation assays based on
general molecular property-based binding interactions, such as charge or
hydrophobicity. In a sample containing multiple molecular species capable of
stimulating scintillation, only species with the proper general molecular
property will localize to the scintillant and stimulate scintillation.
Scintillation counting can then determine the presence of and quantitate the
amount of the molecular species which is bound. This Direct Adsorption
Scintillation Assays (DASA) is more convenient and less expensive to use than
the Scintillation Proximity Assay (SPA), which relies on a specific binding
interaction (e.g., antibody-antigen) to localize a scintillation stimulator near
a scintillator.

These methods are particularly useful for quantitating changes in molecular
properties due to enzymatic processes; that is, the change in molecular
properties between substrate and product. The methods can be readily used in
high-throughput screens to determine compounds which inhibit the enzyme of
interest. The enzyme cascade MurA, MurB, MurC, MurD, MutE, MurF for the
synthesis of uridinediphosphate-N-acetylmuramic acid pentapeptide is disclosed,
as are assays for other enzymes of interest (matrix metalloproteinase, lipase,
kinase, phosphatase).

<PAGE>

Claims

The application as filed includes claims to methods of analyzing samples by the
direct adsorption scintillation assay; claims to determining reaction progress
using the DASA, methods for performing DASAs using particular scintillating
materials, methods for determining the progress of various reactions such as
protease, tRNA transferase, lipase, phosphatase, and kinase catalyzed reactions,
as well as the Mur pentapeptide pathway.

Use of the DASA assay in high throughput screens is claimed, including high
throughput screens for identifying inhibitors of proteases, tRNA transferases,
lipases, phosphatases, kinases, and the enzymes involved in the Mur pentapeptide
pathway. Claims are also presented to devices for performing the assay, in
particular multiwell plates prepared for use in DASA assays.

<PAGE>

                                    EXHIBIT E

                            STOCK PURCHASE AGREEMENT

<PAGE>

                               NOVARTIS PHARMA AG

                                       AND

                                  VERSICOR INC.

                            STOCK PURCHASE AGREEMENT

                                  CONFIDENTIAL

<PAGE>

                                TABLE OF CONTENTS

                                                                            PAGE

1.      PURCHASE AND SALE OF CAPITAL STOCK.....................................1
        1.1    Authorization...................................................1
        1.1.2  Sale and Purchase at First Closing..............................1
        1.1.3  Sale and Purchase at Second Closing.............................1
2.      CLOSING DATE, DELIVERY.................................................2
        2.1    First Closing Date..............................................2
        2.2    Second Closing Date.............................................2
        2.3    Further Assurances..............................................3
3.      REPRESENTATIONS AND WARRANTIES OF THE COMPANY..........................3
        3.1    Organization, Good Standing and Qualification...................3
        3.2    Capitalization and Voting Rights................................3
        3.3    Subsidiaries....................................................4
        3.4    Authorization...................................................4
        3.5    No Conflict.....................................................5
        3.6    Valid Issuance of Preferred and Common Stock....................5
        3.7    Indebtedness and Contractual Liabilities........................5
        3.8    Governmental Consents...........................................5
        3.9    Litigation......................................................5
        3.10   Employees and Consultants.......................................6
        3.11   Patents and Trademarks .........................................6
        3.12   Compliance with Other Instruments...............................7
        3.13   Agreements; Action..............................................7
        3.14   Registration Rights.............................................7
        3.15   Title to Property and Assets....................................7
        3.16   Financial Statements............................................8
        3.17   Employee Benefit Plans..........................................8
        3.18   Tax Returns, Payments and Elections.............................8
        3.19   Insurance.......................................................9
        3.20   Labor Agreements and Actions....................................9
        3.21   Real Property Holding Corporation...............................9

                                       i.
<PAGE>

                                TABLE OF CONTENTS
                                   (CONTINUED)

                                                                            PAGE

        3.22   Offering........................................................9
        3.23   Environmental Matters..........................................10
        3.24   Securities Laws................................................10
        3.25   Licenses and Other Rights; Compliance with Laws................11
        3.26   Reliance.......................................................11
        3.27   Brokerage......................................................11
4.      REPRESENTATIONS AND WARRANTIES OF THE INVESTOR........................11
        4.1    Authorization, Governmental Consents and Compliance with
               Other Instruments .............................................11
        4.2    Purchase Entirely for Own Account..............................11
        4.3    Investment Experience and Accredited Investor Status...........12
        4.4    Restricted Securities .........................................12
        4.5    Further Limitations on Disposition.............................12
        4.6    Legends........................................................12
5.      CONDITIONS TO CLOSING OF INVESTOR.....................................13
        5.1    First Closing..................................................13
        5.2    Second Closing.................................................14
6.      CONDITIONS TO THE COMPANY'S OBLIGATIONS AT THE FIRST AND SECOND
        CLOSINGS..............................................................15
        6.1    Representations and Warranties Correct.........................15
        6.2    Performance....................................................15
7.      MUTUAL CONDITIONS OF CLOSING..........................................15
        7.1    Qualifications.................................................15
        7.2    First Amended and Restated Investors' Rights Agreement.........15
        7.3    Absence of Litigation..........................................15
        7.4    Research Collaboration and License Agreement...................16
        7.5    Shares Available...............................................16
8.      COVENANTS OF THE COMPANY .............................................16
        8.1    Board Observer.................................................16
        8.2    Inspection of Properties.......................................16

                                      ii.
<PAGE>

                                TABLE OF CONTENTS
                                   (CONTINUED)

                                                                            PAGE

        8.3    Termination of Covenants.......................................16
9.      COVENANTS OF THE INVESTOR.............................................16
        9.1    Voting.........................................................16
        9.2    Standstill.....................................................17
        9.3    Right of First Offer...........................................17
10.     MISCELLANEOUS.........................................................18
        10.1   Survival of Warranties.........................................18
        10.2   Indemnification................................................18
        10.3   Remedies.......................................................19
        10.4   Successors and Assigns.........................................19
        10.5   Entire Agreement...............................................19
        10.6   Governing Law and Consent to Jurisdiction......................19
        10.7   Counterparts...................................................19
        10.8   Titles and Subtitles...........................................20
        10.9   Nouns and Pronouns.............................................20
        10.10  Notices........................................................20
        10.11  Finder's Fee...................................................20
        10.12  Expenses.......................................................21
        10.13  Amendments and Waivers.........................................21
        10.14  Severability...................................................21
        10.15  Confidentiality and Publicity..................................21
        10.16  Definitions....................................................21

                                      iii.
<PAGE>

                            STOCK PURCHASE AGREEMENT

      THIS STOCK PURCHASE AGREEMENT (the "Agreement") is made as of the __ day
of ________ ________, 1999, by and between NOVARTIS PHARMA AG ("Novartis" or the
"Investor"), a Corporation organized under the laws of Switzerland, with its
principal place of business at Lichtstrasse 35, CH-4002, Basel, Switzerland, and
VERSICOR, INC. ("Versicor" or the "Company"), a Delaware corporation with its
principal place of business at 34790 Ardentech Court, Fremont, California 94555,
USA.

      The parties hereby agree as follows:

1. PURCHASE AND SALE OF CAPITAL STOCK.

      1.1 Authorization. The Company shall adopt and file with the Secretary of
State of the State of Delaware before the First Closing (as defined in Section
2.1 herein) the Second Restated Certificate of Incorporation in the form
attached hereto as Exhibit A (the "Restated Certificate") and authorize the sale
and issuance of a sufficient number of shares of Series E-1 Preferred Stock (the
"Series E-1 Preferred") and Series E-2 Preferred Stock (the "Series E-2
Preferred") to perform fully its obligations hereunder. The shares of Common
Stock into which such Series E-1 Preferred and Series E-2 Preferred are
converted shall hereinafter be referred to as "Conversion Shares." The Series
E-1 Preferred and Series E-2 Preferred shall have the rights, powers and
privileges set forth in the Restated Certificate.

      1.2 Sale and Purchase at First Closing.

      1.3 Sale and Purchase at Second Closing.

            (a) Price Per Share at Second Closing.

                                       1.
<PAGE>

            (b) Capital Stock to be Issued at Second Closing. At the Second
Closing, the Company shall issue to the Investor the number of shares of Series
E-2 Preferred equal to the Second Purchase Price divided by the Second Closing
Share Price; provided, however, that in the event the Company has completed its
IPO by the Second Closing date, the Company shall issue shares of Common Stock
equal to the Second Purchase Price divided by the Second Closing Share Price.
The Investor understands and consents to the Company's reliance on Purchaser's
commitment hereunder for the purpose of securing adequate financing from other
investors in future preferred stock financings of the Company. The Series E-1
Preferred and Series E-2 Preferred (or, if applicable, the Common Stock issuable
at the Second Closing) are collectively referred to herein as the "Securities."

2. CLOSING DATE, DELIVERY.

      2.1 First Closing Date. The closing of the purchase and sale of the First
Closing Shares hereunder shall be held on the date hereof or such other date as
the Company and the Investor may agree upon (the "First Closing") at the offices
of Cooley Godward LLP, Five Palo Alto Square, 3000 El Camino Real, Palo Alto,
California 94306-2155, USA. The date of the First Closing is hereinafter
referred to as the "First Closing Date." At the First Closing, the Company shall
cause to be issued to the Investor a stock certificate dated as of the First
Closing Date, in the name of the Investor, representing the First Closing Shares
being purchased against payment of the purchase price therefor by check or by
wire transfer to the Company's Bank account. The Company shall deliver such
stock certificate to the Investor at the First Closing or promptly thereafter.
The Company will also make all such deliveries as are contemplated by Section 5
of this Agreement.

      2.2 Second Closing Date. The closing of the purchase and sale of the
Company's capital stock pursuant to Section 1.3 above (the "Second Closing")
shall take place at the Company's option and at any time subsequent to the
Pricing Date but not later than the second year anniversary of the date of this
Agreement. The Company shall give at least ten (10) business days prior written
notice of the Second Closing to the Investor, in a manner provided for in
Section 10.10, including the date, time and location of the Second Closing. At
the Second Closing, the Company shall cause to be issued to the Investor a stock
certificate, in the name of the Investor, representing shares of the Company's
Series E-2 Preferred or Common Stock, whichever is applicable, dated as of the
Second Closing, being purchased against payment of the purchase price therefor
by check or by wire transfer to the Company's bank account, unless the

                                       2.
<PAGE>

Company and Investor agree upon other means of payment. The Company shall
deliver such stock certificate to the Investor at the Second Closing or promptly
thereafter. The Date of the Second Closing is hereinafter referred to as the
"Second Closing Date." The First Closing and the Second Closing shall
individually be referred to as a "Closing" and collectively referred to as
"Closings." The parties agree that Novartis may assign the right and obligation
to purchase the applicable shares of capital stock at either of the Closings,
and all of its other rights and obligations under this Agreement, to an
"Affiliate" as defined in Section 10.16 hereof, in which case the term
"Investor" shall refer herein to such Affiliate.

      2.3 Further Assurances. The Company and the Investor hereby covenant and
agree without the necessity of any further consideration, to execute,
acknowledge and deliver any and all such other documents and take any such other
action as may be reasonably necessary to carry out the intent and purposes of
this Agreement.

3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. Subject to and except as
disclosed by the Company in the Schedule of Exceptions attached hereto as
Exhibit B (which exceptions shall be deemed to be representations and warranties
as if made hereunder), the Company hereby represents and warrants to the
Investor as follows:

      3.1 Organization, Good Standing and Qualification. The Company is a
corporation duly organized, validly existing and in good standing under the laws
of the State of: Delaware. The Company has all requisite corporate power and
corporate authority to own and operate its properties and assets, to carry on
its business as now conducted and as proposed to be conducted, to enter into
this Agreement, to sell the Shares and to carry out the other transactions
contemplated hereunder. The Company is qualified to transact business and is in
good standing in each jurisdiction in which the failure to qualify would have,
or could reasonably be expected to have, a material adverse effect on the
business, properties, financial condition or results of operations of the
Company taken as a whole (a "Material Adverse Effect"). The Company has
delivered to the Investor true, correct and complete copies of the Company's
Restated Certificate and the Company's By-laws in effect on the date hereof. The
Company has not taken any action that conflicts with, constitutes a default
under, or results in a material violation of, any provision of the Company's
Restated Certificate or By-laws.

      3.2 Capitalization and Voting Rights.

            (a) The authorized capital of the Company as of the date hereof
consists of:

                  (i) [7,292,111] shares of Preferred Stock, 36,000 shares of
which have been designated Series A Preferred Stock, all of which are issued and
outstanding immediately prior to the Closing, 1,095,000 shares of which have
been designated Series B Preferred Stock, none of which are issued and
outstanding immediately prior the Closing, 4,550,000 shares of which have been
designated Series C Preferred Stock, 4,400,000 of which are issued and
outstanding immediately prior to the Closing, 500,000 shares of Series D-1
Preferred Stock, none of which are issued and outstanding immediately prior to
the Closing, [333,333] shares of Series D-2 Preferred Stock, none of which are
issued and outstanding immediately prior to the Closing, 500,000 shares of
Series E-1 Preferred Stock, none of which are issued and outstanding

                                       3.
<PAGE>

immediately prior to the Closing and [277,778] shares of Series E-2 Preferred
Stock, none of which are issued and outstanding immediately prior to the
Closing.

                  (ii) [13,000,000] shares of Common Stock, [310,542] shares of
which are issued and outstanding immediately prior to the Closing.

            (b) Except as set forth in Section 3.2 of the Disclosure Schedule
attached hereto as Exhibit B to this Agreement, there are: (i) no outstanding
options, warrants, rights (including conversion or preemptive rights) or
agreements pursuant to which the Company is or may become obligated to issue,
sell or repurchase any shares of its capital stock or any other securities of
the Company; (ii) no restrictions on the transfer of capital stock of the
Company imposed by the Restated Certificate or By-laws of the Company, or any
agreement to which the Company is a party, any order of any court or any
governmental agency to which the Company is subject, or any statute other than
those imposed by relevant state and federal securities laws; (iii) no cumulative
voting rights for any of the Company's capital stock except as provided by law;
(iv) no registration rights under the Securities Act of 1933, as amended (the
"Securities Act") with respect to shares of the Company's capital stock; and (v)
to the best of the Company's knowledge and belief, no options or other rights to
purchase shares of capital stock from shareholders of the Company granted by
such shareholders. The Company has reserved up to [1,321,591] shares of its
Common Stock for the issuance of Common Stock pursuant to the exercise of
outstanding options and warrants or options to be granted in the future under
its 1995 Stock Option Plan and 1997 Equity Incentive Plan.

            (c) Except as set forth in Section 3.2 of the Disclosure Schedule,
the Company is not a party to or is not subject to any agreement or
understanding relating to, and to the Company's knowledge there is no agreement
or understanding between any persons and/or entities which affects or relates
to, the voting of shares of capital stock of the Company or the giving of
written consents by a shareholder or director of the Company.

      3.3 Subsidiaries. The Company has never owned and does not presently own
or control, directly or indirectly, any other corporation, association, or other
business entity and has never owned or controlled and does not currently own or
control, directly or indirectly, any capital stock or other ownership interest,
directly or indirectly, in any corporation, association, partnership, trust,
joint venture or other entity.

      3.4 Authorization. All corporate action on the part of the Company and its
shareholders necessary for the authorization, execution and delivery of this
Agreement, the performance of all obligations of the Company hereunder and the
authorization, issuance and delivery of the Shares and Conversion Shares to be
sold hereunder, has been taken or will be taken prior to the relevant Closings.
This Agreement has been duly executed and delivered by the Company and
constitutes a valid and legally binding obligation of the Company, enforceable
against the Company in accordance with its terms, except as such enforceability
may be limited by applicable bankruptcy, insolvency, reorganization, moratorium
or other laws of general application relating to or affecting enforcement of
creditors rights and equitable principals of general application.

                                       4.
<PAGE>

      3.5 No Conflict. The execution, delivery and performance of this Agreement
and compliance with the provisions hereof by the Company, do not and will not:

            (a) violate any provision of law, statute, ordinance, rule or
regulation or any ruling, writ, injunction, order, judgment or decree of any
court, administrative agency or other governmental body, the violation of which
would have a Material Adverse Effect;

            (b) conflict with or result in any breach of any of the terms,
conditions or provisions of, or constitute (with due notice or lapse of time, or
both) a default (or give rise to any right of termination, cancellation or
acceleration) under (i) any material agreement, document, instrument, contract,
understanding, arrangement, note, indenture, mortgage or lease to which the
Company is a party or under which the Company or any of its assets is bound or
affected, (ii) the Company's Restated Certificate or (iii) the By, laws of the
Company; or

            (c) result in the creation of any Encumbrance upon any of the Shares
or on any of the properties or assets of the Company.

      3.6 Valid Issuance of Preferred and Common Stock. When issued, sold and
delivered in accordance with the terms hereof for the consideration expressed
herein, the Securities and Conversion Shares will be validly issued and
outstanding, fully paid and nonassessable and not subject to any preemptive
rights, rights of first refusal or other similar rights imposed by the Company.

      3.7 Indebtedness and Contractual Liabilities. Except as set forth in
Section 3.7 of the Disclosure Schedule, the-Company has not incurred any unpaid
indebtedness for money borrowed or any other contractual liabilities in excess
of $500,000 individually, or $1,000,000 in the aggregate.

      3.8 Governmental Consents. To the best of the Company's knowledge, no
consent, approval, order or authorization of, or registration, qualification,
designation, declaration or filing with, any federal, state or local
governmental authority on the part of the Company is required in connection with
the consummation of the transactions contemplated by the Agreement, except as
may be required pursuant to the Hart-Scott-Rodino Premerger Notification Act
("HSR Act"), if applicable.

      3.9 Litigation. Except as set forth in Section 3.9 of the Disclosure
Schedule, there is no action, suit, proceeding or investigation pending or, to
the Company's knowledge, currently threatened against the Company which
questions the validity of this Agreement or the right of the Company to enter
into it, or to consummate the transactions contemplated hereby, or which
reasonably would be expected to have, either individually or in the aggregate, a
Material Adverse Effect, or result in any change in the current equity ownership
of the Company, nor is the Company aware that there is any basis for the
foregoing. To the Company's knowledge, there are no legal actions or
investigations pending or threatened involving the employment by or with the
Company of any of the Company's current or former employees, their use in
connection with the Company's business of any information or techniques
allegedly proprietary to any of their former employers, or their obligations
under any agreements with prior employers or alleging a

                                       5.
<PAGE>

violation of any federal, state or local Statute or common law relationship with
the Company The Company is not a party to any order, writ, injunction, judgment
or decree of any court.

      3.10 Employees and Consultants. Except as set forth in Section 3.10 of the
Disclosure Schedule:

            (a) To the Company's knowledge, none of its employees is obligated
under any contract (including licenses, covenants or contracts of any nature) or
other agreement, or subject to any judgment, decree or order of any court or
administrative agency, that would interfere with the use of his best efforts to
promote the interests of the Company or that would conflict with the Company's
business as proposed to be conducted. Neither the execution nor delivery of this
Agreement, nor the carrying on of the Company's business by the employees of the
Company, nor the conduct of the Company's business as proposed, will, to the
Company's knowledge, conflict with or result in a breach of the terms,
conditions or provisions of, or constitute a default under, any material
contract, covenant or instrument under which any of such employees is now
obligated.

            (b) Each employee of, or consultant to, the Company, who has or is
proposed to have access to confidential or proprietary information of the
Company, is a signatory to, and is bound by, an agreement with the Company
relating to noncompetition, nondisclosure, proprietary information and
assignment of patent, copyright and other intellectual property rights.

            (c) No employee of, or consultant to, the Company is in violation of
any term of any employment contract,-patent disclosure agreement or any other
contract or agreement including, but not limited to, those matters relating to
(i) the relationship of any such employee with the Company or to any other party
as a result of the nature of the Company's business as currently conducted, or
(ii) unfair competition, trade secrets or proprietary information.

      3.11 Patents and Trademarks. Except as set forth in Section 3.11 of the
Disclosure Schedule, there are no outstanding options, licenses, or agreements
of any kind relating to the Company's patents, service marks, trademarks,
copyrights, trade secrets, proprietary rights or other intellectual property
(hereinafter collectively the "Intellectual Property"); nor is the Company bound
by or a party to any options, licenses or agreements of any kind with respect to
the Intellectual Property of any other person or entity. The Company has not
received any written communications alleging that the Company has violated or,
by conducting its business as proposed, would violate any of the Intellectual
Property of any other person or entity. To the best of the Company's knowledge,
all of its Intellectual Property was validly obtained and free from any
impediments, including but not limited to patent invalidity or unenforceability.

      3.12 Compliance with Other Instruments. The Company is not in violation or
default of any provisions of the Restated Certificate or the Company's By-laws
or of any instrument, judgment, order, writ or decree.

      3.13 Agreements; Action.

                                       6.
<PAGE>

            (a) Except for agreements explicitly contemplated hereby and as set
forth in Section 3.13(a)of the Disclosure Schedule, there are no agreements,
understandings, transactions or proposed transactions between the Company and
any of its officers, directors, or Affiliates, or any Affiliate thereof of a
nature required to be disclosed pursuant to the provisions of Regulation S-K,
and none of any such individuals or entities has any interest in any party to
any such agreement, understanding, transaction or proposed transaction.

            (b) Except as set forth in Section 3.13(b) of the Disclosure
Schedule, the Company has not (i) declared or paid any dividends, or authorized
or made any distribution upon or with respect to any class or series of its
capital stock, (ii) made any loans or advances to any person, other than
ordinary advances to employees for travel expenses, or (iii) sold, exchanged or
otherwise disposed of any of its assets or rights, other than in the ordinary
course of business.

            (c) The Company has not admitted in writing its inability to pay its
debts generally as they become due, filed or consented to the filing against it
of a petition in bankruptcy or a petition to take advantage of any insolvency
act, made an assignment for the benefit of creditors, consented to the
appointment of a receiver for itself or for the whole or any substantial part of
its property, or had a petition in bankruptcy filed against it, been adjudicated
a bankrupt, or filed a petition or answer seeking reorganization or arrangement
under the federal bankruptcy laws or any other laws of the United States or any
other jurisdiction.

            (d) The Company is in compliance with all obligations, agreements
and conditions contained in any evidence of indebtedness or any loan agreement
or other contract or agreement (whether or not relating to indebtedness) to
which the Company is a party or is subject (collectively, the "Obligations"),
the lack of compliance with which could afford to any person the right to (i)
accelerate any indebtedness or (ii) terminate any right or agreement of the
Company, the termination of which would have a Material Adverse Effect. To the
best of the Company's knowledge and belief, all other parties to such
Obligations are in compliance with the terms and conditions of such Obligations.

      3.14 Registration Rights. Except for agreements explicitly contemplated
hereby or as provided in Section 3.14 of the Disclosure Schedule, the Company
has not granted or agreed to grant any registration rights, including piggyback
rights, to any person or entity.

      3.15 Title to Property and Assets. The Company has good, legal and
merchantable title to all of its assets, including all properties and assets
reflected on its Financial Statements (as defined below), free and clear of all
liens, claims, restrictions or encumbrances, except those assets disposed of
since the Statement Date (as defined below) in the ordinary course of business,
none of which either alone or in the aggregate is material, either in nature or
amount, to the business of the Company. All machinery and equipment included in
such properties which is material to the business of the Company is in good
condition and repair, and each lease of real or personal property to which the
Company is a party is fully effective, affords the Company peaceful and
undisturbed possession of the subject matter of the lease, and is free of any
liens, claims restrictions or encumbrances. To the knowledge of the Company,
each such lease constitutes a valid and binding obligation of, and is
enforceable in accordance with its terms against, the respective parties
thereto. Except as provided in Section 3.15 of the Disclosure

                                       7.
<PAGE>

Schedule, with respect to the property, and assets it leases, the Company is in
all material respects in compliance with such leases, has not received notice of
any allegations that it is in default thereunder in any respect and holds a
valid leasehold interest free of any Encumbrances.

      3.16 Financial Statements. The Company has made available to the Investor
its audited financial statements (including balance sheet, income statement and
statement of cash flows) for the fiscal year ended December 31, 1997 and its
unaudited financial statements (including balance sheet, income statement and
statement of cash flows) as of December 31, 1998 (the "Statement Date") and for
the [twelve]-month period ended December 31, 1998 (collectively, the "Financial
Statements"). The Financial Statements have been prepared in accordance with
generally accepted accounting principles applied on a consistent basis
throughout the periods indicated. The Financial Statements fairly present the
financial condition and operating results of the Company as of the dates, and
for the periods, indicated therein, subject to normal year-end audit
adjustments. Except as set forth in the Financial Statements, the Company has no
material liabilities, contingent or otherwise, other than (i) liabilities
incurred in the ordinary course of business subsequent to December 31, 1998 and
(ii)obligations under contracts and commitments incurred in the ordinary course
of business and not required under generally accepted accounting principles to
be reflected in the Financial Statements, which, in both cases, individually or
in the aggregate are not material to the financial condition or operating
results of the Company. Except as disclosed in the Financial Statements, the
Company is not a guarantor or indemnitor of any indebtedness of any other
person, firm or corporation. The Company maintains and will continue to maintain
a standard system of accounting established and administered in accordance with
generally accepted accounting principles.

      3.17 Employee Benefit Plans. Except as set forth in Section 3.17 of the
Disclosure Schedule, there are no "employee benefit plans" as such term is
defined in Section 3(3) of the Employee Retirement Income Security Act of 1974
("ERISA") maintained by the Company or any stock purchase plan, stock option
plan, fringe benefit plan, bonus plan or any other deferred compensation
agreement, plan, practice or pending arrangement sponsored, maintained or to
which contributions are made by the Company by or on behalf of current or former
employees of the Company, their dependents or any other party. Other than set
forth in Section 3.17 of the Disclosure Schedule, the Company has no current
plans to substantially alter the benefits or coverage available under any of the
employee benefit, employee pension benefit or other plans, arrangements or
practices referred to above, and has retained the right to amend, modify or
terminate any such plan, arrangement or practice.

      3.18 Tax Returns, Payments and Elections. The Company has filed all tax
return and reports as required, and within the time (including possible
extensions) prescribed, by law, including without limitation, all federal, state
and local income, excise or franchise tax returns, real estate and personal
property tax returns, sales and use tax returns, payroll tax returns and other
tax returns or reports required to be filed by it. These returns and reports are
true and correct in all material respects. The Company has paid or made
provision for the payment of all accrued and unpaid taxes and other charges to
which the Company is subject and which are not currently due and payable. The
federal income tax returns of the Company have never been audited by the
Internal Revenue Service, and the Company has not agreed to an extension of the
statute of limitations with respect to any of its tax years. To the Company's
knowledge, neither

                                       8.
<PAGE>

the Internal Revenue Service nor any other taxing authority is now asserting,
nor is threatening to assert, against the Company any deficiency or claim for
additional taxes or interest thereon or penalties in connection therewith; nor,
to the Company's knowledge, does such deficiency or claim or basis for such
deficiency or claim exist. The Company has not made any elections pursuant to
the Code (other than elections which relate solely to methods of accounting,
depreciation or amortization) which would have a Material Adverse Effect.

      3.19 Insurance. The Company has in full force and effect fire, casualty
and liability insurance policies, with coverage, in the case of property
insurance, sufficient in amount (subject to reasonable deductibles) to allow it
to replace any of its properties that might be damaged or destroyed, and in the
case of casualty and liability insurance, in amounts customary and adequate for
businesses similar to the business of the Company.

      3.20 Labor Agreements and Actions. The Company does not have any
collective bargaining agreements covering any of its employees, nor is the
Company bound by or subject to (and none of its assets or properties is bound by
or subject to) any written or oral, express or implied, contract, commitment or
arrangement with any labor union, and no labor union has requested or, to the
knowledge of the Company, has sought to represent any of the employees,
representatives or agents of the Company. There is no strike or other labor
dispute involving the Company pending, or to the knowledge of the Company
threatened, which could have a Material, Adverse Effect (as the Company's
business is presently conducted and as it is proposed to be conducted), nor is
the Company aware of any labor organization activity involving its employees.
The Company is not aware that any officer or key employee, or that any group of
key employees, intend to terminate their employment with the Company, nor does
the Company have a present intention to terminate the employment of any of the
foregoing.

      3.21 Real Property Holding Corporation. The Company is not, and has not
been at any time, a United States real property holding corporation as defined
in Section 897 of the Code.

      3.22 Offering. Subject to the accuracy of the Investor's representations
set forth in Section 4 of this Agreement, the offer, sale and issuance of the
Securities and Conversion Shares to be issued in conformity with the terms of
tiffs Agreement constitute transactions which are: (i) in full compliance with
all applicable laws; and (ii) exempt from the registration requirements of the
Securities Act and from all applicable state registration or qualification
requirements, other than those with which the Company has complied or will
comply with prior to the relevant Closings.

      3.23 Environmental Matters.

            (a) The Company is not in violation of any Environmental Law (as
hereinafter defined) and, to its knowledge, no material expenditures arc or will
be required in Order to comply with any Environmental Law. As used in this
Agreement, "Environmental Law" shall mean any applicable federal, state and
local law, ordinance, rule or regulation that regulates, fixes liability for, or
otherwise relates to, the handling, use (including use in industrial processes,
in construction, as building materials, or otherwise), treatment, storage and
disposal of hazardous and toxic wastes and substances, and to the discharge,
leakage, presence, migration, actual

                                       9.
<PAGE>

Release (as hereinafter defined) or threatened Release (whether by disposal, a
discharge into an> water source or system or into the air, or otherwise) of any
pollutant or effluent.

            (b) The Company has not used, generated, manufactured, refined,
treated. transported, stored, handled, disposed, transferred, produced,
processed or released (hereinafter together defined as "Release") any Hazardous
Materials (as hereinafter defined) on, from or affecting any Property (as
hereinafter defined) in any manner or by any means in violation of any
Environmental Laws and to the best of the Company's knowledge and belief after
due investigation, there is no threat of such Release. As used herein, the term
"Property" shall include, without limitation, land, buildings and laboratory
facilities owned or leased by the Company or as to which the Company now has any
duties, responsibilities (for cleanup, remedy or otherwise) or liabilities under
any Environmental Laws, or as to which the Company or any subsidiary of the
Company may have such duties, responsibilities or liabilities because of past
acts or omissions of the Company or any such subsidiary or their predecessors,
or because the Company or any such subsidiary or their predecessors in the past
was such an owner or operator of, or bore some other relationship with, such
land, buildings or laboratory facilities. The term "Hazardous Materials" shall
include, without limitation, any flammable explosives, petroleum products,
petroleum by-products, radioactive materials, hazardous wastes, hazardous
substances, toxic substances or related materials as defined by Environmental
Laws.

            (c) The Company has not received written notice that the Company is
a party potentially responsible for costs incurred at a cleanup site or
corrective action under any Environmental Laws. The Company has not received any
written requests for information in connection with any inquiry by any
Governmental Authority (as hereinafter defined) concerning disposal sites or
other environmental matters. As used herein, "Governmental Authority" shall mean
any nation or government, any federal, state, municipal, local, provincial,
regional or other political subdivision thereof, and any entity or person
exercising executive, legislative, judicial regulatory or administrative
functions of or pertaining to government.

            (d) The shareholders of the Company have had no control over, or
authority with respect to, the waste disposal operations of the Company.

      3.24 Securities Laws. Neither the Company nor anyone acting on its behalf
has offered securities of the Company for sale to, or solicited any offers to
buy the same from, or sold securities of the Company to, any Person, in any case
so as to subject the Company, its promoter, directors or officers to any
liability under the Securities Act, the Securities Exchange Act of 1934, as
amended (the "Securities Exchange Act"), or any state securities or blue sky law
(collectively, the "Securities Laws"), or any other applicable laws.

      3.25 Licenses and Other Rights; Compliance with Laws. To the Company's
knowledge, the Company has all franchises, permits, licenses and other rights
and privileges necessary to permit it to own its properties and to conduct its
business as presently conducted and is in compliance in all material respects
thereunder. The Company is in compliance in all material respects with all laws
and governmental rules and regulations applicable to its business, properties
and assets, and to the products and services sold by them, including, without
limitation, all such rules, laws and regulations relating to fair employment
practices, occupational

                                      10.
<PAGE>

safety and health and public safety, except where the failure to comply would
not have a Material Adverse Effect.

      3.26 Reliance. The Company understands that the foregoing representations
and warranties shall be deemed material and to have been relied upon by the
Investor. To the best of the Company's knowledge, no representation or warranty
by the Company in this Agreement, and no written statement contained in any
document, certificate or other writing delivered by the Company to the Investor
contains any untrue statement of material fact or omits to state any material
fact necessary to make the statements herein or therein, in light of the
circumstances under which they were made, not misleading.

      3.27 Brokerage. [To Come From Novartis]

4. REPRESENTATIONS AND WARRANTIES OF THE INVESTOR. Novartis hereby represents
and warrants the following:

      4.1 Authorization, Governmental Consents and Compliance with Other
Instruments. All corporate action on the part of the Investor necessary for the
authorization, execution and delivery of this Agreement and the performance of
all obligations of the Investor hereunder has been taken or will be taken prior
to the Closing. This Agreement constitutes a valid and legally binding
obligation of the Investor, enforceable in accordance with its terms, except as
such enforcement is limited by bankruptcy, insolvency and similar laws affecting
creditor rights. No consent, approval, order or authorization of, or
registration, qualification, designation, declaration or filing with, any
federal, state or local governmental authority on the part of the Investor is
required in connection with the consummation of the transactions contemplated by
this Agreement, except as may be required by the HSR Act. The execution,
delivery and performance of this Agreement and the consummation of the
transactions contemplated hereby will not result in any violation or be in
conflict with or constitute, with or without the passage of time and giving of
notice, either a default under any provision of the Investor's corporate charter
or By-laws or any instrument, judgment, order, writ, decree or contract to which
the Investor is a party or by which it is bound.

      4.2 Purchase Entirely for Own Account. By the Investor's execution of this
Agreement, the Investor hereby confirms that the Securities and Conversion
Shares will be acquired for investment for the Investor's own account, not as a
nominee or agent, and not with a view to the resale or distribution of any part
thereof, and the Investor has no present intention of selling, granting any
participation, or otherwise distributing the Securities and Conversion Shares.
By executing this Agreement, the Investor further represents that the Investor
does not have any contract, undertaking, agreement or arrangement with any
person to sell, transfer or grant any participation to such person or to any
third person, with respect to any of the Securities and Conversion Shares.

      4.3 Investment Experience and Accredited Investor Status. The Investor
either (i) is an accredited investor (as defined in Regulation D promulgated
under the Securities Act) or (ii) is not a United States Person as that term is
defined in Regulation S of the Securities Act, as amended and is not acquiring
the Common Shares for the account or benefit of any United States Person. The
Investor is an investor in securities of companies in the development stage and

                                      11.
<PAGE>

acknowledges that it is able to fend for itself, and bear the economic risk of
its investment and has such knowledge and experience in financial or business
matters that it is capable of evaluating the merits and risks of the investment
in the Securities and Conversion Shares hereunder.

      4.4 Restricted Securities. The Investor understands that the Securities
and Conversion Shares, when issued, will be restricted securities under the
federal securities laws inasmuch as they are being acquired from the Company in
a transaction not involving a public offering and that under such laws and
applicable regulations such securities may be resold without registration under
the Securities Act only in certain limited circumstances. In this connection,
the Investor represents that it is familiar with Rule 144, as presently in
effect, and understands the resale limitations imposed thereby and by the
Securities Act.

      4.5 Further Limitations on Disposition. Without in any way limiting the
representations set forth above, the Investor further represents, warrants and
agrees that it will not make any disposition of all or any portion of the
Securities and Conversion Shares, except to an Affiliate of the Investor,
unless:

            (a) There is then in effect a Registration Statement under the
Securities Act covering such proposed disposition and such disposition is made
in accordance with such Registration Statement; or

            (b) The disposition is made pursuant to Rule 144 or similar
provisions of federal securities laws as in effect from time to time; or

            (c) (i) the Investor shall have notified the Company of the proposed
disposition; and (ii) if requested by the Company, the Investor shall have
furnished the Company with an opinion of counsel, reasonably satisfactory to the
Company, that such disposition will not require registration of such Shares
under the Securities Act.

      4.6 Legends. It is understood that the certificates evidencing the Shares
and the Conversion Shares will bear the following legends:

            (a) These securities have not been registered under the Securities
Act of 1933. They may not be sold, offered for sale, pledged or hypothecated in
the absence of a registration statement in effect with respect to the securities
under such Act or an opinion of counsel reasonably satisfactory to the Company
that such registration is not required or unless sold pursuant to Rule 144 of
such Act.

            (b) Any legend required by applicable state securities laws.

5. CONDITIONS TO CLOSING OF INVESTOR.

      5.1 First Closing. The obligations of the Investor to the Company. under
this Agreement are subject to the fulfillment, on or before the First Closing,
of each of the following conditions, unless otherwise waived by the Investor in
writing:

                                      12.
<PAGE>

            (a) Representations and Warranties Correct. The representations and
warranties made by the Company in Section 3 hereof shall be true and correct in
all material respects (except for representations and warranties which are
qualified by materiality, which shall be true and correct in all respects) as of
the First Closing Date with the same force and effect as though such
representations and warranties had been made on the First Closing Date.

            (b) Performance. The Company shall have performed and complied with
all covenants, agreements, obligations and conditions contained in this
Agreement that are required to be performed or complied with by it on or before
the First Closing. All proceedings to have been taken and all waivers and
consents to be obtained in connection with the transactions contemplated by this
Agreement shall have been taken or obtained, and all documents incidental
thereto shall be satisfactory to the Investor and its counsel, and the Investor
and its counsel shall have received copies (executed or certified, as may be
appropriate) of all documents which the Investor or its counsel may reasonably
have requested in connection with such transactions.

            (c) Compliance Certificate. The Company shall have delivered to the
Investor a certificate of the Company executed by the President and Chief
Executive Officer of the Company, certifying to the fulfillment of the
conditions specified in Section 5.1 (a) and (b) of this Agreement.

            (d) [Legal Opinion. All legal matters incident to the purchase of
the Shares shall be satisfactory to the Investor's counsel and the Investor
shall have received from Cooley Godward LLP, counsel for the Company, such
firm's opinion addressed to the Investor and dated the date of the First
Closing, in the form of Exhibit C, hereto.]

            (e) Certification of Resolutions and Officers. The Company shall
have delivered to the Investor a certificate or certificates, dated the date of
the First Closing, Of the Secretary of the Corporation certifying as to (a) the
resolutions of the Company's Board of Directors (and the vote of the
shareholders, if necessary) authorizing the execution and delivery of this
Agreement, the issuance to the Investor of the First Closing Shares, the
execution and delivery of such other documents and instruments as may be
required by this Agreement, and the consummation of the transactions
contemplated hereby, and certifying that such resolutions were duly adopted and
have not been rescinded or amended as of said date, (b) the name and the
signature of the officers of the Company authorized to sign, as appropriate,
this Agreement and the other documents and certificates to be delivered pursuant
to this Agreement by either the Company or any of its officers, and (c) a
specimen certificate representing the First Closing Shares.

            (f) Organizational Documents. The Company shall have made available
to the Investor a copy of (i) the certificates of incorporation for the Company,
certified by the secretary of state of the jurisdiction in which such entity is
incorporated or organized, as of a date not earlier than five business days
prior to the Closing Date and accompanied by a certificate of the Secretary or
Assistant Secretary of such entity, dated as of the Closing Dates, stating that
no amendments have been made to such certificate of incorporation (or similar
organizational documents) since such date, and (ii) the By-laws (or similar
organizational documents) of the Company, certified by the Secretary or
Assistant Secretary of such entity.

                                      13.
<PAGE>

            (g) Certification of No Material Adverse Change. The Company shall
have delivered to the Investor a certificate, dated the date of the Closings, of
the Chief Executive Officer of the Corporation certifying that since the
Statement Date, there has hot been any material adverse change in the financial
condition or operations of the Company, and that except to the extent reflected
in the Financial Statements referred to in Section 3.16 (or in such later
audited financial statements, as the case may be), and except for liabilities
arising in the ordinary. course of business (none of which liabilities either
alone or in the aggregate are material either in nature or amount to the
business of the Company), the Company has no material accrued or contingent
liabilities which are not specifically described in such Financial Statements.

            (h) Good Standing Certificates. At the Closings, the Company shall
have delivered to the Investor good standing certificates issued with respect to
the Company issued by the Secretary of State (or other applicable Governmental
Authority) of the relevant entity's state of incorporation or organization.

      5.2 Second Closing. The obligations of the Investor at the Second Closing
shall be subject to the fulfillment, on or before the Second Closing of each of
the following conditions, unless otherwise waived by the Investor in writing:

            (a) Bring-down Representations and Warranties. The representations
and warranties of the Company contained in Section 3 shall be true and correct
on and as of the Second Closing with the same force and effect as though such
representations and warranties had been made on and as of that date; provided,
however, that the Company shall provide to the Investor a revised Schedule of
Exceptions to the representations and warranties, dated as of the date of the
Second Closing; and provided further, that in the event the Company has closed a
Preferred Financing or IPO on or prior to the Second Closing, the Company may
make material modifications to the representations and warranties and Schedule
of Exceptions hereunder to reflect the representations, warranties and
disclosure provided to and accepted by the investors in such Preferred Financing
or IPO.

            (b) Performance. The Company shall have performed and complied with
all covenants, agreements, obligations and conditions contained in this
Agreement that are required to be performed or complied with by it on or before
the Second Closing.

            (c) Compliance Certificate. The Chief Executive Officer Of the
Company shall deliver to the Investor at the Second Closing a certificate
certifying that the conditions specified in Section 5.2 (a) and (b) have been
fulfilled.

            (d) Rights of Series E-2. If the Company shall issue shares of
Series E-2 Preferred to the Purchaser at the Second Closing pursuant to Section
1.3(b), the Series E-2 Preferred shall have the same rights, preferences and
privileges (except for Original Issue Price) as the Series E-1 Preferred.

6. CONDITIONS TO THE COMPANY'S OBLIGATIONS AT THE FIRST AND SECOND CLOSINGS. The
obligations of the Company to the Investor under this Agreement are subject to
the fulfillment, on or before the First Closing and Second Closing, as
applicable, of each of the following conditions, unless otherwise waived in
writing by the Company:

                                      14.
<PAGE>

      6.1 Representations and Warranties Correct. The representations and
warranties made by the Investor in Section 4 hereof shall be true and correct in
all material respects (except for representations and warranties which are
qualified by materiality, which shall be true and correct in all respects) as of
the date of the First Closing and Second Closing, as applicable, with the same
force and effect as though such representations and warranties had been made on
and as of such date.

      6.2 Performance. All covenants, agreements and conditions contained in
this Agreement to be performed by the Investor on or prior to the First Closing
and Second Closing, as applicable, shall have been performed or complied with in
all material respects.

7. MUTUAL CONDITIONS OF CLOSING. The obligations of each of the Investor and the
Company to consummate the Closings are subject to the fulfillment as of the
Closing Dates of the following conditions:

      7.1 Qualifications. All authorizations, approvals or permits, if any, of
any governmental authority or regulatory body of the United States or of any
state that are required in connection with the lawful issuance and sale of the
capital stock pursuant to this Agreement shall be obtained and effective as of
the applicable Closing Date.

      7.2 First Amended and Restated Investors' Rights Agreement. The Company
and the Investor shall have entered into the First Amended and Restated
Investors' Rights Agreement in the form attached hereto as Exhibit D.

      7.3 Absence of Litigation. There shall be no injunction, actions, suits,
proceeding or investigations pending or currently threatened against the Company
or the Investor which questions the validity of this Agreement or the right of
the Company or the Investor to enter into it, or to consummate the transactions
contemplated hereby.

      7.4 Research Collaboration and License Agreement. The Company and the
Investor shall have entered into the Research Collaboration and License
Agreement in the form attached hereto as Exhibit E (the "Collaboration
Agreement").

      7.5 Shares Available. The Company shall have available under its
Certificate of Incorporation, as amended, sufficient authorized shares of its
capital stock to issue and sell the Shares to the Investor.

8. COVENANTS OF THE COMPANY.

      8.1 Board Observer. So long as the Investor holds at least 50% of the
First Closing Shares, the Company shall permit a representative of the Investor
(the "Representative") to attend in a nonvoting observer capacity all meetings
of the Company's Board of Directors (the "Board") and, in such respect, shall
provide such Representative copies of the Board materials provided to its
directors; provided, however, that the Company may exclude the Representative
from access to any material or meeting or portion thereof if (i) such material
or meeting involves the Company's planned or existing confidential relationships
with other strategic partners, (ii) the Company believes that such exclusion is
reasonably necessary to protect confidential proprietary

                                      15.
<PAGE>

information or (iii) the Company believes upon the advice of counsel that such
exclusion is reasonably necessary to preserve the attorney-client privilege.

      8.2 Inspection of Properties. So long as the Strategic Investor holds at
least 50% of the First Closing Shares, the Company shall permit the Investor
from time to time, at the Investor's expense and upon reasonable advance notice,
to visit and inspect the Company's properties and to discuss the Company's
affairs, finances and accounts with its officers, all at such reasonable times
and with such reasonable frequency as may be requested by the Investor;
provided, however, that the Company shall not be obligated to provide access to
any information which it reasonably considers to be a trade secret or similar
confidential information.

      8.3 Termination of Covenants. The covenants set forth in this Section 8
shall terminate when the sale of securities pursuant to a registration statement
filed by the Company under the Securities Act in connection with the firm
commitment underwritten offering of its securities to the general public is
consummated or when the Company first becomes subject to the periodic reporting
requirements of Sections 12(g) or 15(d) of the Securities Exchange Act,
whichever event shall first occur.

9. COVENANTS OF THE INVESTOR.

      9.1 Voting.

            (a) Shares Governed. The Investor agrees to hold all shares of
Series E-1 Preferred and Series E-2 Preferred now owned or hereinafter acquired
by it registered in its name or beneficially owned by it as of the date hereof
(and any and all other securities of the Company legally or beneficially
acquired by the Investor after the date hereof, other than shares of Common
Stock) (hereinafter collectively referred to as the "Shares") subject to, and to
vote the Shares in accordance with, the provisions of this Section 9.1.

            (b) Voting. In any Company matter in which the Investor has the
right to vote its Shares as a class or series separate from the other
outstanding classes or series of Preferred Stock of the Company (i) pursuant to
Section 2115 of the California Corporation Code (or any successor provision)
with respect to any matter as to which the Investor would not have the right to
vote its Shares as a separate class or series pursuant to the Company's Restated
Certificate or any provision of the Delaware General Corporation Law, or (ii)
pursuant to Section 242 of the Delaware General Corporation Law (or any
successor provision) with respect to any proposed amendment to the Company's
Restated Certificate which alters or changes the powers, preferences or special
rights of each class or series of Preferred Stock of the Company held by the
Investor with a like effect on the powers, preferences or special rights of each
other class or series of Preferred Stock of the Company, then in each case the
Company shall record the total vote of all other capital stock of the Company
eligible to vote on such matter (either by class or in general) without regard
to series or other subdivision of any class. For the purposes of any separate
class or series voting referred to in clauses (i) or (ii)of the preceding
sentence, the Investor agrees to vote its Shares in accordance with the majority
in interest of the other capital stock voting, as recorded by the Company
pursuant to the preceding sentence. This provision shall not apply to any
separate vote of a series of Preferred Stock permitted by Article IV.D.2.d. of
the Company's Restated Certificate.

                                      16.
<PAGE>

            (c) Proxy. Concurrently with the execution of this Agreement. the
Investor agrees to deliver to the Company a proxy in the form attached hereto as
Exhibit F (the "Proxy"), which shall be irrevocable to the extent provided in
Section 212 of the Delaware General Corporation Law, and shall be deemed to be
coupled with an interest, with the total number of shares of capital stock
beneficially owned (as such term is defined in Rule 13d-3 under the Securities
Exchange Act of 1934, as amended) by the Investor set forth therein.

            (d) Termination. This Section 9.1 shall continue in full force and
effect until the earlier of (i) ten (10) years from the date of this Agreement
or (ii) such time as the shares of Series E-1 Preferred and Series E-2 Preferred
have been converted to Common Stock.

      9.2 Standstill. Commencing as of the date of this Agreement and for the
period until one (1) year following the completion of the Collaboration
Agreement (or any amendment, extension or renewal of such Collaboration
Agreement or any newly entered collaboration agreement between the Company and
the Investor), the Investor (including all Affiliates of such Investor) shall
not acquire beneficial ownership of any shares of Common Stock of the Company,
any securities convertible into or exchangeable for Common Stock, or any other
right to acquire Common Stock or such convertible securities, or any rights to
vote securities of the Company, except by way of stock dividends or other
distributions or offerings made available to holders of Common Stock generally,
from the Company or any other person or entity, without the prior written
consent of the Company, which consent may be withheld in its sole discretion;
provided, however, the Investor may acquire shares of Common Stock of the
Company as long as the aggregate ownership of voting securities held by the
Investor does not exceed fifteen percent (15%) of the then outstanding voting
securities of the Company. The Investor shall not be subject to such 15%
limitation (i) in the event of the public announcement that a person or group
has acquired beneficial ownership of 15% or more of the Company's Common Stock
Or (ii) after such time as a person or group commences or announces its
intention to commence a tender or exchange offer, the consummation of which
would result in beneficial ownership by such person or group of 15% or more of
the Company's Common Stock.

      9.3 Right of First Offer.

            (a) The right of the Investor to sell or offer to sell, or otherwise
transfer or distribute any of the Shares in any manner (any such sale,
disposition or transfer hereinafter referred to as a "Transfer"), except to an
Affiliate of the Investor, shall be subject to a right of first refusal of the
Company as set forth in this Section 9.3. Any attempted or purported Transfer of
the Shares by operation of law, by death or otherwise, in violation of this
Section 9.3 shall be null and void and of no legal force or effect. If the
Investor desires to dispose of any or all of the Shares (the "Offered Shares"),
the Investor shall first submit to the Company a bona fide written offer (the
"Offer") to sell the Offered Shares to the Company at a price and on such other
terms and conditions as shall be specified in the Offer. The Offer by its terms
shall remain open and irrevocable for a period of 45 days from the date of
delivery of the Offer to the Company (the "45-Day Period"). The Company shall
notify the Investor prior to the end of the 45-Day Period of its intention to
purchase, or to place with other purchasers, all (but not less than all) of the
Offered Shares by delivering a written notice to the Investor (the "Notice of
Acceptance") which shall fix a closing date that is not more than 20 days after
the date of delivery of such notice. If

                                      17.
<PAGE>

the Company fails to deliver to Investor a Notice of Acceptance as to the
Offered Shares, the Company shall provide written notice to the Investor (the
"Counter-offer") within the 45-Day Period of the price at which, and the other
terms and conditions upon which, the Company or its designees would be willing
to purchase the Offered Shares. Upon receipt of the Counter-offer, the Investor
shall have 45 days within which to elect to sell the Offered Shares to the
Company or its designees pursuant to the Counter-offer. Such election shall be
made by a written notice of election provided to the Company, which notice shall
fix a closing date not more than 20 days after the date of delivery of such
notice. At any time during the 45 days following its receipt of the
Counter-offer, the Investor may sell to any person or entity (other than a
"competitor" of the Company, as defined below) all (but not less than all) of
the Offered Shares; provided, however, that such sale is at a price and upon
terms and conditions that are more favorable to the Investor than those
specified in the Counter. offer. If the Offered Shares are not sold to the
Company or another party within such 45 day period, such Shares shall continue
to be subject to the requirements of this Section 9.3. It shall be a condition
to a Transfer of Shares by the Investor, in whole or in part, to any person or
entity, that such person or entity agrees to be bound by the provisions of this
Section 9.3. For purposes of this Section 9.3, a "competitor" shall mean any
person or entity directly or indirectly engaged in or promoting the research,
development, testing, study or commercialization of products, processes or
methods of treating infectious, viral or fungal diseases.

            (b) The provisions of this Section 9.3 shall not apply to any sale
of Shares that occurs upon or following the consummation of the Company's IPO.

10. MISCELLANEOUS.

      10.1 Survival of Warranties. The warranties and representations of the
Company and the Investor contained in this Agreement (except for those contained
in Section 3.22 but including those contained in the opinion and certificates
delivered pursuant to Section 5 hereof) shall survive until the first
anniversary of the Second Closing Date.

      10.2 Indemnification. Each party hereto (the "Indemnifying Party") shall
indemnify, defend and hold the other party and its directors, officers,
employees, agents and affiliates harmless against any and all liabilities,
losses, costs or damages, together with all reasonable costs and expenses
related thereto (including legal and accounting fees and expenses), arising
from, relating to, or connected with the untruth, inaccuracy or breach of any
statements, representations, warranties or covenants of such Indemnifying Party
contained herein. The foregoing indemnification shall survive the termination of
this Agreement for any reason.

      10.3 Remedies. In case any one or more of the covenants or agreements set
forth in this Agreement shall have been breached by any party hereto, the party
or parties entitled to the benefit of such covenants or agreements may proceed
to protect and enforce their rights either by suit in equity or action at law,
including, but not limited to, an action for damages as a result of any such
breach or an action for specific performance of any such covenant or agreement
contained in this Agreement. The rights, powers and remedies of the parties
under this Agreement are cumulative and not exclusive of any other right, power
or remedy which such parties may have under any other agreement or law. No
single or partial assertion or exercise of

                                      18.
<PAGE>

any right, power or remedy of a party hereunder shall preclude any other or
further assertion or exercise thereof.

      10.4 Successors and Assigns. Except as otherwise expressly provided
herein, the terms and conditions of this Agreement shall inure to the benefit of
and be binding upon the respective successors and assigns of the parties. This
Agreement and the rights and duties of the Company set forth herein may be
freely assigned, in whole or in part, upon the written consent of the Investor,
which consent may not be unreasonably withheld. Notwithstanding the foregoing
sentence, the Company may assign this Agreement, and the rights and the duties
of the Company set forth herein, to an entity or person which purchases all or
substantially all of its assets or voting securities, so long as the successor
agrees in writing to be bound by all of the terms of this Agreement.

      10.5 Entire Agreement. This Agreement and the other writings referred to
herein or delivered pursuant hereto which form a part hereof contain the entire
agreement among the parties with respect to the subject matter hereof and
supersede all prior and contemporaneous arrangements or understandings, whether
written or oral, with respect thereto; provided, however, that this Agreement is
not intended to supersede the Collaboration Agreement of even date herewith
between the Company and the Investor.

      10.6 Governing Law and Consent to Jurisdiction. This Agreement shall be
governed by and construed under the laws of the State of Delaware (without
regard to the conflict of law principles thereof). Each of the parties
irrevocably submits to the exclusive jurisdiction of (a) the Supreme Court of
the State of Delaware, and (b) the United States District Court for Delaware,
for the purposes of any suit, action or other proceeding arising out of this
Agreement or any transaction contemplated hereby. Each of the parties agrees to
commence any action, suit or proceeding relating hereto in the United States
District Court for Delaware or if such suit, action or other proceeding may not
be brought in such court for jurisdictional purposes, in the Supreme Court of
the State of Delaware.

      10.7 Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

      10.8 Titles and Subtitles. The titles and subtitles used in this Agreement
are used for convenience only and are not to be considered in construing or
interpreting this Agreement.

      10.9 Nouns and Pronouns. Whenever the context may require, any pronouns
used herein shall include the corresponding masculine, feminine or neuter forms,
and the singular form of names and pronouns shall include the plural and
vice-versa.

      10.10 Notices. Unless otherwise provided, all notices, requests, consents
and other communications hereunder to any party shall be given in writing and
shall be deemed effectively given upon personal delivery to the party to be
notified or duly sent by first class registered or certified mail, or other
courier service, postage prepaid, or telecopied with a confirmation copy by
regular mail, and addressed or telecopied to the party to be notified at the
address or telecopier number indicated for such party at the address or
telecopier number, as the case may be, set forth

                                      19.
<PAGE>

below or such other address or telecopier number, as the case may be, as may
hereafter be designated in writing by the addressees to the addressor listing
all parties:

            To the Company:        Versicor, Inc.
                                   34790 Ardentech Court
                                   Fremont, California 94555
                                   Attention: Chief Executive Officer

            With a copy (which     Andrei M. Manoliu, Esq.
            shall not constitute   Cooley Godward LLP
            notice) to:            5 Palo Alto Square
                                   3000 El Camino Real
                                   Palo Alto, California 94306-2155

            To the Investor:       Novartis Pharma AG
                                   Lichtstrasse 35
                                   CH-4002 Basel
                                   Switzerland
                                   Attention: Joseph E. Mantle

            With a copy to:        Jeff Benjamin, Esq.
                                   Vice President and Associate General Counsel
                                   Novartis Corporation
                                   564 Morris Avenue
                                   Summit, New Jersey 07901

            All such notices, requests, consents and other communications shall
be deemed to have been received: (a) in the case of personal delivery, on the
date of such delivery; (b) in the case of mailing, on the seventh business day
following the date of such mailing; and (c) in the case of facsimile
transmission, when confirmed by facsimile machine report.

      10.11 Finder's Fee. The Investor agrees to indemnify and to hold harmless
the Company from any liability for any commission or compensation in the nature
of a finder's fee (and the reasonable costs and expenses of defending against
such liability or asserted liability) for which the Investor or any of its
officers, partners, employees, or representatives is responsible. The Company
agrees to indemnify and hold harmless the Investor from any liability for any
commission or compensation in the nature of a finder's fee (and the reasonable
costs and expenses of defending against such liability or asserted liability)
for which the Company or any of its officers, employees or representatives is
responsible.

      10.12 Expenses. Each party shall pay its own fees and expenses with
respect to this Agreement. If any action at law or in equity is necessary to
enforce or interpret the terms of this Agreement or the Articles, the prevailing
party shall be entitled to reasonable attorney's fees, costs and necessary
disbursements in addition to any other relief to which such party may be
entitled.

                                      20.
<PAGE>

      10.13 Amendments and Waivers. Any term of this Agreement may be amended
and the observance of any term of this Agreement may be waived (either generally
or in a particular instance and either retroactively or prospectively), only
with the written consent of the party to be charged.

      10.14 Severability. If one or more provisions of this Agreement are held
to be unenforceable under applicable law, in any jurisdiction, such provision
shall be ineffective, as to such jurisdiction, and the balance of the Agreement
shall be interpreted as if such provision were so excluded, without invalidating
the remaining provisions of this Agreement; and any such prohibition or
unenforceability in any jurisdiction shall not invalidate or render
unenforceable such provision in any other jurisdiction.

      10.15 Confidentiality and Publicity. Neither the Company nor the Investor
will disclose to any person (other than its attorneys, accountants, employees,
officers, and directors) the terms of this Agreement or any of the transactions
contemplated hereby without the prior written consent of the other party, except
as set forth herein and except as may, in the reasonable opinion of such party's
counsel, be required by law (in which event the disclosing party will fast
consult with the other party with respect to such disclosure). If the Company is
required to provide a copy of this Agreement or any related document to any
third party, the Company shall ensure that such document is redacted, to the
extent permitted by law, to eliminate all confidential information. The Investor
shall have the right to review and approve each such: document prior to its
submission to a third party. A period of ten days will be provided for sucho
review unless not permitted by law, in which case the maximum period allowable
shall be provided. The Company and the Investor will consult and reach agreement
with one another as to the form and substance of any press release or any other
public disclosure of the terms of this Agreement or the transactions
contemplated hereby prior to issuing any such press release or making any such
public disclosure; provided, however, that once a mutually agreed upon press
release has been issued, either party may publicly disclose the information
contained in such press release.

      10.16 Definitions. As used in this Agreement, the following terms shall
have the following meanings:

            "Affiliate" means, with respect to any specified Person, any other
Person that directly or indirectly through one or more intermediaries, controls,
is controlled by, or is under common control with, such specified Person.

            "Closing(s)" has the meaning specified in Section 2.2.

            "Code" has the meaning specified in Section 3.17.

            "Collaboration Agreement" has the meaning specified in Section 7.4.

            "Company" has the meaning specified in the Introduction to this
Agreement.

            "Conversion Shares" has the meaning specified in Section 1.1(a)(iv).

                                      21.
<PAGE>

            "Disclosure Schedule" means the Disclosure Schedule attached hereto
as Exhibit B, dated as of the date hereof, and forming a part of this Agreement.

            "Encumbrance(s)" means any security interest, pledge, mortgage, lien
(including, without limitation, environmental and tax liens), charge,
encumbrance, adverse claim, preferential arrangement or restriction of any kind,
including, without limitation, any restriction on the use, voting, transfer,
receipt of income or other exercise of any attributes of ownership.

            "Environmental Law" has the meaning specified in Section 3.23(a).

            "ERISA" has the meaning specified in Section 3.17.

            "Financial Statements" has the meaning specified in Section 3.16.

            "First Closing" has the meaning specified in Section 2.1

            "First Closing Date" has the meaning specified in Section 2.1.

            "First Closing Price Per Share" has the meaning specified in Section
1.3.

            "First Installment" has the meaning specified in Section 1.2.

            "GAAP" has the meaning specified in Section 3.16.

            "Governmental Authority" has the meaning specified in Section
3.23(c).

            "Hazardous Materials" has the meaning specified in Section 3.23(b).

            "HSR Act" has the meaning specified in Section 3.8.

            "Intellectual Property" has the meaning specified in Section 3. l 1.

            "Investor" has the meaning specified in the Introduction and Section
1.2 of this Agreement.

            "Material Adverse Effect" has the meaning specified in Section 3.1.

            "Novartis" has the meaning specified in the Introduction to this
Agreement.

            "Obligations" has the meaning specified in Section 3.13(d).

            "Person" means any individual, partnership, firm, corporation,
association, trust, unincorporated organization or other entity, as well as any
syndicate or group that would be deemed to be a person under Section 13(d)(3) of
the Securities Exchange Act.

            "Property" has the meaning specified in Section 3.23(b)

            "Release" has the meaning specified in Section 3.23(b)

                                      22.
<PAGE>

            "Restated Certificate" has the meaning specified in Section 1.1.

            "SEC" shall mean the Securities and Exchange Commission.

            "Second Closing" has the meaning specified in Section 2.2

            "Second Closing Date" has the meaning specified in Section 2.2

            "Second Closing Price Per Share" has the meaning specified in
Section 1.4.

            "Second Installment" has the meaning specified in Section 1.2.

            "Securities Act" has the meaning specified in Section 3.2C0).

            "Securities Exchange Act" has the meaning specified in Section 3.24.

            "Securities Laws" has the meaning specified in Section 3.24.

            "Shares" has the meaning specified in Section 1.1.

            "Subsidiaries" (or, individually, a "Subsidiary") means any and all
corporations, partnerships, joint ventures, associations and other entities
controlled by the Company directly or indirectly through one or more
intermediaries.

                                      23.
<PAGE>

      IN WITNESS WHEREOF, the parties have executed and delivered this Agreement
as of the date first above written.

                                       NOVARTIS PHARMA AG

                                       By:______________________________________

                                       Name:____________________________________

                                       Title:___________________________________

                                       By:______________________________________

                                       Name:____________________________________

                                       Title:___________________________________

                                       VERSICOR, INC.

                                       By:______________________________________

                                       Name:____________________________________

                                       Title:___________________________________

                            STOCK PURCHASE AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00011-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00011-of-00352.parquet"}]]